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Neuronal apoptosis occurs extensively during the normal development of the 
mammalian  nervous  system  and  ensures  that  appropriate  connections  are  made 
between neurons and their target cells. Developing sympathetic neurons and the PC6-3 
cell  line,  a  PC 12  sub-clone,  are  useful  in  vitro  systems  for  studying  neuronal 
apoptosis. Both sympathetic neurons and neuronally differentiated PC6-3 cells depend 
on nerve growth factor (NGF) for survival and die by apoptosis after NGF withdrawal 
in a transcription and translation-dependent manner. The c-Jun protein is known to be 
required for neuronal cell death following  survival  factor withdrawal,  however the 
direct targets of this basic/leucine zipper transcription factor are unknown. The aim of 
this thesis was to identify and study c-Jun target genes involved in neuronal apoptosis.
In experiments using Affymetrix GeneChip® oligonucleotide microarrays, 78 
genes were identified that had an altered pattern of expression after NGF withdrawal 
from neuronal PC6-3 cells. One of the induced genes, ATF-3, a basic/leucine zipper 
transcription factor that can dimerise with c-Jun, was confirmed as an up-regulated 
transcript during PC6-3 cell apoptosis and this occurred after the induction of c-Jun. In 
sympathetic neurons, atf-3 RNA and protein levels increase between 8 and  16 hours 
after NGF withdrawal and remain elevated at 24 hours. This protein induction occurs 
after that of c-Jun and is inhibited by the c-Jun N-terminal kinase inhibitor SP600125 
and  the  mixed-lineage  kinase  (MLK)  inhibitor  CEP-11004.  This  suggests  that 
induction of ATF-3 may require JNK activity in neurons and that the atf-3 gene might 
be a target of c-Jun.
The  function  of  ATF-3  in  sympathetic  neurons  was  investigated  in 
microinjection  experiments.  Injection  of expression  vectors  for  c-Jun  and  ATF-3 
decreased the survival of sympathetic neurons in the presence of NGF, as measured at 
72  hours  after  injection.  In  contrast,  overexpression  of  ATF-3  or  the  ATF-3 
basic/leucine  zipper  domain  in  the  absence  of  NGF  increased  the  survival  of 
sympathetic neurons. In addition, when ATF-3 expression was knocked down, using a 
pSUPER ATF-3 RNAi expression vector, the amount of cell death observed after 48 
hours of NGF deprivation in neurons was increased.
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13Chapter 1:  Introduction
1.1  Apoptosis
1.1.1  History of apoptosis
The process of cell death was first recognised in the middle of the nineteenth 
century during amphibian metamorphosis (Vogt,  1842). Other examples of cell death 
soon followed: chromatolytic cell death in ovarian follicles, loss of an entire neuron 
population in fish embryos and loss of motor and sensory neurons in chick embryos 
(reviewed  in  Clarke  and  Clarke,  1996).  The  importance  of  cell  death  during 
development was not established until the early  1950s when Glucksmann summarised 
all of the published work on cell death and stated that naturally occurring cell death 
was  observed  at  certain  developmental  stages  during  all  normal  vertebrate 
embryogenesis  (Glucksmann,  1951).  The  term  ‘programmed  cell  death’  was 
introduced to describe a type of cell death that occurred at predictable places and at 
predictable times during development (Lockshin and Williams,  1965).  Inhibitors of 
RNA and protein synthesis were later found to inhibit cell death during amphibian and 
insect  metamorphosis,  indicating  that  macromolecular  synthesis  was  required 
(Lockshin,  1969; Tata,  1966). One further key finding was made by John Saunders, 
who recognized that there were reproducible patterns of cell death in chick embryos 
and  that  death  was  primed  by  time-dependent  intrinsic  stimuli,  which  could  be 
influenced by the environment (Saunders,  1966). In other words, signals from one cell 
could apparently suppress the cell death observed in another.
However,  it  was  not  until  1972  that  the  term  apoptosis  was  defined.  In  a 
landmark paper by Kerr, Wyllie and Currie (Kerr et al.,  1972), they  suggested that 
certain  cells  can  undergo  an  active  form  of cell  death  involving  the  cell’s  own 
biochemical  mechanisms.  Using  classical  ultrastructural  studies,  Kerr  provided 
evidence that cells undergo two very different types of cell death. Necrosis, which had 
already been described, occurs when a cell swells, organelles are destroyed, the cell 
ruptures releasing its contents and this leads to an inflammatory response. In contrast, 
Kerr  also  observed  cells  with  intact  organelles  that  had  shrunken  bodies,  showed 
plasma membrane blebbing and had condensed chromatin (Kerr et al.,  1972). These 
cells,  initially described as “shrunken necrosis” were then rapidly phagocytosed by
14neighbouring  cells  or  macrophages  and  destroyed,  thus  preventing  an  immune 
response.  It was during this time that Kerr and colleagues concluded that the many 
forms of developmental cell death observed by Glucksmann in the 1950s had the same 
features as the cell death they were observing in normal untreated liver and in liver 
cells  treated  with  hepatotoxins  (Kerr,  1969;  Kerr,  1970),  as  well  as  basal  cell 
carcinomas of the skin (Kerr and Searle,  1972). The term “apoptosis” is used in Greek 
to describe the falling of leaves from a tree or petals from a flower and was chosen to 
emphasise  the  importance  of  the  process  during  natural  development  and  as  a 
complementary but opposite role to mitosis.
The idea that a cell has its own built-in death program was not widely accepted 
for almost another 20 years. Kerr and colleagues continued to publish many examples 
of cell death that they now classified as apoptosis, for example, the regression of the 
tadpole tail during metamorphosis (Kerr et al., 1974), the death of proliferating normal 
and neoplastic cells killed by cancer chemotherapeutics (Searle et al.,  1975) and the 
mechanism  of  T-cell  killing  (Don  et  al.,  1977).  In  1980,  Wyllie  reported  that 
thymocytes treated with glucocorticoid undergo apoptosis and that the chromosomal 
DNA was cleaved between nucleosomes by an endonuclease, giving a characteristic 
DNA ladder on an ethidium bromide-stained agarose gel (Wyllie,  1980).  This  is  in 
contrast to cells undergoing necrosis, in which the DNA breakdown  is random and 
results in a diffuse smear. After these findings, another research group published the 
observation  that  radiation  caused  the  DNA  in  lymphocytes  to  break  down  into 
multiples  of  approximately  180  -  200  base  pairs  (Yamada  et al.,  1981).  Wyllie 
incorporated these findings and realised that the DNA ladder formation was indeed a 
hallmark of apoptosis (Wyllie et al.,  1984). This was the first biochemical marker for 
apoptosis and the development of a molecular mechanism to study apoptosis led to a 
rapid expansion of apoptosis research.
Further  interest  in  the  apoptosis  field  was  stimulated  by  work  with  the 
nematode worm Caenorhabditis elegans. Sulston and Horvitz showed that precisely 
131  of the  1090 somatic cells that make up a C. elegans worm, die by apoptosis at a 
precise  time  during  development  (Sulston  and  Horvitz,  1977).  Genetic  studies 
identified genes involved in cell death and its control (Ellis and Horvitz, 1986; Horvitz 
et al.,  1983).  Two  of these  genes,  ced-3 and ced-4  (where  ced  means  ‘cell  death 
abnormal’)  are involved in cell killing, whereas ced-9 is involved in survival. This,
15and the identification of mammalian homologues of these cell death genes (Hengartner 
and  Horvitz,  1994;  Yuan et al.,  1993)  lead to a greater acceptance of an  inherited 
intracellular programme of death within cells.  In  1988, David Vaux,  Suzanne Cory 
and Jerry Adams observed that the principal function of the proto-oncogene bcl-2 is to 
prevent death, and they coined the term ‘survival factor’ (Vaux et al., 1988). Bcl-2, the 
mammalian homologue of ced-9, is the prototype of a family of genes that influence 
cell  survival  by  regulating  the  activity  of  cell  death  effectors.  The  mammalian 
homologues of CED-3, the caspases, cleave cellular substrates at specific aspartic acid 
residues  (Alnemri  et al.,  1996;  Thornberry  et al.,  1997)  and  ultimately  cause  the 
destruction of the cell.
1.1.2  Apoptosis during development
Programmed cell death is an important mechanism in both development and 
homeostasis  in  adult  tissues  for  the  removal  of  either  superfluous,  infected, 
transformed or damaged  cells  and the  elimination  of self-reactive  clones  from  the 
immune  system  (Ellis  et al.,  1991b;  Jacobson  et al.,  1997;  Raff,  1992).  During 
embryogenesis, cell death is involved in  sculpting different parts  of the body.  The 
removal  of the  interdigital  web  between  developing  digits  involves  apoptosis  and 
inhibition of this cell death blocks digit formation (Jacobsen et al., 1996). Cell death is 
also involved in the formation of hollow  structures  such as the preamniotic cavity, 
which is formed by ectodermal cell death (Coucouvanis and Martin,  1995) and in the 
formation of vertebrate neural tube and lens (Weil et al., 1997).
Physiological  apoptosis  occurs  during  development  to  remove  transitory 
organs and tissues, those required by an ancestral species and not the descendent or 
those needed at one stage in development but not another. For example, the pronephric 
tubules that form kidneys  in fish and amphibian  larvae, but which  are not used by 
mammals (Saxen and Sariola, 1987), and during insect and amphibian metamorphosis, 
apoptosis removes cells no longer required such as muscles and neurons involved in 
larval  locomotion  in  insects  or  the  amphibian  tadpole  tail.  This  provides  greater 
flexibility as structures are adapted for different functions at different stages of life or 
in  different  sexes.  The  Mullerian  duct  forms  the  uterus  and  oviduct  in  female 
mammals, but is not needed in males and is thought to be removed by programmed 
cell death (Price et al.,  1977). Conversely, the Wolffian duct forms the vas deferens,
16epididymis and seminal vesicle in males, but is not required in females, and is deleted 
by apoptosis (Smith and Mackay,  1991). In addition, many cells are made in excess 
and later removed by apoptosis when they receive insufficient survival signals. During 
the normal development of the mammalian nervous  system,  apoptosis ensures that 
appropriate connections are made between neurons and their target cells (Oppenheim, 
1991).  It is  thought that neurons  compete  for limiting  amounts  of survival  factors 
produced by their target cells and neurons that fail to obtain sufficient neurotrophic 
support die by apoptosis (Barde,  1989). This would provide a system for eliminating 
cells that are in the wrong place (Raff, 1992).
Finally,  apoptosis  functions  as  part  of  a  quality  control  process  during 
development to ensure that any  abnormal, misplaced,  non-functional or potentially 
dangerous cells are eliminated. In the developing immune system, apoptosis eliminates 
self reactive T and B cells to induce self tolerance (Opferman and Korsmeyer, 2003). 
This  negative  selection  of lymphocytes  by  apoptosis  is  also  used  to  remove  any 
lymphocytes that lack useful antigen receptors. This is again a further example of a 
situation in which cells are produced in vast excess and the numbers are reduced by 
apoptosis when only appropriate signals are available.  During development, when a 
cell  becomes  damaged,  for example the  DNA,  it undergoes  apoptosis  if unable to 
repair the damage (Clarke et al.,  1993; Lowe et al.,  1993).  This  serves  as  an  anti­
cancer mechanism and prevents  any  defects  in  DNA  being  passed onto  offspring. 
Apoptosis may also be involved in the production of specialised differentiated cells. 
Cells  such  as  skin  keratinocytes  and red blood cells,  lose  their nucleus  and  other 
organelles  in  the  process  of differentiation  and  it  has  been  suggested  that  these 
processes may be modified forms of programmed cell death (Testa, 2004; Weil et al., 
1999).
The regulation of cells by apoptosis continues into the adult organism and is 
required  for homeostasis  to maintain  stability  and to  survive.  The  maintenance of 
tissues such as bone and gastric epithelium as well as the removal of excess immune 
cells after infection require apoptosis. Harmful cells, for example, those infected with 
virus,  cells  in  which the  DNA  has become  damaged,  or inappropriately  generated 
autoreactive T-cells, are also eliminated by apoptosis.
171.1.3  Apoptosis and disease
In the adult organism, the number of cells within an organ or tissue has to be 
constant  within  a  certain  range.  Blood  and  skin  cells  for  instance,  are  constantly 
renewed by their respective progenitor cells, but proliferation has to be compensated 
by  cell  death.  Lymphocytes  and  cells  within  reproductive  organs  undergo  cyclic 
expansions  and  contraction  as  they  take  part  in  host  defence  and  reproduction, 
respectively.  In contrast,  neural cells have  a limited capacity  for self-renewal,  and 
most neurons survive for the life of the organism. This balancing process is part of the 
homeostasis required by living organisms. Homeostasis is achieved when the rate of 
mitosis in the tissue is balanced by cell death. If this equilibrium is disturbed, either of 
two  things  happens:  1)  The  cells  are  dividing  faster  than  they  die,  effectively 
developing a tumour, or 2) The cells are dividing slower than they die, which results in 
a disorder of cell loss. Both states can be fatal or highly damaging. Failure of cells to 
undergo apoptosis may be involved in the pathogenesis of a variety of human diseases, 
including  cancer,  autoimmune  disorders  and  viral  infections  (Hoffman  and 
Liebermann, 1994; Thompson, 1995). In addition diseases that can arise from cell loss, 
such as  neurodegenerative disorders, AIDS  (acquired immunodeficiency syndrome) 
and ischaemic injury, have been suggested to involve accelerated rates of apoptosis 
(Akhtar et al., 2004; Estus et al.,  1997; Meyaard et al.,  1992; Namura et al.,  1998; 
Rasola et al., 2001; Thompson, 1995; Vila and Przedborski, 2003).
Cell proliferation is highly regulated, with growth factors and proto-oncogenes 
as  positive  regulators  and  tumour  suppressors  acting  to  oppose  uncontrolled  cell 
proliferation (Levine,  1993; Rozengurt,  1992). Normal cells depend on environmental 
stimuli to maintain their viability and prevent their survival in inappropriate locations 
(Boudreau  et al.,  1995;  Cyster  et al.,  1994;  Raff,  1992;  Williams  et  al.,  1990). 
Metastatic tumour cells, however, are able to overcome these limitations and survive 
at sites distinct from the tissue in which they arose. This is accomplished by alterations 
in the level of expression or function of genes controlling both survival and apoptotic 
signaling  pathways.  The  bcl-2  proto-oncogene  was  initially  identified  in  B-cell 
lymphoma at the  t( 14; 18)  translocation (Cleary  and  Sklar,  1985;  Tsujimoto  et al., 
1985). This translocation results in inappropriate bcl-2 activation and cell survival. It 
was discovered that Bcl-2 acts as a survival factor in cells by preventing apoptosis 
induced by various stimuli (Hockenbery et al.,  1990; Hockenbery et al.,  1993; Nunez
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tumour cells and Bcl-2 expression has been linked to poor prognosis in prostate and 
colon cancers and neuroblastoma (Castle et al.,  1993; Hague et al.,  1994; McDonnell 
et  al.,  1992).  The  tumour  suppressor p53  is  the  most  frequently  mutated  gene  in 
human tumours. It plays a key role in DNA damage repair, cell cycle regulation and 
cellular apoptosis  (Vogelstein  et  al.,  2000).  Thus,  cells  with  aberrant  p53  can  no 
longer initiate apoptosis in response to damaging signals, such as genotoxic stress (Lee 
and Bernstein,  1993; Lowe et al.,  1993).  Failure to die in response to DNA damage 
would result in  cells  with  translocations  or mutations  in  their DNA  surviving  and 
developing into tumours. In addition, the proapoptotic Bcl-2 family members Noxa 
and Puma have been  shown to be direct targets of p53  in  some cells (Nakano and 
Vousden, 2001; Oda et al., 2000; Yu et al., 2001). The apoptotic protease activating 
factor-1   (Apaf-1)  has  been reported as  a transcriptional  target of p53  during  DNA 
damage induced apoptosis in lymphoblastoid cell lines and in neurons (Fortin et al., 
2001; Robles et al., 2001).
Physiological apoptosis is essential for the removal of potentially autoreactive 
lymphocytes during development and for the removal  of excess cells  following an 
immune  response.  Failure  to  remove  these  cells  can  lead  to  autoimmune  disease. 
Stimulation  of  lymphocytes  with  Fas  can  induce  apoptosis  (Dhein  et  al.,  1994; 
Krammer  et  al.,  1994;  Trauth  et  al.,  1989)  and  at  least  two  forms  of  inherited 
autoimmune  disease  had  been  attributed  to  alterations  in  Fas-mediated  apoptosis 
(Drappa et al., 1996; Fisher et al., 1995; Rieux-Laucat et al., 1995).
Excessive apoptosis can cause unwarranted cell death and may lead to diseases 
such  as  immunodeficiency  and  neurodegeneration.  Virus-induced  lymphocyte 
depletion occurs with AIDS, induced by the human immunodeficiency virus (HIV). 
The development of AIDS is associated with depletion of CD4+ T cells. CD4 acts as 
the receptor for viral attachment, facilitating infection. CD4 receptor stimulation has 
been proposed to enhance susceptibility to apoptosis (Banda et al.,  1992; Meyaard et 
al.,  1992). Viral genes have been proposed to induce apoptosis. The HIV protein nef 
causes an increased apoptotic response and down-modulation of Bcl-2 and Bcl-xL  in T 
cell lines (Rasola et al., 2001). In addition, levels of TNF-related apoptosis-inducing 
ligand (TRAIL) are elevated in plasma of HIV-l-infected patients and may contribute 
to  the  death  of CD4+  T  cells  (Herbeuval  et al,  2004).  A  variety  of neurological
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instances involves apoptosis (see section 1.3.2).
1.2  The molecular mechanisms of apoptosis
1.2.1  Programmed cell death in Caenorhabditis elegans
One  of the  best characterised developmental  models  of apoptosis  is  in  the 
nematode C.  elegans  and much of the knowledge  about the  molecular genetics  of 
programmed  cell  death  comes  from  work  performed  on  these  worms.  In  the 
hermaphrodite,  131  of the  1090 original somatic cells formed are destined to die by 
apoptosis, the majority of which are neuronal cells (Sulston and Horvitz,  1977). Genes 
involved  in  the  death  process  were  identified  through  genetic  screens  for mutants 
defective in cell death, leading to the identification of a core apoptotic pathway that is 
evolutionarily conserved (Metzstein  et al.,  1998).  The  first  gene  discovered  in  the 
programmed cell death system, was egl-1 (egg laying defective). This gain-of-function 
mutation caused death of two neurons innervating the vulva, and hence the egg laying 
defect. A number of ced genes (cell death abnormal) were identified as regulators of 
the death process.  Loss-of-function mutations in two of the genes, ced-3 and ced-4, 
were  shown  to  allow  survival  of the  131  somatic  cells  that  normally  die  during 
development  (Ellis  and  Horvitz,  1986;  Yuan  and  Horvitz,  1990). Egl-1  loss-of- 
function mutations also lead to survival of all of the  131  doomed cells (Conradt and 
Horvitz,  1998).  These  gene products  are required for the killing  process,  whereas, 
another ced gene, ced-9 protects cells from undergoing apoptosis. C. elegans lacking 
functional ced-9 die early in development due to massive ectopic cell death, whereas a 
gain-of-function  mutation  in  ced-9 blocks all  cell death  (Hengartner et al.,  1992). 
Interestingly mutant nematodes that have a block in cell death have a normal life span, 
even though they have about  15% more cells and function less well than  wild-type 
worms (Ellis et al.,  1991b). Ced-3 encodes a caspase (section 1.2.2.1), part of a family 
of cysteine proteases that are responsible for the cleavage of critical cellular substrates 
at aspartate residues, and are key components of the cell death machinery (Thomberry 
and Lazebnik,  1998).  CED-4 is a positive regulator of CED-3  (Yang et al.,  1998b). 
This  adaptor  protein  encoded  by  ced-4  is  homologous  to  the  mammalian  Apaf-1 
involved in apoptosome formation (section  1.2.2.4).  Ced-9 encodes an antiapoptotic
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gene  product  has  homology  with  the  Bcl-2  family  of proteins  and  binds  CED-4, 
maintaining it in an inactive state, in which it cannot activate CED-3 (Chinnaiyan et 
al.,  1997; Hengartner and Horvitz,  1994). In addition, CED-9 is negatively regulated 
by EGL-1 (Conradt and Horvitz, 1998), a protein homologous to the mammalian BH3- 
only Bcl-2 family members (section 1.2.2.2), forming a cascade of cell death proteins. 
Only  when  CED-4  is  displaced  from  CED-9  by  EGL-1,  is  the  lethal  proteolytic 
activity of CED-3 released in the dying cells. These proteins form the core regulators 
of C.  elegans  programmed  cell  death  and  are  evolutionarily  conserved  in  both 
Drosophila melanogaster and mammals.
Additional genetic screens identified many other genes -  ced-1, ced-2, ced-5, 
ced-6,  ced-7,  ced-10  and  ced-12  -  that are  required  for the  efficient clearance  of 
apoptotic cells (Chung et al., 2000; Ellis et al.,  1991a; Hedgecock et al.,  1983). Genes 
involved  in  the  death  of specific  cells,  for  example  neurosecretory  motoneurons 
(NSM)  sister cells,  have been  identified.  Ces-1  gain-of-function and ces-2  loss-of- 
function mutations allow survival of the NSM sister cells that are normally destined to 
die  (Ellis  and  Horvitz,  1991).  Ces-1  and ces-2  encode  transcription  factors  that 
regulate egl-1  expression in specific cells (Metzstein et al.,  1996; Thellmann et al., 
2003).
1.2.2  Caspase mediated apoptotic cell death
Apoptosis  can  be  triggered  by  many  different  stimuli,  both  intrinsic  and 
extrinsic. These signals feed into an evolutionary conserved intracellular machinery of 
execution (Green, 2000; Hengartner, 2000), which mainly involves the activation of 
caspases.  Cell  death  can  be  classified  into  three  major pathways  according  to  the 
initiator  caspase  involved:  the  death  receptor  pathway  involving  caspase-8,  the 
mitochondrial  pathway,  in  which  proapoptotic  proteins  are  released  from  the 
mitochondria and which leads to the activation of caspase-9 and effector caspase-3, -6 
or -7, and the ER stress pathway, which involves caspase-12 activation.
1.2.2.1  Caspases
The  key  effector  enzymes  of apoptosis  are  caspases,  a  distinct  family  of 
cysteine proteases that share the ability to cleave their substrates on the carboxyl side
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was  originally  designated  interleukin-1  (3-converting  enzyme,  ICE  (Cerretti  et  al., 
1992; Thornberry et al.,  1992), and found to be homologous to the C. elegans gene 
product ced-3 (Xue et al.,  1996; Yuan et al.,  1993). Since then at least 14 mammalian 
caspases  have been discovered that exist in cells  as  inactive  zymogens,  about two 
thirds  of  which  are  implicated  in  apoptosis.  These  can  be  grouped  according  to 
function.  Caspases-1,  -4,  -5,  -11,  -13  and -14 are thought to mainly be involved in 
cytokine  processing.  In  particular,  caspase-1  and  caspase-11  process  the 
proinflammatory cytokines IL-1  and IL-8 (Kuida et al.,  1995; Li et al.,  1995a; Wang 
et al.,  1998b). Caspase-12 has been shown to be involved in the ER stress pathway in 
mice (section 1.2.2.5). Caspases-2, -3, -6, -7, -8, -9 and -10 are implicated in apoptosis 
(Bergeron  et al.,  1998;  Hakem  et al.,  1998;  Kuida  et al.,  1996;  Nicholson,  1999; 
Varfolomeev et al., 1998).
Although caspases differ in their primary sequence and substrate specificity, 
they  share  several  features.  Each  caspase  is  made  up  of a  tetramer,  a 2(32,  of two 
identical large (17-22 kDa) subunits and two identical small (10-12 kDa) subunits. In 
addition,  each  caspase  is  synthesised  as  an  inactive  zymogen  that  contains  an  N- 
terminal  prodomain,  a large  subunit and  a  small  subunit,  and each  is  activated by 
cleavage into the mature caspase protein. On the basis of structural studies of caspases 
associated with inhibitors and more recently the structure of free caspase-7, a general 
mechanism for caspase activation has emerged (Piana et al., 2003). The proteolytic 
cleavage of a caspase occurs either by autocatalysis or by an upstream protease and 
induces  a dramatic  conformational change that exposes  the catalytic  pocket of the 
enzyme. A caspase that cleaves and activates itself is called an initiator caspase and 
can  go on  to trigger downstream  signalling cascades  that lead to the  activation  of 
executioner caspases.  The  executioner caspases  go on to cleave  numerous  cellular 
targets to destroy normal cellular functions, activate other apoptotic factors, inactivate 
antiapoptotic proteins and eventually lead to the death of the cell (Nicholson, 1999).
The  initiator caspases,  caspase-2,  -8,  -9 and -10 have  long prodomains  with 
motifs  that facilitate  protein-protein interaction,  such  as  the death  effector domain 
(DED) and the caspase activation and recruitment domain (CARD). These caspases 
are regulated mainly through autoproteolytic cleavage, which has been proposed to 
occur through an induced proximity model (Muzio et al.,  1998; Salvesen and Dixit,
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pathway, in  which binding of ligand to receptor,  recruits  procaspase-8  via adaptor 
proteins to the intracellular side of the plasma membrane. This results in a high local 
concentration of zymogen molecules, which mutually cleave and activate one another. 
The  initiator  caspase-9  has  a  more  complex  activation  mechanism.  Proteolytic 
processing of caspase-9 has only a minor effect on the enzyme’s activity (Rodriguez 
and  Lazebnik,  1999;  Stennicke  et al.,  1999)  The  key  requirement  for  caspase-9 
activation is association with Apaf-1. Cytochrome c is released from the mitochondria 
during  apoptosis  and  binds  Apaf-1,  ATP  and  caspase-9  to  from  a  holoenzyme 
complex, the apoptosome (Cain et al., 2000; Li et al., 1997a; Rodriguez and Lazebnik, 
1999;  Zou  et al.,  1997).  This  complex  contains  active  caspase-9,  which  cleaves 
downstream effector caspases, such as caspase-3.
Caspases-3, -6 and -7 are effector caspases. Their inactive zymogens have short 
prodomains that lack any intrinsic enzymatic activity.  Proteolytic cleavage between 
the large and small subunits leads to their activation. In addition, these caspases may 
be regulated by transcription in certain circumstances.  Procaspase-3, for example, is 
present at high levels in many lymphoid and mature myeloid cells but present at low 
levels in breast epithelium and normal neurons (Krajewska et al.,  1997). Studies have 
shown elevated procaspase-3 in neurons following apoptotic insult (de Bilbao et al., 
1999; Ginham et al., 2001; Ni et al., 1998).
Effector  caspases  selectively  cleave  a  restricted  set  of target  polypeptides 
(possibly fewer than 200), usually at one, or at most a few positions in the primary 
sequence (Nicholson,  1999). This most commonly leads to inactivation of the target 
protein,  but  has  also  been  reported  to  activate  proteins,  either  by  cleaving  off a 
negative regulatory domain or inactivating a regulatory subunit. One of the hallmark 
events of apoptosis  is the breakdown of chromosomal  DNA into oligonucleosomal 
fragments.  Caspase-3  activates  CAD  (caspase-activated  DNase),  by  cleaving  its 
inhibitory  subunit (ICAD), allowing it to cut the genomic DNA (Nagata, 2000).  In 
addition,  caspases  can  disable  normal  DNA  repair  processes  by  inactivating 
poly(ADP-ribose)  polymerase  (PARP)  and  DNA-PK,  further  contributing  to  the 
changes  in  DNA  integrity.  Other  targets  of the  caspases  include  nuclear  lamins, 
leading to nuclear shrinkage and budding, and cytoskeletal proteins such as fodrin and 
gelsolin, causing an overall loss of cell shape (Buendia et al.,  1999; Kothakota et al.,
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example,  caspase-8  cleaves  Bid  to  generate  active  tBid,  which  activates  the 
mitochondrial pathway as described in section 1.2.2.3. The antiapoptotic proteins Bcl- 
2 and Bcl-xL  can be cleaved by caspases, converting them into proapoptotic proteins 
(Cheng et al., 1997; Clem et al., 1998; Grandgirard et al., 1998). It has been suggested 
that cleavage removes the protective function of these proteins.
Caspases are regulated by inhibitor-of-apoptosis proteins (IAPs). This family 
includes cIAPl, cIAP2, XIAP, NAIP,  survivin and livin in humans.  These proteins 
inhibit caspases by directly binding to the active enzymes via a BIR (baculovirus IAP 
repeat) domain (Deveraux et al.,  1997; Salvesen and Duckett, 2002; Takahashi et al.,
1998).  IAP proteins contain one or more N-terminal BIR domains and a C-terminal 
RING domain (Deveraux and Reed,  1999; Miller,  1999). The RING domains can act 
as  ubiquitin  ligases,  facilitating  ubiquitination  and  proteosomal  degradation  of the 
bound  caspases  (Huang  et al.,  2000;  Yang  et  al.,  2000).  Some  IAP  proteins  are 
aberrantly up-regulated in certain cancer tissues (Dierlamm et al.,  1999; Imoto et al., 
2001; Vucic et al., 2000). The IAP proteins are in turn regulated through inhibition by 
mammalian SMAC / DIABLO (second mitochondrial-derived activator of apoptosis / 
direct  IAP-binding  protein  with  low  pi),  which  is  released  from  the  mitochondria 
along  with  other proteins  following  activation  of the  mitochondrial  death  pathway 
(section  1.2.2.4).  Caspases  also  appear  to  be  regulated  by  post-translational 
modifications. For  example,  in  TPA  or  EGF-treated  HeLa  cells,  ERK-mediated 
phosphorylation  of caspase-9  at  Thr  125  blocks  the  processing  of caspase-9  and 
subsequent caspase-3 activation (Allan et al., 2003).
1.2.2.2  Bcl-2 family
The Bcl-2 family of proteins are critical regulators of apoptosis, which can act 
as  either  proapoptotic  or  antiapoptotic  molecules,  based  on  their ability  to  kill  or 
protect  cells  in  vitro  and  the  effect  of  gene  knockout  on  cell  death  and  tissue 
homeostasis  in  mice.  The  Bcl-2  proto-oncogene  was  initially  identified  in  B-cell 
lymphoma  at the  t( 14; 18)  translocation  (Cleary  and  Sklar,  1985;  Tsujimoto  et al., 
1985). Bcl-2 is an integral membrane protein mainly localised to the mitochondria, but 
also found in the ER (Akao et al.,  1994; Lithgow et al.,  1994). At the mitochondria, 
Bcl-2  family  members  function  to  control  the  release  of cytochrome  c  and  other
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characterised  by  the  presence  of up  to  four  alpha-helical  Bcl-2  homology  (BH) 
domains,  designated  BH1-4.  Most antiapoptotic  proteins  contain  all  four domains, 
whereas the proapoptotic proteins contain either BH1-3 or BH3 only. These proteins 
have the ability to form homo- or heterodimers, altering their function within the cell.
The  antiapoptotic  members  prevent  the  release  of  mitochondrial  proteins 
involved in apoptosis, by interacting with and inhibiting proapoptotic family members, 
such as Bax (Antonsson et al., 2001; Cheng et al., 2001). In mammals, members of 
this sub group include Bcl-2, Bcl-xL, Bcl-W, Mcl-1, Al/BFL-1, BOO/DIVA and NF- 
13. The BH4 domain of these proteins is required for antiapoptotic activity (Huang et 
al.,  1998; Sugioka et al., 2003). The proapoptotic Bcl-2 family members can be spilt 
into two subfamilies according to their homology with Bcl-2. Bax, Bak and Bok/Mtd 
contain BH1-3 and resemble Bcl-2 fairly closely. In contrast, the other proapoptotic 
members contain only the short (9-16 residue) BH3 domain of Bcl-2 and are otherwise 
unrelated to any known protein. These BH3-only proteins are potent cell killers and 
include, Bid, Bad, Bim, Blk, Bik, Bmf, Hrk/DP5, Bnip3, Nix, Noxa and Puma. The 
BH3 domain of these proteins and of the other proapoptotic members has been shown 
to be essential for their proapoptotic activity (Chittenden et al.,  1995; O'Connor et al., 
1998; Wang et al.,  1998a; Zha et al.,  1997). Replacement of the BH3 region of Bcl-2 
by the BH3 region of Bax converts Bcl-2 from a death antagonist to a death agonist 
(Hunter and Parslow,  1996),  suggesting that there  is  a critical  sequence difference 
which distinguishes the BH3 domain of the antiapoptotic and proapoptotic members of 
the family. Proapoptotic and antiapoptotic members can heterodimerise and influence 
each other’s function, suggesting that their relative concentrations within a cell may 
act as a rheostat for the suicide program (Oltvai et al., 1993).
When  cells  are  exposed  to  apoptotic  stimuli,  proapoptotic  proteins  are 
activated through post-translational modifications or changes in their conformation, as 
well as transcriptional controls. Activation of Bax and Bak involves the translocation 
of cytosolic  monomeric  proteins  to the mitochondrial  membrane,  the formation  of 
oligomers within the membrane and the release of cytochrome c (Gross et al.,  1998; 
Korsmeyer et al., 2000; Wolter et al., 1997). The antiapoptotic proteins Bcl-2 and Bcl- 
xL   localise  to  the  outer  mitochondrial  membrane  and  inactivate  Bax  by 
heterodimerising  with  the  proapoptotic  protein,  preventing  the  formation  of Bax
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only  protein  Bim  is  transcriptionally  controlled  and  also  translocates  to  the 
mitochondria following certain apoptotic stimuli, such as after NGF withdrawal from 
sympathetic  neurons  (Putcha et al., 2001; Whitfield et al.,  2001).  The  cleavage  of 
proapoptotic Bcl-2 family members is another mechanism of regulation.  The BH3- 
only  protein  Bid is cleaved into tBid by caspase-8  during  death receptor-mediated 
apoptosis. This truncated protein then translocates to the mitochondria, where it can 
oligomerise with Bax and Bak to form pores in the membrane (Korsmeyer et al., 2000; 
Li et al.,  1998; Luo et al.,  1998a). In contrast, Bad is regulated by phosphorylation. In 
haematopoietic cells for example, IL-3 stimulation leads to Bad phosphorylation and 
its sequestration in the cytosol by binding to  14-3-3 proteins which prevents it from 
binding to and inhibiting Bcl-xL  (del Peso et al.,  1997; Zha et al.,  1996). Following a 
death signal, such as IL-3 deprivation, Bad becomes dephosphorylated and is found 
associated with Bcl-xL -Bcl-2  and this  interaction  requires  the  BH3  domain  of Bad 
(Kelekar  et al.,  1997;  Ottilie  et al.,  1997;  Zha et al.,  1997).  In  addition,  survival 
signals such as the P-I3K/Akt pathway can directly phosphorylate Bad and inhibit its 
ability  to  induce  apoptosis  (Datta  et  al.,  1997;  del  Peso  et  al.,  1997).  Some 
proapoptotic members are transcriptionally controlled, for example, Noxa and Puma 
are under p53 mediated transcriptional control in response to DNA damage (Nakano 
and  Vousden,  2001;  Oda  et  al.,  2000;  Yu  et al.,  2001).  NGF-withdrawal  from 
sympathetic  neurons  leads  to  increased  expression  of the  BH3-only  protein  DP5 
(Imaizumi et al., 1997).
The pro-survival members of the Bcl-2 family, such as Bcl-2 or Bcl-xL , serve a 
principal, although perhaps not an exclusive role of binding and sequestering BH3- 
only  molecules,  preventing  Bax  or  Bak  activation  (Cheng  et  al.,  2001).  Post- 
translational modification of the Bcl-2 protein has been described in a variety of cell 
models  with  effects  varying  from  enhanced  to  abrogated  function.  Bcl-2  may  be 
activated by phosphorylation at Ser70, but inactivated when phosphorylated perhaps 
by  JNK  at  loop  sites  in  the  protein  which  may  initiate  a  conformational  change 
(Brichese et al., 2004; Haidar et al.,  1997; Ito et al.,  1997;  Maundrell et al.,  1997). 
Bcl-xL  can also undergo phosphorylation, which is thought to negatively regulate its 
activity (Basu and Haidar, 2003; Chang et al.,  1997). Transcriptional regulation can 
also play a part in controlling the activity of antiapoptotic members of the Bcl-2 family
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myeloid progenitor cells (Boise et al.,  1995; Catz and Johnson, 2001; Karlsson et al., 
2003; Lin et al., 1993; Yang et al., 1996).
Bax-deficient mice are viable demonstrating it is not essential for development, 
however,  these  animals  have  abnormalities  in  haematopoietic,  neuronal  and 
gametogenic development (Knudson and Korsmeyer, 1997; Knudson et al., 1995). For 
example, neuronal cell death in the peripheral and central nervous system is decreased, 
in particular sympathetic neurons absolutely require endogenous Bax expression and 
translocation for apoptosis (Deckwerth et al.,  1996;  Deshmukh and Johnson,  1998; 
Putcha et al., 1999; White et al., 1998). Bak knockout mice are viable without obvious 
age-related abnormalities, however box' bak1 ' mice have a dramatic phenotype with 
90% perinatal lethality (Lindsten et al., 2000). These animals have interdigital webs, 
an  accumulation  of neurons  within  the  central  nervous  system  and  splenomegaly. 
Embryonic fibroblasts from the double knockouts show resistance to many apoptotic 
stimuli such as UV radiation and serum withdrawal.
Bcl-2-deficient mice  are  viable  despite  the  widespread  expression  of Bcl-2 
during development (Merry et al.,  1994; Novack and Korsmeyer,  1994). The mice are 
runted and die a few months after birth due to renal failure. In addition, a lack of Bcl-2 
causes  premature  loss  of  lymphoid  cells  and  melanocytes,  resulting  in 
immunodeficiency and loss of hair pigmentation, respectively (Nakayama et al.,  1993; 
Veis  et al.,  1993).  Bcl-xL   deficient  mice  die  at  E13  with  extensive  apoptosis  of 
postmitotic differentiating neurons in the developing brain, spinal cord and dorsal root 
ganglia (Motoyama et al., 1995).
Mouse models of the BH3-only family members also exist.  The majority of 
Bim-deficient mice die during embryonic development around E9.5 (Bouillet et al.,
1999). Survivors have abnormal homeostasis within the haematopoietic compartment. 
The  absence  of  Bim  increases  the  survival  of resting  lymphocytes  and  protects 
activated T and B cells against cytokine withdrawal. With age, Bim-deficient animals 
demonstrate progressive lymphadenopathy and splenomegaly with a dramatic increase 
in  plasma cell  numbers  and corresponding immunoglobulin  levels  (Bouillet et al., 
1999; O'Reilly et al., 2000). Neurons from bim1 ' mice show delayed developmental 
and induced apoptosis (Putcha et al., 2001). Mice deficient in DP5 are fertile, show no 
gross abnormalities, and appear normal (Imaizumi et al., 2004). Analysis of neuronal
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axotomy-induced motoneuron death in vivo.
1.2.2.3  The death receptor pathway
Receptor-mediated  apoptosis  has  been  demonstrated  for  numerous  growth 
factors, including transforming growth factor |3 and cytokines, such as tumour necrosis 
factor  (TNF)  (Oberhammer et  al.,  1992;  Shinagawa  et al.,  1991).  This  extrinsic 
pathway is recruited through activation of cell-surface receptors, such as Fas/CD95, 
TRAIL  receptors,  and  the  tumour necrosis  factor receptor  1  (TNFR1).  This  large 
family  of death  receptors  are  transmembrane  proteins  expressed on  the  surface  of 
target cells.  Fas  ligand (FasL)  binds  to the Fas receptor,  TRAIL binds  the TRAIL 
receptors, DR4 and DR5, and TNF and lymphotoxin a  bind to TNFR1 (Ashkenazi and 
Dixit,  1998).  The  N-terminus  on  the  extracellular  side  of the  membrane  contains 
between one and six ligand binding domains. Within the cell, the C-terminus consists 
of a  60-70  residue  region,  known  as  the  death  domain  (DD).  Upon  activation  by 
ligand, the receptors form a cluster, bringing together the death domains. This leads to 
the  recruitment  of  adaptor  proteins  FADD  (Fas/APO-1-associated  death  domain 
protein),  TRADD  (TNFR1-associated  protein  with  death  domain),  RIP  (receptor 
interacting protein), RAIDD (RIP-associated ICH-1  homologous protein with a death 
domain) or MADD (MAP kinase-activating death domain protein) depending on the 
receptor (Boldin et al.,  1995; Chinnaiyan et al.,  1995; Duan and Dixit,  1997; Hsu et 
al.,  1995; Schievella et al.,  1997; Stanger et al.,  1995). The binding of these adaptor 
proteins  with  death  effector domains  (DEDs)  leads  to  the  formation  of the  death- 
inducing signalling complex (DISC), and it is this DISC that recruits the precursor 
enzymes,  procaspase-8  or procaspase-10,  leading  to their activation  by  proximity- 
induced self cleavage and/or dimerisation (Muzio et al.,  1998;  Salvesen  and Dixit, 
1999; Shi, 2004).
At this point, death receptor signalling diverges in different cells (see Figure 
1.1).  In type I cells formation of the DISC leads to recruitment of procaspase-8, its 
cleavage  and  therefore  activation  of caspase-8  (Muzio  et al.,  1998),  which  then 
directly cleaves and activates procaspase-3.  In type II  cells,  caspase-8  activation  is 
much less efficient and generally insufficient to activate caspase-3. However, in these 
cells  activated caspase-8  activates other caspases  indirectly  by  cleaving  the  Bcl-2
28family  member  Bid.  Truncated  Bid  (tBid)  subsequently  goes  on  to  activate  the 
mitochondrial  pathway  by  translocating  to  the  mitochondria  and  triggering  Bax 
oligomerisation (Wei et al., 2000). This leads to the release of multiple polypeptides 
from the mitochondria, including cytochrome c. This binds to Apaf-1  and causes an 
ATP-dependent conformational  change  that results  in  Apaf-1  oligomerisation,  and 
binding  to  procaspase-9  (Li  et al.,  1997a).  The  formation  of  this  complex,  the 
apoptosome,  results  in  procaspase-9  cleavage  to  caspase-9,  which  in  turn 
proteolytically activates caspase-3 (section  1.2.2.4). This provides a means of cross­
talk and integration between the death-receptor and mitochondrial pathways, however, 
under most conditions cross-talk is minimal. The existence of these distinct pathways 
is supported by genetic and biochemical experiments. Targeted disruption of the genes 
for FADD and procaspase-8 renders cells resistant to death receptor ligands, but not to 
ionizing radiation or anti-cancer drugs in vitro. Also, disruption of Bid prevents FasL- 
induced hepatic damage in vivo, but not immune cell death (Gross et al.,  1999; Yin et 
al.,  1999). Bid-deficient mice undergo developmental cell death relatively normally, 
which contrasts sharply with the embryonic lethality of FADD or caspase-8 deficiency 
(Varfolomeev et al., 1998; Yeh et al., 1998).
There  are  three  distinct  mechanisms  involved  in  the  regulation  of  death 
receptor activity. Inhibitors of procaspase recruitment and/or activation of the DISC 
have been  identified (Hu et al.,  1997; Inohara et al.,  1997),  such as cFLIP (FLICE 
inhibitory protein). FLIP has two isoforms FLIP-long and FLIP-short, which bind to 
FADD, procaspase-8 and procaspase-10, via their DED domains (Irmler et al.,  1997). 
This interaction blocks procaspase processing at the DISC. Cells transfected with FLIP 
are resistant to death receptor-induced stimuli, but not other apoptotic stimuli, such as 
UV-irradiation. Another mechanism of regulation is through the expression of decoy 
receptors  closely  related to  the TRAIL receptors  DR4  and  DR5  (Golstein,  1997). 
These either lack the cytoplasmic domain (DcRl) or have a truncated death domain in 
the cytoplasmic region (DcR2) and thus are unable to activate downstream signalling. 
These  receptors  sequester TRAIL  ligand  away  from  the  DR4  and  DR5  receptors 
(Marsters et al.,  1997). Another decoy receptor (DcR3) has been described, that can 
bind to FasL and thus prevent FasL from binding to Fas (Pitti et al.,  1998). The third 
mechanism of regulation is through direct inhibition of the proteolytic activity of the 
initiator procaspases,  such as procaspase-8  and -10.  For example,  the  viral  protein
29Figure 1.1  The death receptor pathway
The extrinsic death receptor pathway is activated when death ligands bind to 
their specific  cell  surface  death  receptors.  For example,  the binding of Fas  ligand 
(FasL) binds to the Fas receptor, leads to its activation. The cytoplasmic domain of the 
receptor contains a death domain (DD). Upon activation by ligand, the receptors form 
a  cluster,  bringing  together  the  death  domains  and  leading  to  the  recruitment  of 
adaptor proteins,  such as FADD (Fas/APO-1 -associated death domain protein). The 
binding of these adaptor proteins  with death effector domains (DEDs) leads to the 
formation of the death-inducing signalling complex (DISC), and it is this DISC that 
recruits  the  precursor  enzymes,  procaspase-8  or  procaspase-10,  leading  to  their 
activation. At this point, death receptor signalling diverges in different cells. In type I 
cells, the activated caspase-8  directly cleaves and activates procaspase-3.  In type II 
cells, activated caspase-8 cleaves the Bcl-2 family member Bid to form truncated Bid 
(tBid). This activates the mitochondrial pathway by translocating to the mitochondria 
and triggering Bax oligomerisation. This leads to the release of multiple proapoptotic 
polypeptides from the mitochondria, including cytochrome c. This binds to Apaf-1 and 
procaspase-9,  forming  the  apoptosome.  The  formation  of this  complex  results  in 
procaspase-9 cleavage to caspase-9, which in turn proteolytically activates caspase3. 
This  provides  a means of cross-talk and integration between the death-receptor and 
mitochondrial pathways.
Taken from (Kaufmann and Hengartner, 2001).
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31crmA can inhibit both the autoproteolytic activation of procaspase-8  as well as the 
ability  of caspase-8  to cleave Bid  (Komiyama et al.,  1994;  Ray  et al.,  1992).  The 
silencer of death domains (SODD) is associated with the death domain of the TNFR1 
in  the  absence  of TNF treatment,  preventing  spontaneous  activation  (Jiang et al., 
1999).
1.2.2.4  Mitochondrial pathway
The  mitochondrion  is  the  central  energy  store  within  a cell,  containing  the 
respiratory assembly, the enzymes of the citric acid cycle and the enzymes of fatty 
acid  oxidation.  However,  the  mitochondria  also  play  a  central  role  in  apoptosis 
triggered by  many  stimuli, by releasing proapoptotic  proteins  into the  cytosol  (see 
Figure  1.2). Mitochondria integrate upstream death signals through the Bcl-2 family 
members and coordinate caspase activation through the release of cytochrome c as a 
result of the outer mitochondrial membrane becoming permeable. The discovery that 
cytochrome c was a critical component of caspase activation, came from studies using 
a cell-free system to study caspase activation in vitro (Liu et al.,  1996).  It was found 
that addition of dATP induced activation of caspase-3, a major executioner caspase in 
HeLa  cell  cytosolic  extracts.  Purification  of the  first  protein  required  for  dATP- 
triggered  caspase-3  activation  turned  out  to  be  cytochrome  c.  Further  analysis 
identified  two  other components,  Apaf-1  and  caspase-9,  as  being  required  for the 
activation  of  downstream  caspases  (Li  et  al.,  1997a;  Zou  et  al.,  1997).  When 
cytochrome  c  is  released  from  the  mitochondria,  it  accumulates  in  the  cytoplasm 
where it binds to Apaf-1  forming the oligomeric Apaf-1/cytochrome c apoptosome in 
the  presence  of  ATP.  This  complex  then  recruits  procaspase-9  and  induces  its 
activation.  Unlike  conventional  caspase  activation,  in  which  complete  proteolytic 
cleavage of the caspase is both necessary and sufficient for its activation, caspase-9 
activation requires constant association of the enzyme with the apoptosome (Jiang and 
Wang,  2000;  Rodriguez  and  Lazebnik,  1999).  The  apoptosome  consists  of seven 
molecules  of Apaf-1,  arranged in a symmetrical  wheel-like  structure.  Each  Apaf-1 
molecule  interacts  with  the  adjacent Apaf-1  molecule  via their N-terminal  CARD 
domain  in  the  centre  of the  structure  (Acehan  et al.,  2002).  This  region  recruits 
procaspase-9 through CARD domain interaction and induces a conformational change
32in the enzyme, leading to an active holoenzyme complex that activates downstream 
effector caspases, such as caspase-3 and caspase-7.
Mice  deficient in  caspase-3,  caspase-9  or Apaf-1  have  a similar phenotype 
(Cecconi  et al.,  1998;  Hakem et al.,  1998;  Kuida  et al.,  1998;  Kuida  et a l,  1996; 
Yoshida  et a l,  1998).  A  lack  of any  one  of these  proteins  leads  to embryonic or 
perinatal death due to deficits in the central nervous system, reflecting the failure of 
apoptosis during neural development. In caspase-9 '  knockout mice, caspase-3 was not 
activated, supporting the proposal that caspase-9 is upstream of caspase-3. Caspase-9- 
deficient thymocytes are resistant to radiation and dexamethasone-induced death, but 
remain sensitive to TNFa or ligation of Fas (Hakem et a l,  1998; Kuida et a l,  1998), 
supporting the presence of distinct cell death-receptor and mitochondrial pathways. 
Similarly, apaf-1'1 ' thymocytes are sensitive to Fas-induced killing, whereas Apaf-1 - 
deficient  embryonic  fibroblasts  resemble  cells  overexpressing  Bcl-2,  as  they  are 
resistant  to  other cell  death  stimuli  known  to  activate  the  mitochondrial  pathway 
(Cecconi  et al,  1998;  Yoshida et al,  1998).  Caspase-3  deficient thymocytes  and 
hepatocytes do not display all of the typical apoptotic features of membrane blebbing 
and nuclear fragmentation, which indicates its substrates are essential for the features 
of apoptotic morphology (Zheng et al, 1998).
Upstream of the mitochondria, Bcl-2 family  members regulate apoptosis by 
controlling the release of cytochrome c. In particular, overexpression of Bcl-2 and Bcl- 
xL  inhibits cell death by preventing cytochrome c release, whereas Bax overexpression 
triggers cytochrome c release from the mitochondria in the absence of any apoptotic 
stimuli (Finucane et al,  1999; Jurgensmeier et a l,  1998; Pastorino et al,  1998; Yang 
et al,  1997c). Based on the structural similarity of Bcl-xL  to the pore-forming subunit 
of diphtheria toxin (Muchmore et al,  1996), it had been suggested that Bcl-2 proteins 
may act by inserting, following a conformational change, into the outer mitochondrial 
membrane, where they could form channels or pores. Bax/Bak oligomerisation on the 
mitochondrial membrane is essential for release of cytochrome c (Wei et al, 2001; 
Zong  et al,  2001).  Bax  and tBid can decrease the  stability of planar phospholipid 
bilayers,  and  so  may  directly  act on  the  outer mitochondrial  membrane  allowing 
intermembrane proteins to simply diffuse out into the cytsol  (Basanez et al,  1999; 
Kudla et al, 2000).
33Figure 1.2  The mitochondrial pathway
The intrinsic cell death pathway, through the mitochondria, integrates upstream 
death signals through the Bcl-2 family members and coordinates caspase activation 
through the release of cytochrome c as a result of the outer mitochondrial membrane 
becoming permeable.  Upstream of the mitochondria, Bcl-2 family members regulate 
apoptosis by controlling the release of cytochrome c.  Overexpression of Bcl-2 and 
Bcl-xL   inhibits  cell  death  by  preventing  cytochrome  c  release,  whereas  Bax 
overexpression triggers cytochrome c release. Bcl-2 family proteins, such as Bax and 
Bak may act by inserting into the outer mitochondrial membrane, where they could 
form channels or pores. It has been proposed that Bcl-2 family proteins may associate 
with other mitochondrial membrane proteins, such as VDAC and PTP, and regulate 
channel  activity.  Apoptotic  signals may  alter mitochondrial  physiology,  leading to 
swelling of the organelle and rupture of the outer mitochondrial membrane.
When cytochrome c is released from the mitochondria, it accumulates in the 
cytoplasm  where  it  binds  to  Apaf-1  forming  the  oligomeric  Apaf-1/cytochrome  c 
apoptosome  in  the  presence  of ATP.  This  complex  then  recruits  procaspase-9  and 
induces its activation. Recruitment of procaspase-9 induces a conformational change 
in  the  enzyme,  leading  to  an  active  holoenzyme  complex  to  activate  downstream 
effector caspases, such as caspase-3 and caspase-7. These executioner caspases go on 
to cleave numerous cellular targets to destroy normal cellular functions, activate other 
apoptotic factors, inactivate antiapoptotic proteins and eventually lead to the death of 
the  cell.  Other  important  proapoptotic  polypeptides  are  released  from  the 
mitochondria. SMAC and Omi/HtrA2 inactivate IAP proteins, a group of polypeptides 
that inhibit caspase activation, thus allowing caspases to execute apoptosis. AIF is a 
mitochondrial oxidoreductase with potent apoptotic activity, which induces chromatin 
condensation and DNA fragmentation in isolated nuclei.
Taken from (Zimmermann et al., 2001).
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Key Substrates  APOPTOSISAlternatively, it has been proposed that Bcl-2 family proteins may associate 
with  other mitochondrial  membrane  proteins,  such  as  the  voltage-dependent anion 
channel (VDAC), since several Bcl-2 family members can bind to it and regulate its 
channel  activity  (Shimizu  et al.,  1999).  A model has  also been proposed,  in which 
apoptotic  signals  alter mitochondrial physiology,  for example  ion exchange,  which 
leads to swelling of the organelle and rupture of the outer mitochondrial membrane. 
This  would  release  intermembrane  proteins  into  the  cytosol.  The  permeability 
transition pore (PTP) is a high conductance unselective channel formed from contact 
between inner and outer mitochondrial proteins (Crompton et al.,  1999).  Opening of 
this channel can be triggered by calcium, reactive oxygen species, changes in pH or 
low mitochondrial membrane potential, and possibly Bax (Marzo et al.,  1998a). This 
results  in  osmotic  swelling  of  the  mitochondrial  matrix,  due  to  its  high  solute 
concentration resulting from disruption of the chemical equilibrium with the channel 
opening. Bcl-2 family members can regulate PTP opening (Marzo et al.,  1998b). Bcl-2 
can prevent the PTP-mediated mitochondrial depolarization (Kroemer,  1997; Shimizu 
et al.,  1998) whereas Bax can provoke mitochondrial membrane potential loss, matrix 
swelling and cytochrome c release (Marzo et al.,  1998a; Narita et al.,  1998; Pastorino 
et al.,  1998). Thus Bcl-2 family members seem to regulate an aspect of mitochondrial 
physiology more general than the redistribution of cytochrome c.
Cytochrome c  is  not the only  protein  to be  released  from the  mitochondria 
during activation of the intrinsic cell death pathway. Another important proapoptotic 
polypeptide released from the mitochondria is SMAC (also termed Diablo), originally 
isolated on the basis of its ability to facilitate caspase activation in cell-free extracts 
with cytochrome c, Apaf-1  and procaspase-9 (Du et al., 2000; Verhagen et al., 2000). 
SMAC  binds  to  and  inactivates  IAP proteins,  a  group  of polypeptides  that  inhibit 
caspase  activation,  thus  allowing  caspases  to execute  apoptosis.  Structural  studies 
indicate that the N-terminal four amino acid residues of SMAC bind a groove in the 
third BIR domain of XIAP, the domain implicated in caspase-9 binding (Takahashi et 
al., 1998). A peptide consisting of these four amino acid residues can also interact with 
and  bind  XIAP,  providing  a  potential  drug  development  strategy  to  inhibit  these 
proteins in cancer cells. Another protein Omi/HtrA2 also inhibits IAP proteins when 
released from the mitochondria. This is a serine protease that can cleave and inactivate
36IAP  proteins  (Jin  et al.,  2003;  Yang  et al.,  2003)  and  could  therefore  be  a  more 
efficient IAP suppressor.
Apoptosis-inducing factor (AIF) is a mitochondrial oxidoreductase with potent 
apoptotic activity and was isolated through its ability to induce caspase-independent 
chromatin condensation and DNA fragmentation in isolated nuclei (Susin et al., 1999). 
However, the exact mechanism of this remains unclear, and it has been suggested from 
AIF gene knockout experiments that it may have a role in embryonic development 
(Joza et al., 2001). In addition to AIF, mitochondria release endonuclease G, which is 
also implicated in DNA degradation during apoptosis (Li et al., 2001; Parrish et al.,
2001). AIF and endonuclease G have mainly been implicated in caspase-independent 
cell death mechanisms, although endonuclease G may work in parallel with caspases 
in some cells.
1.2.2.5  ER stress pathway
The  endoplasmic  reticulum  (ER)  is  a  highly  dynamic  organelle,  which  in 
addition  to  synthesizing  and  packaging  proteins  also  plays  a central  role  in  many 
signalling  processes.  Input  signals  to  the  ER  are  extensive  and  include  calcium, 
inositol  1,4,5-trisphosphate and reactive oxygen species (Berridge, 2002). The main 
output signal is calcium. The release of calcium from the ER controls the levels of 
cytoplasmic free calcium and thus many cellular functions.  The release of calcium 
through, for example, calcium sensitive receptors (calcium-induced calcium release) 
spreads  signals  throughout the  cell  and  is  particularly  important  in  the  control  of 
muscle cells and neurons.
The function of the ER is intimately connected to the mitochondria, with the 
mitochondria taking up calcium to assist in the recovery phase of the calcium signal 
(Csordas  and Hajnoczky,  2001;  Rizzuto et al.,  1998).  If the  normal  equilibrium  is 
altered, with calcium accumulating in the mitochondria, a number of stress signals are 
induced, such as the formation of the PTP, collapse of the mitochondrial membrane 
potential  and  release  of cytochrome  c  and  AIF,  that  activate  caspases  and  induce 
apoptosis, as discussed in section 1.2.2.4.
Disruption  of calcium homeostasis  affects  protein  synthesis  and conversely 
accumulation  of misfolded  proteins  can  alter the  ER  calcium  balance.  Chaperone 
proteins  within  the  ER  lumen,  such  as  GRP78,  are  responsible  for folding  newly
37synthesised  proteins  into  their  tertiary  structure.  However,  stress  factors,  such  as 
decreased calcium levels  in the ER lumen,  results  in dysfunctional chaperones  and 
accumulation of misfolded proteins (Ferri and Kroemer, 2001; Kaufman,  1999). This 
unfolded  protein  response  pathway  shuts  down  general  protein  synthesis,  while 
upregulating ER resident chaperone proteins and other regulatory components. This 
gives the cell sufficient time to correct the folding problem incurred by the ER stress 
prior to synthesizing additional proteins (Ma et al., 2002). The protein kinase PERK 
phosphorylates the alpha subunit of the translation initiation factor 2 (eIF2a) causing 
its inactivation and impaired initiation of protein synthesis (Harding et al.,  1999; Ron,
2002). In addition, this pathway of ER stress response results in the activation of ATF- 
6,  which  is  released  from  the  ER  to  enter  the  nucleus,  where  it  can  activate  the 
transcription of the GADD153/CHOP gene (Gotoh et al., 2002). If the damage to the 
ER is extensive and homeostasis cannot be resumed, then apoptosis is initiated.
The ER can play a direct role in activating a number of caspases  in murine 
cells  (Ferri  and  Kroemer,  2001;  Morishima  et al.,  2002;  Nakagawa  et al.,  2000). 
Caspase-12  is  associated  with  the  ER  membrane  and  is  released  by  proteolytic 
cleavage following ER stress. Caspase-12 can activate caspase-9 without cytochrome c 
release in C2C12 myoblast cells under ER stress (Morishima et al., 2002), leading to 
effector caspase activation and apoptosis. The Bcl-2 family of proteins has also been 
implicated in the regulation of the apoptotic ER pathway. Bcl-2 can be found localised 
to the ER in addition to the mitochondria (Lithgow et al.,  1994). This association with 
the ER may  stabilise calcium homeostasis and suppress oxidative stress  (He et al., 
1997). When Bcl-2 is overexpressed in cells, there is a decrease in calcium stored in 
the ER. Bcl-2 may act by increasing the leak of calcium from the ER lumen, leading to 
reduced receptor-induced calcium release and reduced levels of calcium within the 
mitochondria (Foyouzi-Youssefi et al., 2000; Pinton et al., 2000). Bcl-xL  can suppress 
ER  stress-induced  apoptosis  and  caspase-12  activation,  perhaps  by  preventing 
proapoptotic  proteins  from  translocating  to  the  ER  and  activating  caspase-12 
(Morishima et al., 2004). The proapoptotic protein Bim was found to translocate to the 
ER in cells under ER stress, possibly causing the indirect activation of caspase-12, and 
this  leads  to  apoptosis  (Morishima  et al.,  2004).  Bax  and  Bak  can  increase  the 
permeability of the ER membrane to calcium, which would increase mitochondrial 
calcium levels, and oligomerisation of Bax/Bak has been proposed to activate caspase-
3812  (McConkey  and  Orrenius,  1997;  Scorrano  et  al.,  2003;  Zong  et  al.,  2003). 
Therefore,  the  levels  of Bcl-2  family  members  in  the  ER  and  mitochondria  may 
determine whether either or both of the ER and mitochondrial pathways are activated 
during ER stress.
1.2.3  Caspase-independent cell death
The process of apoptosis is characterised by morphological features distinct 
from that of necrosis.  Features  of apoptotic  cells  are  shrinkage,  plasma membrane 
blebbing, mostly intact organelles, extensive condensation and fragmentation of the 
DNA and finally the ordered removal of the cell by phagocytosis (Kerr et al.,  1972). 
Necrotic cells undergo a violent and quick form of degeneration affecting extensive 
cell populations, characterised by cytoplasm swelling, destruction of organelles and 
plasma membrane,  leading to the release of the cell contents,  and an inflammatory 
response.
It is likely that all nucleated animal cells constitutively express all the proteins 
required for apoptosis as evidenced by the use of the drug staurosporine. This inhibits 
protein  kinases  and  causes  cells  to  undergo  apoptosis,  even  in  the  presence  of 
cycloheximide  to  inhibit  new  protein  synthesis  (Ishizaki  et al.,  1995;  Weil  et al.,
1996).  This  is  also true  for Drosophila  melanogaster and C. elegans (Shaham and 
Horvitz,  1996;  Steller,  1995). The only reported exception is human red blood cells 
(Weil et al.,  1996), which do not contain a nucleus or other organelles.  However, it 
had  also  been  shown  that  the  nucleus  is  not  required  for  cell  death  in  cells  that 
normally  have  one,  since  anucleated  cytoplasts  are  capable  of undergoing  STS- 
induced apoptosis (Jacobson et al.,  1994). Thus the cell death machinery lies in the 
cytoplasm  of nucleated  cells.  Although  all  of the  proteins  required  to  execute  the 
programme of cell death seem to be constitutively expressed in animal cells, apoptosis 
can often be inhibited by inhibitors of transcription and translation indicating that new 
macromolecular synthesis is required to activate the pre-existing cell death programme 
(Martin et al., 1988).
The  division  of cell  death  into  necrosis  or  apoptosis  can  be  viewed  as  an 
oversimplification.  In  general,  necrosis  has  been  attributed  to  accidental  and 
uncontrolled  death,  whereas  apoptosis  presents  features  of  a  controlled  death 
programme. Evidence is now available for multiple alternative death pathways, as well
39as cross-talk between different intracellular pathways  involved in each form of cell 
death. Recently caspase-independent apoptotic cell deaths have been described, where 
caspase inhibition fails to block programmed cell death, but apoptotic morphology is 
still  observed  (Carmody  and  Cotter,  2000;  Lorenzo  et  al.,  1999;  Mathiasen  et al., 
1999). DNA damage or Bax overexpression can kill cells in the presence of a broad- 
spectrum caspase inhibitor zVADfmk (McCarthy et al.,  1997b; Xiang et al.,  1996). 
The insertion of Bax into the mitochondrial membrane facilitates cytochrome c release 
(Jurgensmeier et al.,  1998), but may also provoke mitochondrial membrane potential 
loss and matrix swelling, leading to the release of the mitochondrial contents (Marzo 
et al.,  1998b; Narita et al.,  1998; Pastorino et al.,  1998).  Mitochondria release other 
apoptotic  molecules  such  as  the  caspase-independent  endonuclease  G  and  AIF. 
Endonuclease G has been implicated in the cleavage of DNA during apoptosis (Li et 
al., 2001; Parrish et al., 2001). Following apoptotic stimuli, AIF is released from the 
mitochondria  and  migrates  to  the  nucleus  and  participates  in  the  induction  of 
chromatin condensation in a zVADfmk-insensitive manner (Susin et al., 1999).
Certain  hallmarks  of  apoptosis  may  be  triggered  by  enzymes  other  than 
caspases.  Cell  deaths  involving  the  activation  of other proteases,  such  as  calpains 
(Squier  et  al.,  1994),  the  proteasome  (Hirsch  et  al.,  1998)  and  serine  proteases 
(Hughes et al.,  1998) have been described. The calpains participate in apoptosis in 
response  to  hypoxia  in  hepatocytes  (Bronk  and  Gores,  1993)  and  in  neuronal 
degeneration (Saito et al.,  1993). These are calcium-requiring enzymes and so may be 
activated  in  response  to  increased cytoplasmic  calcium  levels,  for example  during 
mitochondrial damage or ER stress.  Calpains have also been reported to cleave the 
cytoskeletal protein fodrin upstream of caspases, causing the membrane blebbing seen 
in caspase-independent apoptosis (Waterhouse et al.,  1998). The serine proteases have 
a role in early chromatin cleavage and are activated during apoptosis of thymocytes 
induced  by  glucocorticoids  (Mann  et  al.,  2000).  These  proteases  participate  in  a 
pathway  involving  the  activation  of the  endonuclease  leucocyte  elastase  inhibitor 
DNase  II,  which  is  also involved in cell death of retinal  cells  during development 
(Torriglia  et  al.,  2001).  The  serine  protease  Omi/HtrA2  is  released  from  the 
mitochondria during apoptosis and directly inhibits XIAP function (van  Loo  et al.,
2002), suggesting co-operation between serine proteases and caspases under certain 
circumstances.
401.3  Neuronal Apoptosis
1.3.1  Neuronal apoptosis during development
Neuronal apoptosis occurs extensively during the normal development of the 
mammalian nervous system, ensuring that neuronal populations of the correct size are 
established and inappropriate connections are eliminated. It is estimated that at least 
half of the original cell population is eliminated by apoptosis during embryonic and 
early postnatal development (Oppenheim, 1991). Neurons are produced in excess and 
compete for limiting amounts of survival factors produced by their target cells and 
those  neurons  that  fail  to  obtain  sufficient  neurotrophic  support  die  by  apoptosis 
(Barde,  1989;  Cowan  et  al.,  1984;  Levi-Montalcini,  1987).  Neurons  also  receive 
support  from  glial  cells,  pre-synaptic  cells  and  steroid  hormones  (Linden,  1994; 
Lindsay,  1979;  Nordeen et al.,  1985;  Okado  and  Oppenheim,  1984).  The  trophic 
dependence  of the  developing  neurons  also  eliminates  unwanted  or  unnecessary 
neurons,  such  as  in  the  creation  of  sexually  dimorphic  structures  during  both 
invertebrate and vertebrate development (Bottjer and Arnold, 1997).
The  neurotrophins,  NGF,  BDNF,  NT-3  and  NT-4/5  are  essential  for  the 
development  of  the  vertebrate  nervous  system,  and  can  promote  survival, 
differentiation, and maintenance of neuronal function in the CNS and in PNS neurons 
(Lewin  and Barde,  1996;  Snider,  1994).  These  proteins  bind  to  the  Trk  family  of 
receptor tyrosine kinases and the p75 receptor (p75NTR), a TNF receptor superfamily 
member. For example, NGF acts through TrkA, BDNF and NT-4 through TrkB  and 
NT-3 via TrkC (Chao, 1992). The p75 receptor can bind each of the neurotrophins, but 
with lower affinity, and can regulate the binding affinity of the Trk receptor for its 
ligand (Bibel et al., 1999; Dechant and Barde, 1997). For example, NGF and NT-3 can 
both  bind  to  TrkA,  however  p75NTR  restricts  the  signalling  of  TrkA  to  NGF 
(Benedetti  et al.,  1993).  The  p75NTR  forms  heteromultimeric  complexes  with  the 
different Trk  receptors  and this  association  increases  the  affinity  of Trks  for their 
ligands. In TrkA-expressing cells, p75NTR enhances NGF signalling through TrkA at 
non-saturating  NGF  levels  and  increases  TrkA  phosphorylation  (Lee  et al.,  1994; 
Ryden et al.,  1997). However, recent studies also indicate that the binding of NGF to 
p75NTR in the absence of TrkA may promote cell death rather than prevent it. The 
p75NTR can mediate cell death in a ligand-dependent manner, as does the structurally
41related Fas receptor (Bamji et al.,  1998; Casaccia-Bonnefil et al.,  1996; Davey and 
Davies, 1998; Frade and Barde, 1999).
Binding of neurotrophins to Trk receptors results in receptor dimerisation and 
activation.  This  kinase  activation  initially  occurs  through  phosphorylation  of 
conserved tyrosine residues in the autoregulatory loop, leading to further activation of 
the  kinase  and  subsequent  phosphorylation  of other  tyrosine  residues  (Barbacid, 
1995).  Receptor autophosphorylation  leads  to  the  recruitment of adaptor proteins, 
such as SHC, FRS-2 (Kouhara et al.,  1997) and SH2B/rAPS (Qian et al.,  1998), and 
triggers  the  activation  of downstream  survival  signalling  cascades,  such  as  the 
PI3K/Akt and MAPK pathways (section 1.3.4).
1.3.2  Neuronal apoptosis and disease
Neuronal  apoptosis  has  been  implicated  in  a number of diseases,  including 
neurodegeneration  and  stroke.  The  study  of  programmed  cell  death  in 
neurodegeneration  initially  focused  on  post-mortem  tissues  and  tended  to  give 
conflicting results, probably due to detection difficulty due to a low rate of neuronal 
loss and the rapid engulfment of apoptotic cells. Also post-mortem specimens typically 
come from advanced stages of the disease when most affected neurons would be lost. 
More research  is  now being carried out to assess the molecular components of the 
apoptosis  machinery  involved  in  neurodegeneration  and  animal  models  of human 
neurodegenerative disease have been useful.
Parkinson’s  disease  (PD)  is  a  common  neurodegenerative  disorder 
characterised  by  resting  tremor,  slowness  of  movement,  rigidity  and  postural 
instability.  As the disease progresses, many patients develop cognitive dysfunction, 
including  anxiety,  depression  and  dementia  (Lang  and  Lozano,  1998a;  Lang  and 
Lozano,  1998b).  Symptoms  arise  due  to  the  loss  of dopaminergic  neurons  in  the 
substantia nigra pars compacta (SNPC). The etiology of PD is not fully understood, 
but animal models, human post-mortem material and genetic analyses have provided 
important clues  (Dawson et al., 2002; Mizuno et al., 2001; Polymeropoulos, 2000). 
Initial  experiments  showed TUNEL-positive  neurons  in  the  brains  of PD  patients, 
supporting  the  occurrence  of  apoptosis  in  the  disease  (Mochizuki  et al.,  1996). 
However,  subsequent  studies  using  a greater variety  of morphological  tools,  have 
either succeeded (Anglade et al.,  1997; Tatton et al.,  1998; Tompkins et al.,  1997) or
42failed (Banati et al.,  1998; Kosel et al.,  1997; Wullner et al.,  1999) to find apoptotic 
neurons in post-mortem tissue. Studies using neuronal cell culture systems have shown 
that oxidative stress generated by toxic metabolites of dopamine or dopamine itself 
induces  apoptosis  (Junn  and Mouradian,  2001;  Masserano  et al.,  1996;  Ziv  et al.,
1994)  and this  can  be  partially  inhibited by  overexpression  of Bcl-2  (Offen  et al., 
1997; Ziv et al.,  1997). In particular, caspase-3 and caspase-9 are activated through 
p38 MAPK and cytochrome c in SH-SY5Y neuroblastoma cells and JNK activity is 
increased  in  striatal  cultures  following  dopamine  treatment  (Junn  and  Mouradian, 
2001; Luo et al., 1998b).
Significant insights into the pathogenesis of PD have been achieved by the use 
of  the  neurotoxin  MPTP  (l-methyl-4-phenyl-l ,2,3,6-tetrahydropyridine). 
Administration of MPTP reproduces most of the hallmarks of PD, including dramatic 
degeneration of dopaminergic neurons in mice (Petroske et al., 2001; Przedborski and 
Jackson-Lewis,  1998).  DNA fragmentation is observed in the substantia nigra (SN) 
and increased c-Jun expression in the nigrostriatum (Nishi,  1997; Tatton and Kish,
1997).  The  dopaminergic  neuron  loss  and  c-Jun  activation  observed  after  MPTP 
treatment can be inhibited by JNK inhibition (Saporito et al.,  1999; Xia et al., 2001). 
In  addition,  the  level  of Bax  mRNA  and  protein  increases  in  MPTP-treated  mice 
(Hassouna et al.,  1996; Vila et al., 2001) and this may be mediated by p53 (Duan et 
al., 2002; Trimmer et al.,  1996). Bcl-2 levels have also been shown to decrease in the 
SN following MPTP treatment (Vila et al., 2001). In cell culture models, for example 
SH-SY5Y cells, MPTP-induced apoptosis may involve p53, bcl-2 family genes, JNK 
activation, caspase activity and DNA fragmentation (Kitamura et al.,  1998; Xia et al.,
2001).  Other in  vivo animal models of PD exist.  Hemiparkinsonian rats  have been 
produced  by  injection  of  6-OHDA,  a  dopamine  metabolite,  into  one  side  of the 
ventrotegmental bundle. This leads to apoptotic death of dopaminergic neurons of the 
SN (He et al., 2000; Zuch et al., 2000), with increased neuronal survival observed if 
Bcl-2 is overexpressed one week prior to injection (Yamada et al.,  1999). Finally, the 
molecule a-synuclein has been linked to PD, due to its accumulation in Lewy bodies 
and neurites, and mutations in this gene are associated with familial PD (Olanow and 
Tatton,  1999;  Polymeropoulos  et al.,  1997).  In MPTP-treated animals, a-synuclein 
accumulates in the cytosol of dopaminergic neurons of the SNPC (Vila et al., 2000). 
Expression of mutant a-synuclein in cell culture promotes apoptosis and cytochrome c
43stimulates the aggregation of a-synuclein in vitro (El-Agnaf et al.,  1998; Kakimura et 
al., 2001).
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting 
upper motor neurons  in  the cerebral  cortex  and  lower motor neurons  in  the  spinal 
chord.  This  leads  to  progressive  loss  of voluntary  muscle  function  and  paralysis, 
speech and swallowing difficulties and ultimately respiratory failure and death within 
2-5  years  after onset.  Familial  cases  of the  disease  are  linked  to  mutations  in  the 
superoxide dismutase-1  (SOD1) gene that lead to a decrease in the enzyme activity 
(Deng et al.,  1993; Przedborski et al.,  1996). Mice deficient in SOD1  do not develop 
motor  neuron  disease  (Reaume  et al.,  1996),  however,  transgenic  expression  of 
different  human  SOD1  mutations  in  mice  and  rats  replicates  the  clinical  and 
pathological hallmarks of ALS (Gurney et al.,  1994; Nagai et al., 2001; Wong et al., 
1995). This indicates that the cytotoxicity of mutant SOD1  is a gain-of-function effect 
(Brown, 1995). Transfected neuronal cells expressing mutant SOD1 undergo apoptosis 
(Ghadge et al.,  1997; Rabizadeh et al.,  1995), as do primary neurons from transgenic 
mice  expressing  mutant  SOD1  (Mena  et  al.,  1997).  Biochemical  studies  have 
implicated  the  Bcl-2  family  in  ALS.  Decreased  expression  of bcl-2  mRNA  and 
increased dp5 and bax mRNA have been reported in post-mortem ALS patients and 
transgenic mice (Ekegren et al.,  1999; Martin,  1999; Mena et al.,  1997; Shinoe et al., 
2001;  Vukosavic  et al.,  1999).  In  addition,  Bax  dimerises  and  translocates  to  the 
mitochondria, cytochrome c is released and caspase-9 is activated in transgenic mice 
expressing mutant SOD1  (Guegan et al., 2001; Martin,  1999) and overexpression of 
Bcl-2 mitigates neurodegeneration and prolongs survival of these mice (Vukosavic et 
al., 1999). Inhibition of cytochrome c release delays onset of the disease and increases 
survival of SOD1 transgenic mice (Zhu et al., 2002) and caspase-3 activation has been 
reported  in  the  spinal  chords  of patients  with  ALS  (Martin,  1999),  giving  further 
evidence for activation of the mitochondrial pathway during ALS.
Cerebrovascular disease is one of the leading causes of human morbidity and 
mortality worldwide. The brain is particularly vulnerable to hypoxic-ischaemic injury, 
for example, that seen focally in stroke or globally after cardiac arrest. Historically cell 
death  after ischaemic  injury  was considered to be  a rapid,  necrotic form of death, 
resulting  from  excitotoxicity  caused  by  overstimulation  of  neuronal  glutamate 
receptors  (Choi,  1992).  Indeed neurons  in  the  most  severely  affected  areas  do  die
44rapidly, however there is also a more gradual loss of neurons outside the stroke’s core 
where  the  oxygen  supply  is  reduced  but  not  eliminated,  or  in  cases  where  the 
ischaemic  injury  is mild,  perhaps during cardiac  surgery  (Arrowsmith et al., 2000; 
Barinaga,  1998;  Du  et  al.,  1996;  Hossmann,  2001;  Pulsinelli  et al.,  1982).  The 
observation that cycloheximide reduced this delayed neuronal death in rats (Goto et 
al.,  1990; Shigeno et al.,  1990) and that some cell deaths after ischaemia show DNA 
fragmentation,  TUNEL-labelling  and  activation  of  caspases  indicated  a  role  for 
apoptosis in these neurons (Choi,  1996; Li et al.,  1995b). Caspase activation has been 
observed  in  three  different models  of ischaemic  injury:  the  middle  cerebral  artery 
occlusion (MCAO) model of focal cerebral ischaemia in rats and mice (Friedlander et 
al.,  1997; Hara et al.,  1997; Loddick et al.,  1996; Namura et al.,  1998), the carotid 
artery occlusion model of transient global ischaemia in adult rats (Chen et al.,  1998) 
and in the model of hypoxic-ischaemic brain injury (H-I) in neonatal rats (Cheng et 
al.,  1998).  In  the  MCAO  model  of stroke,  down-regulation  of antiapoptotic  Bcl-2 
family  members,  and  upregulation  of p53,  Bax  and  Fas  have  all  been  reported 
(Hossmann, 2001; Li et al.,  1997b; Love, 2003; Matsuyama et al.,  1995; Waldmeier,
2003).  Bcl-2 overexpression can lead to diminished neuronal cell death and infarct 
reduction (Howard et al., 2002; Lawrence et al.,  1997; Martinou et al.,  1994). Bcl-2 
deficient  mice  show  increased  infarct  size  and  more  severe  neurological  deficits 
following  transient  MCAO,  compared  with  heterozygote  and  wild-type  littermates 
(Hata et al.,  1999).  Bax deficient animals exhibit significantly decreased caspase-3 
activation  and infarct volume as  compared to  wild-type  littermates  in  the  neonatal 
hypoxic-ischaemic model (Gibson et al., 2001). The JNK signalling pathway has been 
implicated in ischaemic apoptosis (Irving and Bamford, 2002) and targeted deletion of 
the JNK isoform Jnk3, which is selectively expressed in the nervous system and heart 
(Gupta et al.,  1996; Kuan et al.,  1999), reduces the stress-induced JNK activity and 
protects mice from brain injury after cerebral ischaemia-hypoxia (Kuan et al., 2003).
1.3.3  In vitro models of neuronal apoptosis
1.3.3.1  Sympathetic neurons
Sympathetic neurons, which form part of the peripheral nervous system, have 
proved  to  be  a useful  in vitro model for studying neuronal  apoptosis  mechanisms. 
During development these neurons depend on NGF from approximately embryonic
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both in vivo and in vitro (Coughlin and Collins,  1985; Levi-Montalcini,  1987; Wright 
et al.,  1983).  Deletion of the gene for NGF or its receptor TrkA results in extensive 
neuron loss in vivo (Crowley et al.,  1994; Smeyne et al.,  1994). Sympathetic neurons 
can be isolated from the superior cervical ganglia of one-day-old rats and cultured in 
vitro in the presence of NGF. Removal of NGF from the growth medium results in a 
cell  death  with  the  classic  features  of  apoptosis.  This  cell  death  in  culture  is 
representative of the physiological cell death in which neurons are deprived of NGF in 
vivo. The period between postnatal days 3 and 7 is the major time of developmental 
death for sympathetic neurons, when approximately one third of these neurons die 24- 
48  hours  later  (Wright  et  al.,  1983).  The  NGF  withdrawal-induced  death  of 
sympathetic  neurons  requires de  novo  transcription  and  translation  (Martin  et al., 
1988) that ultimately leads to cytochrome c release from the mitochondria and caspase 
activation (Deshmukh and Johnson, 1998; Neame et al., 1998).
Sympathetic neurons undergoing apoptosis following NGF withdrawal, do not 
exhibit any morphological changes until 12 hours after NGF deprivation in vitro. After 
this  time,  neurites  begin  to  degenerate,  the  plasma  membrane  loses  its  smooth 
appearance and cells begin to shrink, with half the neurons atrophied by 24-36 hours. 
After 48 hours of NGF withdrawal, at least 95% of the neurons are dead (Deckwerth 
and Johnson,  1993; Edwards and Tolkovsky,  1994; Martin et al.,  1988). Neurons can 
be rescued from cell death by the re-addition of NGF to cultured cells, before they are 
irreversibly  committed  to  die.  The  cell  death  commitment  point  for  sympathetic 
neurons is defined as, the time after NGF deprivation when half the neuron population 
can no longer be rescued by NGF re-addition. This is around 22 hours for sympathetic 
neurons (Deckwerth and Johnson, 1993).
1.3.3.2  PC12/PC6-3 cell line
Clonal  cell  lines  that express  neuronal  properties  are  useful  in  vitro  model 
systems  for  studying  the  nervous  system.  The  PC 12  cell  line  was  derived  from  a 
transplantable  rat  adrenal  pheochromocytoma  (Greene  and  Tischler,  1976). 
Chromaffin granule-containing cells from this tumour were found to respond to NGF 
by exiting the cell cycle and extending long, branching neurite-like processes (Tischler 
and Greene,  1975).  These cells develop a phenotype  similar to that of sympathetic
46neurons if differentiated in the presence of NGF, and then die by apoptosis after NGF 
withdrawal  (Mesner et al.,  1992;  Rukenstein  et al.,  1991).  In  addition,  PC 12 cells 
display many of the biochemical changes characteristic of sympathetic neurons after 
NGF withdrawal and this NGF withdrawal-induced death of PC 12 cells requires de 
novo transcription and translation (Mesner et al.,  1992). PC6-3 cells are a sub-clone of 
PC 12 cells, isolated due to their increased sensitivity to NGF removal (Pittman et al., 
1993). After 14 days in the presence of NGF, PC6-3 cells have a very well developed 
neuronal morphology. Following the removal of NGF, the first morphological signs of 
cell death at the light microscopic level occur after about  16 hours and involve the 
thinning and beading of the neurites.  By 20 hr after removal of NGF,  a number of 
neurites have been lost and some of the cell bodies are beginning to degenerate. After 
24-30  hours  of  NGF  withdrawal,  extensive  loss  of  neurites  occurs  and  cellular 
degeneration  is  obvious.  Apoptosis of this  PC6-3  sub-clone  also requires de  novo 
transcription and translation.
1.3.4  Survival pathways
The binding of trophic factors to their receptors elicits a variety of signalling 
responses, depending on the receptor and the cell type (Kaplan and Miller,  1997). The 
two  pathways  that  have  been  implicated  the  most  in  neuronal  survival  are  the 
phosphatidylinositol-3-OH  kinase  (PI3K)  and  mitogen-activated  protein  kinase 
(MAPK) pathways.
1.3.4.1  PI3K pathway
The PI3K signalling pathway is activated by many types of cellular stimuli or 
toxic  insults  and  regulates  fundamental  cellular  functions  such  as  transcription, 
translation,  proliferation,  growth,  and  survival  (Datta  et  al.,  1999;  Vivanco  and 
Sawyers, 2002).  Survival signals generally activate intracellular signalling pathways 
by binding to transmembrane receptors which posses intrinsic tyrosine kinase activity, 
or that are indirectly coupled to tyrosine kinases, or to G-protein coupled receptors 
(Clark and Brugge, 1995; Segal and Greenberg, 1996; Weiner and Chun, 1999).
In neurons, trophic factors bind to Trk receptors causing their dimerisation and 
activation  through  autophosphorylation,  leading  to  the  recruitment  of  adaptor 
molecules at the plasma membrane. Trk receptors can activate PI3K through at least
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normally present in the cytosol and can be directly activated by either recruitment to 
an  activated  Trk  receptor,  or indirectly  through  activated  Ras.  These  active  PI3K 
enzymes catalyse the formation of the lipid 3'-phosphorylated phosphoinositides, for 
example PIP2 and PIP3, which regulate the localisation and activity of key components 
in  cell  survival,  including  Akt/protein kinase  B  and  3-phosphoinositide-dependent 
kinases (PDKs). Akt is recruited to the plasma membrane through the interaction of its 
pleckstrin-homology domain with the phospholipid products of PI3K. Akt is activated 
through  phosphorylation  by  PDKs  and  then  in  turn  it  phosphorylates  substrates 
involved in promoting survival of the cells. Signalling through Ras can also activate 
the PI3K-Akt pathway.  Recruitment of the  adaptor Grb-2  via  She recruitment and 
phosphorylation  leads  to  activation  of the  Ras  exchange  factor  SOS.  This  in  turn 
activates Ras which then activates PI3K.
PI3K was first implicated in the suppression of apoptosis in a study by Yao 
and Cooper (Yao and Cooper,  1995) in which the signal transduction pathways that 
control growth factor-mediated survival of the PC 12 cell line were investigated. This 
study demonstrated that inhibition of PI3K activity abrogated the ability of NGF to 
promote  cell  survival.  Since  then,  the  PI3K  pathway  has  been  implicated  in  the 
survival of many  neuronal cell types, including sympathetic  neurons  (Crowder and 
Freeman,  1998; Miller et al.,  1997; Philpott et al.,  1997). Active Akt protein supports 
the survival of neurons in the absence of trophic factor support, whereas dominant- 
negative mutants  of Akt inhibit neuronal  survival  even  in the  presence of survival 
factors (Datta et al., 1999).
Akt  targets  several  key  proteins  to  keep  neurons  alive.  Activation  of Akt 
induces the phosphorylation of the proapoptotic BH3-only protein Bad and promotes 
its interaction with the chaperone protein 14-3-3. This sequesters Bad in the cytoplasm 
thus preventing its proapoptotic activity, the binding and inhibition of Bcl-xL  (Datta et 
al.,  1997; Yang et al.,  1995). The Forkhead box transcription factor, class O (FOXO) 
subfamily  of Forkhead transcriptional regulators  (FKHR,  FKHRL1  and  AFX),  are 
directly controlled by phosphorylation by Akt (Biggs et al.,  1999; Brunet et al.,  1999; 
Kops et al., 1999). The phosphorylated FOXO transcription factors are bound by 14-3- 
3 and retained in the cytoplasm, away from their target genes. The gene encoding the 
BH3-only protein Bim is a direct target of FKHRL1  in sympathetic neurons deprived
48of NGF, and inhibition of FOXO activity can protect against this death (Gilley et al.,
2003). Akt has also been reported to regulate CREB and NF-kB transcription through 
phosphorylation  of CREB  or  IkB  kinase,  resulting  in  the  stimulation  of survival 
pathways  (Du  and  Montminy,  1998;  Kane  et  al.,  1999;  Riccio  et  al.,  1999).  In 
sympathetic neurons, CREB mutants block NGF-induced survival and CREB may act 
through transcriptional activation of bcl-2 (Riccio et al., 1999).
1.3.4.2  MAPK pathway
Neurotrophins stimulate the docking of the adaptor protein She to activated Trk 
receptors at the plasma membrane, triggering the recruitment and activation of the 
small  GTP-binding  protein  Ras,  and  the  activation  of the  downstream  mitogen- 
activated protein kinase (MAPK) signalling cascade, the Raf/ERK pathway or PI3K 
(Bonni et al.,  1999). Ras regulates neuronal differentiation, but also promotes survival. 
In  PC 12  cells,  addition  of NGF  leads  to  activation  of the  Ras-Raf pathway  and 
phosphorylation  of  extracellular  signal-regulated  kinase  (ERK),  leading  to 
differentiation  and  prevents  apoptosis  induced  by  NGF  withdrawal  (Kaplan  and 
Miller,  1997;  Xia et al.,  1995).  However,  ERK  activation  is  not necessary  for the 
survival-promoting  effects  of NGF on  sympathetic  neurons  (Creedon  et al.,  1996; 
Virdee et al.,  1997). The effect of the MAP kinase pathway on survival of cerebellar 
granule neurons is mediated at least in part by the activation of the pp90 ribosomal S6 
kinase (RSK) family members. These phosphorylate the BH3-only protein Bad and 
can activate the transcription factor CREB and thereby increase expression of Bcl-2 
(Bonni et al., 1999; Riccio et al., 1999).
1.3.5  Apoptosis of sympathetic neurons
Removal  of  NGF  from  its  receptors  on  the  plasma  membrane  triggers  a 
downstream signalling cascade (see Figure 1.3) involving the JNK/c-Jun pathway that 
leads to Bax translocation, cytochrome c release from the mitochondria and caspase 
activation (Deshmukh and Johnson, 1998; Neame et al., 1998; Putcha et al., 1999).
1.3.5.1  JNK/c-Jun pathway
The  involvement  of the  c-Jun  N-terminal  kinase  (JNK)  /  stress  activated 
protein kinase (SAPK) pathway in apoptosis has been much studied. JNK proteins are
49phosphorylated  and  activated  in  response  to  apoptotic  stimuli  such  as  TNF,  DNA 
damage, heat shock, ischaemia-reperfusion, oxidative stress, axonal injury and loss of 
trophic  support  (Herdegen  and  Waetzig,  2001;  Ip  and  Davis,  1998;  Kyriakis  and 
Avruch,  1996; Maroney et al.,  1999; Raingeaud et al.,  1995; Xia et al.,  1995). These 
kinases are activated by exposure of cells to stress, with the specific roles dependent 
upon  the  cellular  context.  Indeed,  the  JNK  pathway  has  been  implicated  in  both 
apoptosis and survival signalling (Davis, 2000; Ip and Davis,  1998).
The removal of NGF from sympathetic neurons leads to a slow and sustained 
increase in JNK activity (Eilers et al.,  1998; Virdee et al.,  1997). This JNK activity is 
necessary for c-Jun phosphorylation, c-jun promoter activation and NGF withdrawal- 
induced death (Eilers et al., 2001). There are three mammalian Jnk genes, Jnkl, Jnkl 
and JnkS, which encode different JNK isoforms with different substrate specificities 
and activities in response to different stimuli (Gupta et al.,  1996). JNK1 and JNK2 are 
ubiquitously expressed, whereas JNK3 is selectively expressed in the brain, and to a 
lesser extent in  the  heart and testes  (Kuan  et al.,  1999;  Martin et al.,  1996).  Mice 
deficient in Jnk3 do not have any obvious abnormal phenotype and these animals are 
born normally. Hippocampal neurons from these animals are protected from kainate- 
induced  excitotoxicity,  consistent  with  an  involvement  of  c-Jun  induction  and 
transcriptional  activity  in this  neurotoxic  response  (Yang  et al.,  1997b).  A  similar 
result was observed in mice with mutations in the c-jun gene that replaced the JNK 
phosphorylation sites at serines 63 and 73 with alanine residues (Behrens et al., 1999). 
Sympathetic neurons from Jnkl1 ' mice are more resistant to NGF withdrawal induced 
death than heterozygous littermate controls (Bruckner et al., 2001). In these neurons, 
Jnk3  deficiency  leads  to  decreased  c-jun  induction  and  c-Jun  phosphorylation 
following NGF deprivation. Jnkl'1 ' and Jnkl1 ' mice are viable, but are immunodeficient 
due to altered T-cell differentiation (Constant et al., 2000; Dong et al.,  1998; Yang et 
al.,  1998a). Jnkl'1 ' mice have compromised neuronal microtubule assembly (Chang et 
al., 2003) and are protected from obesity-induced insulin resistance (Hirosumi et al.,
2002). Jn kl1 '  mice  have  decreased  induction  of interferon-a 1  and -p transcription 
following infection (Chu et al.,  1999) and show moderately decreased joint damage in 
a model  of passive  collagen-induced arthritis  (Han  et al.,  2002).  Double knockout 
mice for both Jnkl  and Jnk2 die during embryogenesis due to increased apoptosis in 
the forebrain  and decreased apoptosis in the lateral edges of the hindbrain prior to
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antiapoptotic roles for JNK1  and JNK2 during development of the brain. Embryonic 
fibroblasts  from Jnkl1 '  Jnkl'1 '  double  knockout  mice  lack  expression  of  all  JNK 
protein  and JNK activity, reflecting the neuronal-specific expression pattern of the 
Jnk3 gene (Toumier et al., 2000). These cells show profound defects in stress-induced 
apoptosis,  for example in response to UV radiation, but showed no defects in Fas- 
induced apoptosis. The absence of JNK caused a defect in the mitochondrial death 
signaling pathway, including the failure to release cytochrome c and activate caspase- 
3,  indicating  that  mitochondria  are  influenced  by  proapoptotic  signal transduction 
through the JNK pathway (section 1.3.5.3).
Several upstream components of the JNK/c-Jun pathway have been identified 
in sympathetic neurons (see Figure  1.3). The most distal of these are the Rho small 
GTPase family members Racl  and Cdc42.  Activated mutants  of Cdc42  and Racl 
induce  apoptosis  of sympathetic  neurons,  by  activating  the  c-Jun  transcriptional 
pathway, and Cdc42 is required for NGF withdrawal-induced death (Bazenet et al.,
1998). Conversely, dominant negative mutants of these GTPases prevent elevation of 
c-Jun and death by NGF-withdrawal in sympathetic neurons.  Cdc42-induced death 
and c-jun activation were blocked by inhibition of apoptosis signal-regulated kinase 1  
(ASK1),  suggesting that ASK1  is downstream of Cdc42  in the  signalling pathway 
(Kanamoto  et al.,  2000).  ASK1  is  activated after NGF withdrawal  in  sympathetic 
neurons.  In  sympathetic  neurons, JNK and c-Jun  activation  and NGF withdrawal- 
induced death, can be inhibited by a kinase-inactive mutant of ASK1. Overexpression 
of ASK 1-AN, a constitutively active mutant of ASK1, activated JNK, and induced 
apoptosis in both neuronally differentiated PC 12 cells and sympathetic neurons.
Several other MAPKKK have been reported to activate the JNK  signalling 
cascade, such as the MEKK proteins and the mixed-lineage kinases (MLKs). MEKK1 
activates  SEK1/MKK4  which  in  turn  can  phosphorylate  JNK  (Yan  et al.,  1994). 
Overexpression of MEKK1  in sympathetic neurons increases c-Jun levels and c-Jun 
phosphorylation and induces apoptosis in the presence of NGF (Eilers et al.,  1998). 
These effects were prevented by co-expression of SEKAL, a SEK1/MKK4 dominant 
negative  mutant,  indicating  that  MEKK1  acts  by  activating  MKK4  to  induce 
apoptosis in these cells. However, overexpression of SEKAL in sympathetic neurons 
did not block  induction of c-Jun protein, c-Jun phosphorylation or apoptosis  after
51Figure 1.3  Signalling events upstream of cytochrome c release in sympathetic 
neurons undergoing NGF withdrawal-induced apoptosis
Several  components  of  the  JNK/c-Jun  pathway  have  been  identified  in 
sympathetic  neurons.  The  Rho  small  GTPase  family  members  Racl  and  Cdc42 
activate the c-Jun transcriptional pathway, and Cdc42 is required for NGF withdrawal- 
induced death.  Cdc42-induced death and c-jun activation were blocked by inhibition 
of ASK1, and ASK1  is activated after NGF withdrawal in sympathetic neurons. This 
suggests that ASK1 is downstream of Cdc42 in the signalling pathway. In sympathetic 
neurons, overexpression of MEKK1  increases c-Jun levels and c-Jun phosphorylation 
and induces apoptosis in the presence of NGF. These effects were prevented by co­
expression  of SEKAL,  a  SEK1/MKK4  dominant  negative  mutant,  suggesting  that 
MEKK1  acts  by  activating  MKK4  to  induce  apoptosis  in  these  cells.  However, 
overexpression of SEKAL in  sympathetic  neurons did not block induction of c-Jun 
protein, c-Jun phosphorylation or apoptosis after NGF withdrawal, which suggests the 
presence  of  an  MKK4-independent  pathway.  MLK  proteins  can  function  as 
MAPKKKs and lead to the activation of JNKs via activation of MAPK kinases, such 
as MKK4/MKK7.  In sympathetic neurons, overexpression of MLK family members 
induced cell death via the JNK pathway and expression of dominant negative MLKs 
protected these cells from NGF-withdrawal induced death. MLKs been shown to act 
downstream of Cdc42 and upstream of MKK4 and MKK7 in the JNK pathway. JNK 
proteins are activated by MKK4 and MKK7, which phosphorylate JNK on specific 
threonine and tyrosine residues. The removal of NGF from sympathetic neurons leads 
to a slow and sustained increase in JNK activity. This JNK activity is necessary for c- 
Jun phosphorylation, c-jun promoter activation and NGF withdrawal-induced death. 
JNKs bind to the transactivation domain and phosphorylate c-Jun on serines 63 and 
73, increasing the transcriptional activity of the protein. c-Jun  activates transcription 
via AP-1  DNA binding sites present in the promoters of target genes and also in c-jun 
itself.  In sympathetic neurons, expression of dominant negative c-Jun (FLAGA169) 
protects the neurons from NGF withdrawal-induced death by preventing cytochrome c 
release  from  the  mitochondria,  indicating  that  c-Jun  functions  upstream  of  the 
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53NGF  withdrawal,  which  suggests  the  presence  of a  SEK1-independent  pathway, 
perhaps through ASK1 or the MLKs.
The  MLK  proteins  represent  an  additional  protein  kinase  family  with  the 
potential to be involved in the JNK activation pathway. These proteins can function as 
MAPKKKs and lead to the activation of JNKs via activation of MAPK kinases, such 
as MKK4 (Bock et al., 2000; Cuenda and Dorow,  1998; Hirai et al.,  1997; Tibbies et 
al.,  1996).  In  sympathetic  neurons  and  neuronally  differentiated  PC 12  cells, 
overexpression of MLK family members induced cell death via the JNK pathway and 
expression of dominant negative MLKs protected these cells from NGF-withdrawal 
induced death (Xu et al., 2001). MLKs been shown to act downstream of Cdc42 and 
upstream of MKK4 and MKK7 in the JNK pathway and are thought to be the direct 
targets of the semisynthetic JNK pathway inhibitor CEP-1347 (Maroney et al., 2001). 
This inhibitor protects sympathetic neurons and neuronally differentiated PC 12 cells 
against death  induced by  NGF-withdrawal,  exposure  to  UV  radiation or oxidative 
stress  (Maroney  et al.,  1999).  In  NGF-deprived  sympathetic  neurons,  CEP-1347 
blocks the release of cytochrome c and maintains the metabolic function and growth of 
the neurons (Harris et al., 2002). The trophic effects of CEP-1347 might be mediated 
through  the  PI3K  survival  pathway.  Recent  studies  have  shown  that  CEP-1347 
activates Akt and ERK and a blockade of PI3K or MEK activity ablates the effect of 
CEP-1347  on cell  survival  (Roux  et al.,  2002).  In  addition,  the  CEP-1347  related 
compound,  CEP-11004,  has  been  found  to  induce  an  increase  in  the  mRNA  and 
protein levels of TrkA, the NGF receptor, resulting in ligand-independent activation of 
the TrkA receptor and the downstream PI3K pathway, in sympathetic neurons (Wang 
et al., 2005). Therefore the neuroprotective and neurotrophic effects of CEP-1347 may 
involve the activation of several signaling pathways. The JNK/c-Jun pathway can also 
be  inhibited  with  the  JNK  inhibitor  SP600125.  This  acts  as  a  reversible  ATP- 
competitive inhibitor against JNK1, JNK2 and JNK3 (Bennett et al., 2001).
The JNKs  are  activated by  the  dual  specificity  MAPK  kinases,  MKK4  and 
MKK7,  which  phosphorylate  JNK  on  specific  threonine  and  tyrosine  residues 
(Derijard et al.,  1995;  Lawler et al.,  1998;  Lin  et al.,  1995; Toumier et al.,  1997). 
Disruption of the genes for MKK4 and MKK7 results in embryonic death (Dong et al., 
2000;  Ganiatsas  et  al.,  1998;  Nishina et al.,  1999;  Swat et  al.,  1998;  Yang  et  al.,
541997a).  The death of M k k 4 embryos appears to be due to liver apoptosis and this 
phenotype is similar to that observed for c-jun1 ' embryos (Hilberg et al., 1993).
JNK proteins bind to the transactivation domain and phosphorylate c-Jun on 
serines  63  and 73  (Hibi et al.,  1993;  Ip and Davis,  1998;  Karin et al.,  1997).  This 
increases the transcriptional activity of the protein. The c-Jun transcription factor acts 
via AP-1 DNA binding sites present in the promoters of target genes and also in c-jun 
itself (Angel et al., 1988). c-Jun binds to DNA as homodimers or as heterodimers with 
other  basic/leucine  zipper  transcription  factors,  such  as  Jun  D  and  activating 
transcription factor 2 (ATF-2), to regulate gene expression (Deng and Karin,  1993; 
Hai and Curran,  1991). ATF-2 is also a target for JNK phosphorylation (Gupta et al., 
1995; van Dam et al., 1995).
1.3.5.2  c-Jun
The transcription factor c-Jun is a member of the AP-1 family. AP-1 was one of 
the  first transcription factors to be  identified and controls  a wide range  of cellular 
processes, including cell proliferation, death, survival and differentiation (Angel and 
Karin,  1991; Maki et al.,  1987;  Vogt and Bos,  1990).  AP-1  is a dimer made up of 
basic/leucine  zipper  (bZIP)  proteins  of the  Jun,  Fos  and  ATF  subfamilies,  which 
recognise either TPA response elements (TRE) or cAMP response elements (CRE) in 
DNA (Karin et al.,  1997). c-Jun is a potent activator of transcription and its level of 
expression and transcriptional activity are controlled by the MAPK family of proteins, 
in  particular JNK  (Karin,  1995).  Phosphorylation  of c-Jun  increases  its  ability  to 
activate target genes,  such as cyclin Dl,  FasL and c-jun  itself (Angel et al.,  1988; 
Schreiber et al., 1999; Shaulian and Karin, 2001; Whitfield et al., 2001).
Sympathetic neurons express several members of the AP-1 family: c-Jun, JunB, 
JunD,  Fra-1  and  ATF-2  (Ham et al.,  1995).  The  levels  of c-Jun  protein,  c-Jun  N- 
terminal phosphorylation and c-jun promoter activity increase after NGF withdrawal 
and  this  requires  JNK  activity  (Eilers  et al.,  2001;  Estus  et al.,  1994;  Ham  et al.,
1995). c-jun promoter activation following NGF withdrawal requires the jun 1  and jun2 
TRE elements, which are DNA binding sites for c-Jun/ATF-2 heterodimers (Eilers et 
al.,  1998). c-jun knockout mice die during embryonic development at day  12.5 due to 
hepatic failure (Hilberg et al., 1993). To study the role of c-Jun in neurons, a floxed c- 
jun gene has been successfully knocked out in sympathetic neurons in vitro (infected
55with a CRE adenovirus) and this inhibited NGF withdrawal-induced death (Palmada et 
al,  2002).  Microinjection  of sympathetic  neurons  with  a dominant  negative  c-Jun 
(FLAGA169) or antibodies specific for c-Jun, protects sympathetic neurons from NGF 
withdrawal-induced death (Ham et al.,  1995).  FLAGA169 lacks the N-terminal  168 
amino acids encoding the transactivation domain, but can still dimerise and bind DNA 
via the  bZIP domain  (Hirai  et al.,  1989)  and  acts  as  a  dominant  negative  mutant 
against  AP-1  family  members  (Brown  et  al.,  1994;  Castellazzi  et  al.,  1991). 
Expression of dominant negative c-Jun also inhibits apoptosis in differentiated PC 12 
cells and cerebellar granule neurons following survival factor withdrawal (Watson et 
al., 1998; Xia et al., 1995).
c-Jun has also been implicated in axonal regeneration in adult peripheral and 
central  nervous  system  neurons  that  have  been  axotomised  (Dragunow,  1992; 
Herdegen et al., 1998; Herdegen and Waetzig, 2001). A recent study using mice with a 
conditional  knockout of c-Jun  in  neural  cells  (c-Junm),  showed that CNS-specific 
inactivation of c-jun caused severe defects in the axonal response, leading to impaired 
target reinnervation (Raivich et al., 2004). These c-Jun-deficient motoneurons were 
resistant to axotomy-induced cell death, supporting a role for c-Jun in both neuronal 
apoptosis and axonal regeneration. The transcription factor ATF-3 is also up-regulated 
in response to axotomy with a similar expression pattern to c-Jun (Takeda et al., 2000; 
Tsujino et al., 2000). Expression of ATF-3 enhances c-Jun-mediated neurite sprouting 
in  PC 12  cells  (Pearson  et al.,  2003)  and suggests that expression of these proteins 
following  axotomy  represents  an  attempt by  an  injured  cell  to  activate  an  axonal 
regeneration response.
1.3.5.3  Mechanism of JNK-dependent neuronal apoptosis
JNK activation is known to be required for the stress-induced mitochondrial 
death pathway (Toumier et al., 2000). In sympathetic neurons, expression of dominant 
negative c-Jun (FLAGA169) protects the neurons from NGF withdrawal-induced death 
by  preventing  cytochrome  c  release  from  the  mitochondria,  suggesting  that  c-Jun 
functions  upstream  of the  mitochondria  in  sympathetic  neurons  (Whitfield  et  al., 
2001).  Cytochrome  c  release  is  required  for  this  NGF-withdrawal-induced  death 
(Neame et al.,  1998). The release of cytochrome c occurs before caspase function and 
requires Bax translocation and new protein synthesis (Deshmukh and Johnson,  1998;
56Putcha et al.,  1999). However, microinjection of purified cytochrome c on its own is 
insufficient to induce cell death in NGF-maintained  sympathetic  neurons, but does 
induce death in Bax deficient or cycloheximide-treated neurons deprived of NGF. This 
suggests that these neurons require the  induction of other simultaneous  events that 
occur after NGF withdrawal, to become competent-to-die in response to cytochrome c 
injection.  This  is  now  thought  to  be  a  decrease  in  the  level  of XIAP  after  NGF 
withdrawal (see later).
Bax  is essential for sympathetic  neuron  apoptosis  (Deckwerth et al.,  1996). 
Bax '  sympathetic neurons are independent of NGF for survival and do not die after 
NGF withdrawal. Overexpression of Bax kills sympathetic neurons in the presence of 
NGF and increases the rate of cell death following NGF withdrawal, an effect that was 
blocked by co-expression of Bcl-xL  or caspase inhibition (Vekrellis et al.,  1997). Bcl- 
xL  can inhibit sympathetic neuronal apoptosis after NGF withdrawal (Gonzalez-Garcia 
et al.,  1995), although levels of Bcl-xL  remain relatively constant during sympathetic 
neuron apoptosis (Aloyz et al.,  1998; Whitfield et al., 2001). The targeted disruption 
of the  bax  gene  protected  against  Bcl-xL   deficiency-induced  neuronal  death, 
suggesting  that  these  proteins  act  within  the  same  cell  death  pathway  in  neurons 
(Shindler et al., 1997).
In  sympathetic  neurons,  overexpression  of the  antiapoptotic  protein  Bcl-2 
inhibits apoptosis  and sympathetic  neurons from one-day-old bcl-2'1 ' mice undergo 
apoptosis more rapidly than neurons from control littermates after NGF deprivation in 
culture  (Garcia  et al.,  1992;  Greenlund et al.,  1995).  Bcl-2  protects  against  NGF- 
withdrawal induced death by preventing cytochrome c release from the mitochondria 
and caspase activation (Putcha et al.,  1999). However, overexpression of Bcl-2 does 
not  block  the  increase  in  c-Jun  protein  level  that  occurs  after  NGF  withdrawal, 
suggesting that c-Jun acts upstream of Bcl-2 (Ham et al., 1995).
BH3-only proteins such as Bad, Bim, Bid and DP5 are proapoptotic and may 
directly dimerise with Bcl-2 or Bcl-xL  to inhibit their action (O'Connor et al.,  1998; 
Ottilie et al.,  1997;  Yang et al.,  1995).  In  sympathetic neurons,  Bim is  induced by 
NGF withdrawal and experiments with neurons isolated from bim'1 ' mice indicate that 
Bim  is  required  for  normal  NGF  withdrawal-induced  death  (Putcha et al.,  2001; 
Whitfield et al., 2001). On the other hand the levels of the Bid and Bad proteins do not 
change and these proteins are not essential for death after NGF deprivation (Putcha et
57al.,  2002).  DP5  RNA  and  protein  levels  also  increase  in  sympathetic  neurons 
following NGF withdrawal and overexpression of DP5  leads to increased neuronal 
apoptosis in the presence of NGF (Imaizumi et al,  1997). This cell death induced by 
DP5  is  inhibited  by  co-expression  of Bcl-2.  DP5  can  interact  with  Bcl-xL   during 
cortical neuronal apoptosis following exposure to amyloid beta protein and may inhibit 
the survival activity of Bcl-xL  (Imaizumi et al., 1999). Sympathetic neurons from dpS'1 ' 
mice show a small delay in NGF withdrawal induced death in vitro (Imaizumi et al,
2004). However, motoneurons from dp57"  mice were resistant to cell death induced by 
axotomy,  indicating that DP5  plays an important role in this form of neuronal cell 
death.
The induction of DP5 and Bim in sympathetic neurons is partially dependent 
on JNK  signalling.  The  MLK  inhibitor CEP-1347,  which  inhibits JNK  activation, 
reduced  the  induction  of  DP5  and  Bim  in  sympathetic  neurons  following  NGF 
withdrawal  (Harris  and  Johnson,  2001).  This  is  consistent  with  the  findings  of 
Whitfield et al (2001) who reported that Bim induction is decreased in NGF-deprived 
sympathetic  neurons that express dominant negative c-Jun  (Whitfield et al, 2001). 
Bim '  neurons deprived of NGF still show increased c-Jun phosphorylation but have 
delayed cytochrome c release, again indicating that Bim acts somewhere between c- 
Jun activation and mitochondrial cytochrome c release (Putcha et al, 2001).
The  bim  gene  is  a target for FKHRL1  in  sympathetic  neurons  deprived of 
NGF, and inhibition of FOXO activity can protect against this death (Gilley et al,
2003). In the presence of NGF, FKHRL1  is phosphorylated in a PI3K-Akt dependent 
manner and localised in the cytoplasm. However, in the absence of NGF, FKHRL1 is 
dephosphorylated, becomes localised to the nucleus and activates bim gene expression. 
Inhibition  of the  PI3K  pathway  and  activation  of the  JNK  pathway  seem  to  both 
contribute to the induction of Bim in sympathetic neurons. Bim can also be regulated 
by  phosphorylation.  NGF  reduces  Bim  protein  levels  and  increases  Bim 
phosphorylation in an ERK-dependent manner in neuronally differentiated PC 12 cells, 
leading to a suppression of its proapoptotic activity  (Biswas and Greene, 2002).  In 
serum-stimulated fibroblasts,  ERK-mediated  phosphorylation  of Bim  at  serine  65 
leads  to  a  substantial  increase  in  the  turnover  of  the  protein  via  the  ubiquitin- 
proteasome pathway  (Ley  et al.,  2003;  Ley  et  al.,  2004).  However,  in the  case  of 
sympathetic  and  cerebellar  granule  neurons  it  has  been  reported  that,  following
58survival  factor withdrawal,  Bim  is  phosphorylated  by  JNK  at  serine  65  and  this 
potentiates  the  proapoptotic  activity  of Bim  in  these  cells  by  an  as  yet  unknown 
mechanism (Becker et al., 2004; Putcha et al., 2003).
Neuronal  cells  undergoing  apoptosis  release  cytochrome  c,  which  leads  to 
apoptosome formation and caspase activation. Treatment of sympathetic neurons with 
caspase  inhibitors,  such  as  the  cell-permeable,  pan-caspase  inhibitor  BOC- 
aspartyl(OMe)-fluoromethylketone  (BAF),  or  expression  of  the  baculovirus  p35 
protein, reduces the death of these cells in vitro (Deshmukh et al.,  1996; Martinou et 
al.,  1995; McCarthy et al.,  1997a). Caspase activity increases in neuronal PC 12 cells 
(Stefanis et al.,  1996) and sympathetic neurons (Deshmukh et al.,  1996), deprived of 
NGF. The effector caspases in PC 12 cells appear to be caspase-2 and -3, whereas in 
sympathetic neurons only caspase-2 has been reported to be activated (Deshmukh et 
al.,  1996;  Haviv et al.,  1998;  Stefanis et al.,  1997; Troy et al.,  1997).  Sympathetic 
neurons cultured from caspase-2 null mice,  however,  still retain their sensitivity to 
NGF  deprivation  (Bergeron  et  al.,  1998),  perhaps  due  to  a  developmental 
compensation by other caspases (Troy et al., 2001). Caspase-9 knockout mice die due 
to deficits  in  the central  nervous  system,  reflecting  the  failure of apoptosis during 
neural development (Hakem et al.,  1998; Kuida et al.,  1998) and sympathetic neurons 
isolated from caspase-9-null embryos have a delay in NGF withdrawal-induced death 
(Deshmukh et al., 2000). The importance of the mitochondria and caspase activation 
in sympathetic neuron apoptosis is also supported by the involvement of SMAC and 
IAP. SMAC binds to and inactivates IAP proteins, a group of polypeptides that inhibit 
caspase activation. Expression of exogenous SMAC induces apoptosis in sympathetic 
neurons (Deshmukh et al., 2002), whereas the overexpression of IAPs block apoptosis 
in  sympathetic  neurons deprived of NGF (Wiese  et al.,  1999;  Yu  et al.,  2003).  A 
decrease in XIAP expression seems to be a critical event that induces competence-to- 
die in these cells. Sympathetic neurons maintained in NGF are resistant to injection of 
cytochrome c, in contrast to XIAP-deficient neurons, which die rapidly with cytosolic 
cytochrome c alone (Potts et al., 2003). In addition, XIAP levels decrease after NGF 
withdrawal in competent neurons. This indicates that the removal of XIAP inhibition 
is both necessary and sufficient for cytochrome c to activate caspases in sympathetic 
neurons.
591.4  Aims of the thesis
The JNK/c-Jun pathway promotes apoptosis in sympathetic neurons deprived 
of NGF, but little is known about the transcriptional targets of this pathway. The aim 
of this study  was to use Affymetrix GeneChip® arrays to identify genes involved in 
neuronal apoptosis after NGF withdrawal. Differentiated PC6-3 cells deprived of NGF 
were  used  as  a  model  of neuronal  apoptosis,  to  generate  sufficient  RNA  for  the 
Affymetrix analysis.
One  of the  regulated  genes  identified  by  microarray  analysis,  ATF-3,  was 
studied  further in  PC6-3  cells  and  sympathetic  neurons.  ATF-3  RNA  and  protein 
levels  were  found  to  increase  after  NGF  withdrawal  in  both  PC6-3  cells  and 
sympathetic neurons. Regulation of ATF-3 expression by the MLK/JNK pathway was 
investigated using chemical inhibitors of MLK and JNK activity and the role of ATF-3 
in sympathetic neurons was studied in microinjection experiments.
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2.1  Materials
2.1.1  Chemicals and equipment
A.G. Scientific Incorporated 
SP600125
Ambion Incorporated
glycogen, phenol:chloroform:isoamyl alcohol (25:24:1, saturated with  10 mM 
Tris-HCl pH 8.0/1 mM EDTA), RNA 6000 ladder, RNaseZAP
Affymetrix
Rat Genome U34A GeneChip® arrays, GeneChip® Fluidics Station 400
Agilent Technologies
Agilent 2100 Bioanalyzer, Agilent RNA 6000 Nano LabChip kit
Amersham Biosciences
Hybond™-C  Extra  nitrocellulose,  ECL/ECL+  western  blotting  detection 
system, HEPES, ProbeQuant™ G-50 Microcolumns, Typhoon™ phosphorimager 8600 
and  phosphorimager  screens,  ImageMaster  VDS-CL,  ImageMaster  Total  Lab 
software, MOPS
Amresco
formamide, 10 x SSC
Applied Biosystems
ABI PRISM® BigDye™ Terminator Cycle Sequencing Ready Reaction Kit
Becton-Dickinson and Company
Bacto™ tryptone, Bacto™ yeast extract, Bacto™ agar
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chloroform, isopropyl alcohol, methanol, glass slides, ethylenediamine tetra- 
acetic acid (EDTA), NaCl, NaOH, polyvinylpyrrolidone, Tris, HC1, MgCl2
Bio-Rad Laboratories
N,N,N’N’-tetramethylethylenediamine  (TEMED),  GS  Gene  Linker™  UV 
chamber, Kaleidoscope Prestained molecular weight marker, Bradford assay reagent, 





Axiovert 200 and  S100 inverted fluorescence microscopes,  Axiocam digital
camera
Cedarlane Laboratories Ltd




Citifluor AF1 glycerol/PBS solution
Clontech
rat brain cDNA library, Advantage-GC 2 PCR kit
Coming Incorporated
Costar 0.22 pM Spin-X centrifuge tube filters
62Eppendorf
Micro  Centrifuge  Model  5415C,  microloaders,  microinjection  equipment: 
micromanipulator (5171), transjector (5246)
Enzo Diagnostics, Incorporated








RPMI  1640  medium,  L-glutamine,  penicillin/streptomycin,  L-15  medium, 
Dulbecco's Minimal Essential Medium (DMEM), 0.24 kb -  9.5 kb RNA ladder,  1   kb 
DNA  ladder,  dithiothreitol  (DTT),  First  strand  cDNA  buffer,  SSII  Reverse 
Transcriptase, Second strand cDNA buffer, DNA ligase, DNA polymerase I, RNase H, 
T4 DNA polymerase, Superscript™ RNase H' reverse transcriptase, DH5a competent 
cells, Lipofectamine 2000, TRIzol® reagent, Opti-MEM® I  reduced  serum medium, 
pcDNAl
Intracel
1.2  mm od x 0.8 mm id x 10 cm glass capillaries
John Weiss
dissection scissors and forceps
Kodak
X-OMAT scientific imaging film
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37.5:1 acrylamide to bisacrylamide Protogel® solution (30% w/v), 10 x TBE
NEN™ Life Science
Genescreen Plus hybridisation transfer membrane
New England Biolabs
T4 polynucleotide kinase, T4 polynucleotide kinase buffer
Oligoengine™
Oligoengine™ software, pSUPER RNAi vector
PAA laboratories 
horse serum





2.5S NGF (for PC6-3 cells), RNasin, T4 DNA Ligase, T4 DNA Ligase buffer, 
T4 DNA Polymerase, T4 DNA Polymerase buffer, deoxyribonucleotide triphosphates 
(dNTPs), restriction endonucleases, restriction endonuclease digestion buffers, bovine 
serum albumin (BSA), Klenow enzyme, PCR reagents: MgCl2, Taq DNA Polymerase, 
PCR buffer
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RNeasy mini kit, mRNA isolation kit, gel extraction kit, HiSpeed plasmid maxi 
kit, PCR purification kit, QIAprep spin miniprep kit, Oligotex mRNA mini kit
Roche
calf intestine alkaline phosphatase
Sigma-Aldrich Chemical Company
trypsin,  poly-L-lysine,  5-fluoro-2-deoxyuridine,  uridine,  laminin,  diethyl 
pyrocarbonate (DEPC), formaldehyde, sterile phosphate-buffered saline (±Ca2+, Mg2+ ), 
trypsin/EDTA,  ethidium  bromide,  bovine  serum  albumin  (BSA),  sodium  dodecyl 
sulphate  (SDS),  triton  X-100,  2-mercaptoethanol,  Tween  20,  bromophenol  blue, 
xylene cyanol, Ponceau S solution, REDTaq DNA Polymerase, REDTaq PCR buffer, 
ampicillin, guinea pig IgG, paraformaldehyde, dimethyl sulphoxide (DMSO), ethylene 
glycol-bis  (P-aminoethyl  ether)-N,N,N’N’,-tetraacetic  acid  (EGTA),  goat  serum, 
protein  inhibitor  cocktail,  Hoechst  33342,  chloramphenicol,  sodium  acetate, 
ammonium persulphate
Sigma Genosys
T7-(dT)2 4  primer,  PCR  primers,  T7  primer,  SP6  primer,  siRNA 
oligonucleotides
Silicon Genetics
GeneSpring 6 data analysis software
Sorvall










Worthington Biochemical Corporation 
collagenase type 2
Wolf laboratories
Uvi tec UV transilluminator
2.1.2  Antibodies
Amersham Biosciences
Donkey anti-rabbit horse radish peroxidase-conjugated Ig (Cat # NA934V) 
Sheep anti-mouse horse radish peroxidase-conjugated Ig (Cat # NA931V)
BD Transduction Laboratories
Mouse monoclonal anti-Bcl-xL  antibody (Cat # B22620)
Mouse monoclonal anti-c-Jun antibody (Cat # J31920)
Chemicon
Mouse anti-NGF antibody (Cat # MAB5260-60UG)
Jackson Immunoresearch Laboratories
Donkey anti-mouse IgG, FITC-conjugated (Cat #715-095-150)
Donkey anti-rabbit IgG, FITC-conjugated (Cat # 711-095-152)
Donkey anti-guinea pig IgG, TRITC-conjugated (Cat # 706-025-148)
66Santa Cruz Biotechnology, Incorporated
Rabbit polyclonal anti-ATF-3 antibody (C-19, Cat # SC-188)
Goat anti-Rat IgG-horse radish peroxidase conjugated (Cat # SC-2032)
Serotec
Rat monoclonal anti-alpha-tubulin antibody (Cat # MCAP77)
Sigma
Mouse monoclonal M2 anti-FLAG® epitope antibody (Cat # F3165) 
Promega
Mouse monoclonal anti-p-galactosidase antibody (Cat # Z3783)
2.1.3  Plasmids
CMVlacZ was described by Alberts et al. (1993) 
pcDNAl was purchased from Invitrogen 
pCDFLAGBcl-xL  was described by Vekrellis et al. (1997) 

















5' -T  A  AT  ACG  ACTC  ACT  AT  AGGG-3'
SP6
5'-GATTTAGGTGACACTATAG-3'
2.1.5  Stock Solutions
TE
TNE
2 x protein loading buffer
10 mM Tris-Cl pH 8.0 
1  mM EDTA
10 mM Tris-Cl pH 8.0 
1 mM EDTA 
100 mM NaCl
0.1 MTris-HCl pH 6.8 
4% SDS 
20% glycerol 





Tris Buffered Saline (TBS)/ 
0.1% Tween 20 (TBS-T)
10 mM Tris-Cl, pH 7.6 
150 mM sodium chloride 
0.5 mM EDTA 
1  mM EGTA 
1% SDS
30 pM pepstatin A 
80 pM bestatin 
40 pM leupeptin 
1.6 pM aprotinin 
28 pM E-64
2.08  mM AEBSF
15%
15% acrylamide 










25 mM Tris 
192 mM glycine 
0.1% SDS
10 mM Tris-Cl, pH 8.0 
150 mM NaCl 
0.1% Tween-20
695% milk/TBS-T 5% Marvel
10 mM Tris-Cl, pH 8.0 
150 mM NaCl 
0.1% Tween-20
GeneChip® non-stringent wash buffer 6 x SSPE 
0.01% Tween 20 
0.005% Antifoam 0-30
GeneChip® array hybridisation buffer 100 mM MES 
1 M [Na+]
20 mM EDTA 
0.01% Tween 20
GeneChip® fragmentation buffer 40 mM Tris-acetate, pH 8.1 
100 mM potassium acetate 
30 mM magnesium acetate
Denhardt's solution 0.1% BSA
0.1% Ficoll™400
0.1% polyvinylpyrrolidone
SSPE 0.15 M sodium chloride 
10 mM sodium phosphate 
1  mM EDTA
northern blot hybridisation solution 5 x SSPE
5 x Denhardt's solution 
10% dextran sulphate 
0.5% SDS
DEPC-treated water 0.1% diethyl pyrocarbonate
701 xOLB





6 x DNA loading buffer
solutions  A:B:C  in  the  ratio  10:25:15 
Solution A: 52 mM Tris-HCl 
0.125 MMgCl2  
75% 2-mercaptoethanol 
20 mM dGTP, dTTP, dATP 
Solution B: 2 M HEPES, pH 6.6 
Solution C: hexadeoxynucleotides 
pd(N)6 in TE (90 OD 
units/ml)
20 mM MOPS 
8 mM sodium acetate 
1  mM EDTA




1  mM EDTA 
0.4% bromophenol blue
1 % Bacto™ tryptone 
0.5% Bacto™ yeast extract 
17 mM NaCl
LB containing 1.5% Bacto™ agar
0.24% bromophenol blue 
0.24% xylene cyanol 
30% glycerol 
60 mM EDTA, pH 8.0
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Western blot transfer buffer  25 mM Tris
0.2 M glycine 
20% methanol
NaCl-saturated isopropanol:water  50% isopropanol
50% sterile water
NaCl added until 2 phases appear
722.2  Methods
2.2.1  Tissue Culture
2.2.1.1  PC6-3 cell culture
Undifferentiated PC6-3 cells were cultured in dishes coated with  1   x poly-L- 
lysine and collagen at 10 mg/ml in RPMI  1640 medium supplemented with 10% horse 
serum,  5%  foetal  calf serum (FCS),  2  mM  glutamine  and  penicillin-streptomycin. 
Cells were kept in 5%  C02  at 37°C.  PC6-3  cells were subcultured every 7 days by 
removing the growth medium, rinsing the cells with PBS,  incubating for 5  minutes 
with  1   x trypsin/EDTA and harvesting the cells by centrifugation. The cell pellet was 
resuspended in RPMI  1640 medium supplemented as above and plated at a density of 
1  x 106  cells per 9 cm dish.
PC6-3  cells  were  differentiated  by  plating  1   x  106  cells  per  9  cm  dish  in 
differentiation medium, which consisted of RPMI  1640 medium supplemented with 
2% horse serum,  1% FCS, 2 mM glutamine, penicillin-streptomycin and NGF at  100 
ng/ml. The cells were differentiated for 7 days before being used for experiments. In 
NGF withdrawal experiments, cells were cultured without NGF by carefully rinsing 
the  cells  once  in  differentiation  medium  lacking  NGF  and  refeeding  with 
differentiation medium supplemented with 100 ng/ml of anti-NGF antibody.
2.2.1.2  Sympathetic neuron culture
Sympathetic neurons from the superior cervical ganglia (SCG) of one-day-old 
Sprague Dawley rats (supplied by the Biological Services Unit, University College 
London) were isolated and cultured as described (Whitfield et al., 2004). Briefly, after 
dissection, the ganglia were desheathed in LI5 medium supplemented with 0.1% FCS 
and penicillin-streptomycin. Ganglia were digested in 0.025% trypsin in PBS followed 
by 0 .2% collagenase type 2 in PBS (containing Mg2+  and Ca2+ ) for 30 minutes each at 
37°C. Dissociated ganglia were triturated gently, centrifuged for 10 minutes at  1000 
rpm and resuspended in SCG medium. SCG medium consisted of Dulbecco's Minimal 
Essential  Medium  (DMEM)  supplemented  with  10%  FCS,  2  mM  glutamine, 
penicillin-streptomycin  and  NGF  (50  ng/ml).  The  antimitotic  agents
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the  proliferation  of non-neuronal  cells.  Neurons  were  pre-plated for 2  hours  in  an 
uncoated  9cm  dish  to  remove  non-neuronal  cells.  The  supernatant  enriched  in 
sympathetic  neurons  was  centrifuged at  1000  rpm for  10  minutes  and the  pelleted 
neurons  resuspended  in  SCG  medium.  Neurons  were  plated  on  poly-L-lysine  and 
laminin  coated  coverslips  at  a  density  of  8,000-10,000  neurons  per  coverslip. 
Coverslips, placed in 3.5 cm dishes, were incubated at 37°C in  10% C02 for 2 hours 
prior to the addition of 2 ml of SCG medium. Neurons were incubated in  10% C02  at 
37°C and grown for 6-7 days in the presence of NGF before use in experiments. In 
NGF withdrawal experiments neurons were cultured without NGF by carefully rinsing 
the cells twice in SCG medium lacking NGF and then refeeding with SCG medium 
supplemented with anti-NGF antibody at 100 ng/ml.
2.2.1.3  Treatment of sympathetic neurons with chemical inhibitors CEP-11004 
and SP600125
Sympathetic neurons were grown in the presence of NGF for 6-7 days before 
treatment. Neurons were then cultured in the presence or absence of NGF for 24 hours 
and in the presence or absence of each inhibitor or DMSO as control. CEP-11004 and 
SP600125  stock solutions were 4 mM and 20 mM respectively in DMSO and were 
stored at -20°C. CEP-11004 was added to neurons at 400 nM and SP600125 was used 
at 20 pM. Protein was extracted and samples analysed by western blotting experiments 
(section 2.2.5).
2.2.1.4  Cos-7 cell culture
Cos-7 cells were cultured in dishes coated with  1   x poly-L-lysine in DMEM 
medium supplemented with 10% FCS, 2 mM glutamine and penicillin-streptomycin in 
5% C02  at 37°C. Cos-7 cells were passaged when approximately 70-80% confluent by 
rinsing  the  cells  with  PBS,  incubating  for  5  minutes  with  1   x  trypsin/EDTA  and 
harvesting  the  cells  by  centrifugation.  Cells  were resuspended  in  DMEM  medium 
supplemented as above and plated on 1  x poly-L-lysine coated dishes.
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Cos-7 or PC6-3 cells were grown in 9 cm or 6 cm dishes respectively, until 90- 
95% confluent at the time of transfection. One day prior to transfection, the medium 
was changed to growth medium without antibiotics. Lipofectamine™ 2000 was used 
to transfect cells with plasmid DNA. DNA (5-8  pg) was added to 273 pi (6 cm dish) 
or 821  pi (9 cm dish) Opti-MEM® I reduced serum medium.  Lipofectamine™ 2000 
(20-40  pi)  was  added to 273  pi  (6 cm dish)  or 821  pi  (9  cm dish)  Opti-MEM®  I 
reduced serum medium and incubated at room temperature for 5 minutes. The diluted 
DNA and lipofectamine solutions were mixed together gently and incubated at room 
temperature for 20 minutes. The DNA/lipofectamine mix was added to the cells by 
gentle pipetting and mixed by slowly rocking the dishes. Cells were then incubated for 
48 hours prior to protein extraction.
2.2.2  RNA manipulations
2.2.2.1  RNA Extraction
2.2.2.1.1  PC6-3 cells
Total RNA was prepared from PC6-3 cells using TRIzol®. Cells were placed 
on ice, the medium removed and 2 ml of TRIzol was added per dish to lyse the cells. 
Cell  lysates  were  passed  through  a  pipette  several  times  and  stored  on  ice. 
Homogenised  samples  were  incubated  at  15  -  30°C  for 5  minutes  and 0.2  ml  of 
chloroform  was  added  per ml  of TRIzol.  Samples  were  vigorously  shaken  for  15 
seconds and incubated at  15  -  30°C for 2 minutes.  Centrifugation of the samples at
1,780  x g for 15 minutes at 4°C was performed and the upper aqueous phase removed 
and stored on ice. Addition of 0.5 ml of isopropyl alcohol per ml of TRIzol, followed 
by  incubation  at  15  -  30°C  for  10  minutes  and centrifugation  at  1,780  x  g  for  10 
minutes precipitated the RNA. The pellets were washed once in 75% ethanol (1 ml per 
ml  of TRIzol),  vortexed  and  centrifuged  at  1,780  x  g  for 5  minutes  at 4°C.  RNA 
pellets were air dried briefly and dissolved in DEPC-treated water containing 1 unit/pl 
of RNasin.
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RNA  was  extracted  from  sympathetic  neurons  by  rinsing  the  cells  from 
coverslips using ice-cold PBS and spinning the cells at  16,000 x g for 5  minutes at 
4°C.  Pelleted cells were lysed in  350  pi of buffer RLT and RNA was extracted as 
described in the Qiagen RNeasy mini kit handbook. RNA was eluted from the RNeasy 
columns in 30 pi of RNase-free water.
2.2.2.2  mRNA purification
This  method  is  a  modification  of  the  protocol  supplied  with  the  Qiagen 
Oligotex  mRNA  mini  kit.  Oligotex resin consists of polystyrene-latex particles of 
uniform size with dC 10^30 oligonucleotides covalently linked to the surface, which bind 
mRNA. Total RNA was made up to  100 pi with DEPC-treated water.  100  pi of 2 x 
binding buffer and 30-50 pi of Oligotex suspension were added to each sample, mixed 
well  and  incubated  at  65°C  for  3  minutes.  Samples  were  incubated  at  room 
temperature for 15 minutes, mixed every 3 minutes, and then centrifuged at 16,000 x g 
for  3  minutes.  Oligotex  pellets  were  washed twice  in  300  pi  of wash  buffer.  The 
mRNA was eluted from the Oligotex beads with two  100 pi volumes of pre-heated 
elution buffer, by pipetting several times and vortexing, and then incubating at 75°C 
for  2  minutes.  Samples  were  centrifuged  at  16,000  x  g  for  3  minutes  and  the 
supernatant stored on ice. mRNA samples were prepared by precipitating overnight 
with 0.1  volumes of 3 M sodium acetate and 2.5 volumes of 100% ethanol at -70°C. 
Samples were centrifuged at 16,000 x g for 30 minutes at 4°C, washed in 70% ethanol, 
centrifuged for a further 15 minutes at 4°C and resuspended in DEPC-treated water.
2.2.2.3  Assessing RNA quality using the Agilent 2100 Bioanalyzer
mRNA (100-200 ng) was analysed using the Agilent RNA 6000 Nano LabChip 
kit. Initially electrodes were decontaminated using RNaseZAP reagent as instructed. 
RNA 6000 Nano gel matrix was prepared by centrifugation for 10 minutes at 1,500 x g 
through a spin filter. The gel was stored at 4°C in 65 pi aliquots. RNA 6000 Nano dye 
concentrate was vortexed for 10 seconds and centrifuged briefly to collect the sample 
at the bottom of the tube.  1  pi dye was added to 65  pi filtered gel, vortexed to mix 
thoroughly and centrifuged at  16,000  x  g for  10  minutes  at room temperature.  An 
RNA 6000 Nano LabChip was placed on the Chip Priming Station. The gel-dye mix
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plunger  of the  Chip  Primer  Station.  After  30  seconds  the  plunger  was  released. 
Additional gel-dye mix (9 pi) was added to each of the wells marked ’G’. RNA 6000 
Nano Marker (5 pi) was added to the well corresponding to the ladder and each of the 
12 sample wells on the chip. RNA 6000 ladder (1  pi) and the RNA samples (1  pi) to 
be  analysed were heat denatured at 70°C  for 2  minutes  before being  added to the 
appropriate  wells  on  the  chip.  When  less  than  12  RNA  samples  were  used,  the 
remaining wells were made up to the same volume with RNA 6000 Nano Marker (1 
pi). The chip was placed in the adaptor of the vortex mixer and vortexed for 1  minute 
at the IKA vortexer set-point (2400 rpm). The RNA 6000 Nano LabChip was inserted 
into  the  Agilent  2100  Bioanalyzer,  ensuring  the  electrodes  in  the  cartridge  were 
inserted into the wells of the chip. The mRNA Nano Assay was performed. Once the 
run  was  complete  the  chip  was  removed  immediately  from  the  bioanalyzer  and 
electrodes cleaned with RNase-free water as instructed.
2.2.2.4  Northern Blot Analysis
mRNA samples (3-6 pg) were electrophoresed on a 1  % agarose-formaldehyde 
gel consisting of 1% agarose, 6% formaldehyde and  1   x MOPS buffer at 100 V for 3 
hours.  RNA  samples  and 0.24  kb  -  9.5  kb  RNA  ladder were  heated to  65°C in 2 
volumes of RNA sample buffer and placed on ice for 2 minutes. RNA loading buffer 
(0.5 volumes) was added to the samples. In addition, ethidium bromide (0.5 pg) was 
added  to  the  RNA  ladder  sample  for  visualisation  under  UV  light.  Following 
electrophoresis, gels were rinsed with DEPC-treated water for  10 minutes and then 
twice  with  10  x  SSC  for  15  minutes  with  shaking.  Blotting onto Genescreen  Plus 
hybridisation transfer membrane was performed overnight using  10 x SSC (Sambrook 
et al., 1989).
The RNA was covalently linked to the membrane by UV irradiation using a GS 
Gene Linker™  UV chamber. The nitrocellulose membrane was rehydrated in 5 x SSC 
for 10 minutes with shaking and then incubated in hybridisation solution for 1-2 hours 
at 65°C. Salmon sperm DNA (50 pg/ml) was added during this prehybridisation stage 
to block non-specific binding of radioactive DNA probes to the membrane.  Salmon 
sperm DNA was prepared by boiling for  10 minutes  and then cooling on ice for 5 
minutes prior to addition to the hybridisation solution. DNA probes were labelled with
77[a-32P]dCTP  (3000  Ci/mmol)  by  boiling  the  DNA  in  1   x  Oligo-Labelling  Buffer 
(OLB) for 5  minutes and then incubating on ice for 2 minutes before addition of 5 
units  of Klenow  enzyme,  10  pg  of  BSA  and  30  pCi  of  [a-32P]dCTP.  Labelling 
reactions were performed at room temperature for a minimum of 4 hours. DNA probes 
were denatured and the unincorporated deoxyribonucleotide triphosphates  (dNTPs) 
removed from the probe DNA using ProbeQuant™ G-50 microcolumns. Each column 
was centrifuged for 2 minutes at 400 x g into a microfuge tube and the flow-through 
discarded. The column was placed into a fresh tube containing 33 pi of 1  M NaOH. 80 
pi of 0.1% SDS in TE was added to the DNA probe and this was then added to the 
column.  Samples  were  centrifuged  for 2  minutes  at 400  x  g.  Columns  containing 
unincorporated nucleotides were discarded and the DNA was neutralised with an equal 
volume of 1   M Tris-Cl (pH 8.5).  Probes were added to the hybridisation bottle and 
incubated at 65 °C overnight.
Membranes were washed in 2 x SSC, 0.1% SDS at room temperature for  10 
minutes  and  then  twice  in  1   x  SSC,  0.1%  SDS  for  15  minutes.  Membranes  were 
wrapped in  Saran Wrap and exposed to a phosphorimager screen for  1-4  nights  at 
room temperature. Screens were scanned using a Typhoon™ 8600 phosphorimager and 
the RNA bands quantitated using Image Quant analysis software.
2.2.2.5  RT-PCR
Total  RNA  from  PC6-3  cells  (1  pg)  or  SCG  neurons  (10  pi)  was  reverse 
transcribed using Superscript™  RNase  H' reverse transcriptase as described by the 
manufacturer. Reactions were inactivated by heating at 70°C for 15 minutes. RNase H 
(2  units)  was  added,  and  the  samples  were  incubated  for 20  minutes  at  37°C,  to 
remove RNA complementary to the cDNA. The final reaction volume of 20 pi was 
diluted 1  in 10 to give 200 pi and 10 pi was used in each PCR reaction.
PCR reactions  (50  pi)  were prepared using  10  pi of cDNA in  1   x REDTaq 
PCR buffer with each dNTP (0.2 mM),  100 pmoles of each primer and 2.5 units of 
REDTaq DNA Polymerase. PCR was performed for the minimum number of cycles 
required to detect a product with cDNA prepared at time 0. Reaction conditions were 
94°C for 1  minute, 60°C for 1 minute and 72°C for 1 minute for typically 18-35 cycles 
and a final extension at 72°C for 5 minutes.
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GGCAA-3' and reverse 5'-GCGAGCGCGCTGCGCTTGTA-3', ATF-3, forward 5'-CA 
TGGATCCATGATGCTTCAACATCCAGGC-3' and reverse 5'-CTTGAATTCTTAG 
CTCTGCAATGTTCCTTC-3'  and DP5,  forward  5'-GTTGGATCCATGTGCCCGT 
GTCCCCGGC-3' and reverse 5'-ATTGGATCCCTACGCGCTCCGCCTGCCG-3'.
After  amplification,  the  cDNAs  were  separated  on  1.5%  agarose  gels, 
visualised by  staining  with ethidium bromide,  and  images  were captured using  an 
ImageMaster VDS-CL and quantitated using ImageMaster Total Lab software.
2.2.3  Affymetrix GeneChip® analysis
2.2.3.1  RNA extraction from PC6-3 cells
PC6-3  cells were differentiated in the presence of NGF for 7 days and then 
cultured in the presence or absence of NGF for 16 hours. At this time, total RNA was 
extracted  and  mRNA  purified,  as  described  previously,  for  use  in  Affymetrix 
GeneChip® analysis.
2.2.3.2  cDNA synthesis
mRNA  (3-5  pg)  was hybridised to  100 pmoles of T7-01igo(dT)2 4 primer at 
70°C  for  10 minutes.  Samples  were centrifuged briefly  and incubated on ice.  First 
strand cDNA buffer,  10 mM dithiothreitol (DTT) and 0.5 mM dNTPs were added and 
the temperature of the reactions adjusted to 37°C for 2 minutes. First strand synthesis 
was  initiated  by  addition  of  600-1000  units  of  SSII  Reverse  Transcriptase  and 
incubation at 37°C for 1  hour. Reactions were placed on ice and centrifuged briefly to 
bring down condensation.  Second strand buffer, 0.2 mM dNTPs,  10 units of DNA 
Ligase, 40 units of DNA polymerase I and 2 units of RNase H were added to the first 
strand reactions and incubated at 16°C for 2 hours. Reactions were incubated with  10 
units of T4 DNA polymerase at 16°C for 5 minutes and then EDTA was added to 30 
pM.
An  equal  volume  of phenol:chloroform:isoamyl  alcohol  (25:24:1,  saturated 
with 10 mM Tris-HCl pH 8.0/1 mM EDTA) was added to cDNA samples, which were 
vortexed  and centrifuged  at  16,000  x  g  for 5  minutes.  The  top  aqueous  layer was
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alcohol (24:1) was added. The samples were vortexed and centrifuged at  16,000 x g 
for a further 5 minutes. 0.5 volumes of 7.5 M ammonium acetate and 2.5 volumes of 
100% ethanol were added and the DNA was precipitated on ice for  1   hour.  5  pg of 
glycogen  was  added to aid visualisation of the pellet.  Samples  were centrifuged at 
16,000 x g for 20 minutes at 4°C, washed in 75% ethanol and centrifuged for a further 
10 minutes at 4°C.  DNA pellets were air dried and resuspended in  12  pil of DEPC- 
treated water.
2.2.3.3  Synthesis of biotin-labelled cRNA (in vitro transcription)
Biotin-labelled  cRNA  was  prepared  from  1   pg  of cDNA  using  the  ENZO 
Bio  Array™ High Yield™ RNA transcript labeling kit as  instructed.  Qiagen  RNeasy 
columns  were used to clean up the cRNA.  Samples were precipitated for  1   hour at 
-20°C  using  0.5  volumes  of 7.5  M  ammonium  acetate  and  2.5  volumes  of  100% 
ethanol.  Glycogen  (5  pg)  was  added  to  aid  visualisation  of the  pellet.  RNA  was 
centrifuged at 16,000 x g for 30 minutes at 4°C, washed twice in 80% ethanol (stored 
at -20°C) and air dried at room temperature for 5 minutes. Pellets were resuspended in 
20 pi of DEPC-treated water. Labelled RNA (20 pg) was fragmented in fragmentation 
buffer  at  94°C  for  35  minutes  to  prepare  target  RNA  for  hybridisation  to  the 
Affymetrix GeneChip® arrays.
2.2.3.4  Affymetrix GeneChip® array hybridisation
Rat  Genome  U34A  GeneChip®  arrays  were  filled  with  GeneChip®  array 
hybridisation buffer and incubated at 45°C with rotation for  10 minutes. During this 
time hybridisation cocktails for each target were prepared. Fragmented RNA (15 pg) 
was mixed with control oligonucleotide B2 (50 pM), Eukaryotic hybridisation controls 
- BioB, BioC, BioD and ere (1.5, 5, 25 and 100 pM respectively), herring sperm DNA 
(0.1 mg/ml), acetylated BSA (0.5 mg/ml), hybridisation buffer (as above) and made up 
to the appropriate volume with DEPC-treated water. Each hybridisation cocktail was 
heated to 99°C for 5 minutes and then incubated at 45°C for 5 minutes. Samples were 
centrifuged  at  16,000  x  g  for  5  minutes  to  remove  any  insoluble  material. 
Hybridisation buffer was removed from the GeneChip® arrays and replaced with the
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for 16 hours.
2.2.3.5  Washing, staining and scanning of Affymetrix GeneChip® arrays
After  16 hours of hybridisation, the hybridisation cocktail was removed from 
the  arrays  and  replaced  with  Non-Stringent  wash  buffer.  The  GeneChip® Fluidics 
Station 400 was used with the Affymetrix antibody amplification procedure to wash 
and stain the arrays as instructed in the user's manual.  The GeneChip® arrays were 
scanned by the Hewlett-Packard GeneArray™ scanner at the excitation wavelength of 
488 nm. The amount of light emitted at 570 nm is proportional to the amount of bound 
target at each location on the array.
2.2.3.6  Analysis of Affymetrix GeneChip® array data
Data was collected using MAS 5.0 with the U34A gene set. This was analysed 
using GeneSpring 6 data analysis software (Silicon Genetics). Samples in the presence 
of NGF were set at a value of one. Data from samples in the absence of NGF were 
normalised  to  the  data  from  samples  in  the  presence  of  NGF  for  each  of  the 
GeneChip® experiments (normalisation to individual samples). Further filtering of the 
data was performed.  Genes that changed more than 1.5 fold and which were present in 
either 2 of 3 or 3 of 3 experiments were selected. Additional analysis was performed 
on these lists to generate statistically significant gene changes.
2.2.4  DNA manipulations
2.2.4.1  Polymerase Chain Reaction (PCR)
2.2.4.1.1  DP5
DP5 cDNA was amplified from a rat brain cDNA library. The primers used to 
amplify  DP5 were, forward 5'-GTTGGATCCATGTGCCCGTGTCCCCGGC-3' and 
reverse 5'-ATTGGATCCCTACGCGCTCCGCCTGCCG-3'. The cDNA was amplified 
using the Advantage-GC  2 PCR kit for GC rich sequences.  Reactions (25  pi) were 
prepared using 2.5  pi of cDNA library in  1  x advantage PCR buffer with each dNTP 
(0.2  mM),  100  pmoles  of each  primer,  1   M  advantage  GC  melt  solution  and  1   x
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40 cycles of 94°C for 1   minute and 68°C for 1   minute then a final extension at 68°C 
for 5 minutes.
2.2.4.1.2  ATF-3
ATF-3 cDNA was amplified from a rat brain cDNA library. The primers used 
to  amplify  ATF-3 were, forward 5'-CATGGATCCATGATGCTTCAACATCCAG 
GC-3'  and  reverse  5'-CTTGAATTCTTAGCTCTGCAATGTTCCTTC-3'.  PCR 
reactions (25 pi) were prepared using 2.5 pi of cDNA library in  1  x PCR buffer with 
each dNTP (0.2 mM), 50 pmoles of each primer,  1.5 mM MgCl2  and 2.5 units of Taq 
DNA Polymerase. Reaction conditions were 94°C for 5 minutes followed by 40 cycles 
of 94°C  for  30  seconds,  60°C  for 30  seconds  and 72°C  for  1   minute then  a final 
extension at 72°C for 5 minutes.
2.2.4.1.3 ATF-3bZIP
The ATF-3bZIP domain of ATF-3 was amplified from the ATF-3 cDNA. The 
primers used to amplify the ATF-3bZIP domain were, forward 5'-GTTGGATCCCCT 
GAAGAAGATGAGAGAAAAAG-3' and reverse 5'-CGAGAATTCTTGAGCATGT 
AAATCAGATGCTG-3'.  PCR reactions  (25  pi) were prepared using approximately 
100 ng of ATF-3 cDNA in  1  x PCR buffer with each dNTP (0.2 mM),  100 pmoles of 
each  primer and  2.5  units  of REDTaq  DNA  Polymerase.  Reactions  were  initially 
incubated at 94°C for 2 minutes and then 94°C for  1  minute, 58°C for 1   minute and 
72°C for 1 minute for 30 cycles and then a final extension at 72°C for 5 minutes.
2.2.4.2  Restriction endonuclease digestion
Plasmid  DNA  (1  pg)  was  digested by mixing  with  an excess  of restriction 
enzyme, typically  10 units/pg DNA, in the appropriate  1   x restriction enzyme buffer 
with  BSA  at 0.5-1  pg/pl.  Reactions  were  performed for 2-3  hours at 37°C.  When 
plasmid DNA was subsequently to be used in ligation reactions, enzymes were heat 
inactivated at 68°C for  15 minutes followed by the addition of calf intestine alkaline 
phosphatase (1 unit) in  1 x calf intestine alkaline phosphatase buffer for 30 minutes at 
37°C. Reactions were inactivated by addition of 20 mM EGTA and heating to 65°C 
for 10 minutes. Digested DNA was electrophoresed on a 1% agarose gel, visualized by 
staining  with  ethidium  bromide  and  purified using  a  Qiagen  gel  extraction  kit  as 
instructed.
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Digested  plasmid  DNA  (approximately  200  ng)  and  insert  cDNA 
(approximately 50 ng) were ligated using  10 units of T4 DNA Ligase in  1   x T4 DNA 
Ligase buffer at 16°C overnight.
2.2.4.4  Bacterial transformation
DH5a cells (50 p-1) were transformed with ligation mixtures or plasmids by 
incubating together on ice for 30 minutes, followed by heat shock at 37°C for 1  minute 
and incubation on ice for 2 minutes. LB medium (950 pi) was added to the cells and 
incubation  at  37°C with shaking was performed for  1   hour.  Cells were pelleted by 
centrifugation at 16,000 x g for 2 minutes and resuspended in approximately 100 pi of 
the supernatant. Cells were spread on LB-agar plates containing ampicillin at 50 pg/ml 
and grown overnight at 37°C.
2.2.4.5  Plasmid preparations
2.2.4.5.1  Small scale plasmid preparations (minipreps)
Single colonies were inoculated into 5 ml of LB medium containing ampicillin 
(50  p<g/ml)  and grown overnight at  37°C with  shaking.  Plasmid DNA was purified 
from 4 ml  liquid cultures using the QIAprep Spin miniprep kit as  instructed  in the 
manufacturer’s  handbook.  This  protocol  involves  the  alkaline  lysis  of the  cells 
followed by absorption of the DNA onto a silica gel membrane that binds up to 20 pg 
of DNA in the presence of a high concentration of chaotropic salt. Endonucleases and 
salts are removed by subsequent wash steps and DNA samples are eluted in a small 
volume of low-salt Tris buffer or water.
2.2.4.5.2  Large scale plasmid preparations (maxipreps)
Single colonies were inoculated into 5 ml of LB medium containing ampicillin 
(50 pg/ml) and grown overnight at 37°C with shaking. An aliquot of 4 ml was used to 
inoculate 400 ml of LB medium containing ampicillin (50 pg/ml) and cultures were 
grown at 37°C  with  shaking until  an optical density  at 600  nm of  1.  At this  stage 
chloramphenicol was added to a final concentration of 170 pg/ml for amplification of 
the plasmid DNA and cultures incubated for a further 16 hours overnight.
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at 4°C in a Sorvall RC-5B PLUS Superspeed refrigerated centrifuge and plasmid DNA 
purified using the Qiagen HiSpeed plasmid maxi kit as instructed. This purification 
protocol is based on an alkaline lysis procedure, followed by binding of plasmid DNA 
to  an  anion-exchange  resin  under  appropriate  low-salt  and  pH  conditions.  RNA, 
proteins, dyes, and low-molecular-weight impurities are removed by a medium-salt 
wash. Plasmid DNA is eluted in a high-salt buffer and then concentrated and desalted 
by isopropanol precipitation.
Plasmid DNA was further purified by centrifugation through a CsCl-ethidium 
bromide  gradient.  DNA  samples  were  mixed  with  11  ml  of CsCl/TE  (0.95  g  of 
CsCl/ml  TE)  and  400  p,l  of  ethidium  bromide  (10  mg/ml)  and  transferred  to 
ultracentrifuge tubes using a 19 G needle and syringe. Tubes and lids were balanced to 
within 0.01 g and sealed using an ultracentrifuge tube crimper machine. Samples were 
centrifuged  at  57,000  rpm  for  at  least  16  hours  in  a  Sorvall  Discovery  90 
ultracentrifuge  at  20°C  with  slow  deceleration  at  the  end  of the  run.  The  lower 
ethidium bromide stained band containing supercoiled DNA was extracted from the 
tubes using a  19 G needle and syringe, with a second needle used to release the air 
from the top of the tube. DNA was transferred to a 15 ml centrifuge tube and extracted 
with NaCl-saturated isopropanol:water. An equal volume of saturated isopropanol was 
added to the DNA solution and mixed vigorously. After allowing the two phases to 
separate, the upper phase was discarded. This was repeated until the DNA solution 
was  colourless.  The  DNA  was  transferred  to  a  50  ml  polypropylene  tube  with  3 
volumes of water and precipitated by adding 2 volumes of ethanol and incubating at 
4°C for 15 minutes. The tube was then centrifuged for 30 minutes at  1,780 x g. The 
DNA pellet was washed with 70% ethanol, centrifuged for a further  15  minutes  at
1,780  x g, air dried and redissolved in TE.
2.2.4.6  Agarose gel electrophoresis of DNA
To analyse DNA by agarose gel electrophoresis, 6 x DNA loading buffer was 
added to the samples. The DNA was then resolved on 1-1.5% agarose gels, prepared in 
1  x TBE with 0.5 pg/ml of ethidium bromide. In addition a 1  kb DNA ladder was also 
loaded onto gels to determine the size of DNA fragments separated on the gel. DNA 
was visualised using a Uvi tec UV transilluminator.
842.2.4.7  Construction of pSUPERATF-3 vectors
RNAi  sequences were designed using the Oligoengine™  design  tool  on  the 
Oligoengine website (oligoengine.com). Three  19-nucleotide sequences were selected 
at positions 158 (5'-CCTTTGCCATCGGATGTCC-3'), 268 (5'-GGAGGCGGCGGGA 
AAGAAA-3') and 484 (5'-CGCCGGAAGACGAGAGGAA-3') of the ATF-3 coding 
sequence.  These  were incorporated into two  64-nucleotide  sequences  containing  a 
hairpin sequence and Bglll and Hindlll restriction enzyme sites, as illustrated below 
for sequence 158.




Each pair of 64 base oligonucleotides (500 ng) was phosphorylated by addition of T4 
polynucleotide kinase (10 units),  1  x T4 polynucleotide kinase buffer and  1   mM ATP 
and incubating at 37°C for 1  hour. The phosphorylated oligonucleotides (100 ng) were 
annealed together in TNE buffer at 65°C for 30 minutes  and then allowed to cool 
slowly to room temperature.
pSUPER vector (2  pg)  was  digested  with  Bglll  (10  units)  and  Hindlll  (10 
units) restriction enzymes in  1   x Buffer B at 37°C for 2 hours. Calf intestine alkaline 
phosphatase (1 unit) in 1 x calf intestine alkaline phosphatase buffer was added for 30 
minutes at 37°C. Reactions were stopped by adding EGTA to 20 mM and heating to 
65°C  for  10  minutes.  Digested  DNA  was  electrophoresed  on  a  1%  agarose  gel, 
visualized  by  staining  with  ethidium  bromide  and  purified  using  a  Qiagen  gel 
extraction kit as instructed. Vector and oligonucleotide insert were ligated and used to 
transform DH5a cells as described previously.
2.2.4.8  DNA Sequencing
Sequencing  was  performed  using  the  ABI  PRISM®  BigDye™  Terminator 
Cycle  Sequencing  Ready  Reaction  kit.  Reactions  (15  pi)  were  prepared  using 
approximately 500 ng of DNA with 6 pi of BigDye and 50 pmoles of either T7 or SP6 
primers. PCR reactions were at 96°C for 30 seconds, 50°C for 30 seconds and 60°C 
for 4 minutes for 25  cycles. DNA was precipitated on ice for 30 minutes using 0.1 
volumes of 3 M ammonium acetate and 2.5 volumes of 100% ethanol. Samples were
85centrifuged at 16,000 x g for 30 minutes at 4°C, washed in 70% ethanol, vortexed and 
incubated at room temperature for 10 minutes. Samples were centrifuged for a further 
15 minutes at 4°C and the DNA pellets air dried. Samples were run on an ABI Prism 
377 DNA sequencer by Mr.  Martin Woodward and DNA sequences analysed using 
MacVector software.
2.2.5  Protein Analysis
2.2.5.1  Preparation of protein extracts
2.2.5.1.1  PC6-3 and Cos-7 cells
Medium was removed from the cells and kept on ice. Ice cold PBS was added 
to each plate, the cells were scraped off and added to the removed medium on ice. 
Plates were rinsed with an additional 1  ml of PBS to collect any remaining cells. Cells 
were pelleted by centrifugation at 400 x g for 5 minutes at 4°C and then resuspended 
in 500 pi of PBS. At this stage, samples were transferred into  1.5 ml microfuge tubes 
and the cells re-pelleted by centrifugation at  16,000 x g for 5  minutes  at 4°C.  Cell 
pellets were resuspended in 200 pi of SDS lysis buffer supplemented with a protease 
inhibitor cocktail and mixed. Samples were incubated at 90°C for 20 minutes, mixed 
and  then  centrifuged  at  16,000  x  g  for  20  minutes  at  4°C.  The  supernatant  was 
removed, snap frozen on dry ice and stored at -80°C.
2.2.5.1.2  Sympathetic neurons
Neurons  grown on glass coverslips were rinsed twice with PBS.  Cells were 
rinsed off the coverslips using ice cold PBS  supplemented with a protease inhibitor 
cocktail and cells pelleted by centrifugation at  16,000 x g for 5 minutes. Cells were 
lysed directly in 2 x protein loading buffer by vortexing for 1  minute and boiling for 5 
minutes. Samples were run on an SDS-polyacrylamide gel (see section 2.2.5.3).
2.2.5.2  Protein concentration
The concentration of proteins was determined by the Bradford method using a 
Bio-Rad  kit  as  instructed  by  the  manufacturer,  with  y-globulin  as  a  standard.  A 
standard curve was prepared by plotting the OD595 against amount of y-globulin (pg).
862.2.5.3  Western Blot Analysis
Protein samples and Kaleidoscope Prestained molecular weight marker were 
mixed with 2 x protein loading buffer and boiled for 5 minutes. Samples were run on 
15%  SDS-polyacrylamide  gels  in  SDS  electrophoresis  buffer at  80-100  V  for 2-3 
hours using the Mini-PROTEAN 3 electrophoresis system from Bio-Rad. Gels were 
transferred to Hybond-C nitrocellulose as described (Sambrook et al., 1989) at 100 V 
for  1   hour at room  temperature  or 20  V  overnight  at 4°C  with  constant  stirring. 
Membranes were stained with Ponceau S solution for 5 minutes, to establish transfer 
efficiency.
Membranes were blocked overnight at 4°C or for 1   hour at room temperature, 
with shaking, in 5% milk/TBS-T. Primary antibodies were added in 5% milk/TBS-T at 
the appropriate dilution for  1-2 hours at room temperature with rotation. Blots were 
washed three times in 5% milk/TBS-T. HRP-linked secondary antibodies were diluted 
1  in 2000 in 5% milk/TBS-T and added to membranes for 1   hour with rotation. Blots 
were  washed  three  times  in  5%  milk/TBS-T  followed  by  a  final  wash  in  TBS-T. 
Antibodies  were  detected  using  an  ECL  or ECL+  reagent kit  as  instructed  by  the 
manufacturer and membranes were exposed to X-ray film, usually X-OMAT imaging 
film from Kodak. Western blots were scanned on a Bio-Rad GS800 densitometer and 
the protein bands quantitated using Bio-Rad Quantity One® software.
2.2.6  Microinjection of sympathetic neurons
Sympathetic neurons were grown in the presence of NGF for 5-7 days before 
microinjection.  DNA  mixtures  were  injected  directly  into  the  nucleus  of  150-250 
neurons per coverslip. Injection mixes contained 0.001-0.4 ng/pl of DNA constructs in 
0.5 x PBS with  guinea pig IgG (2.5 ng/pl) as the injection marker. Mixes were filtered 
through Costar Spin-X columns by centrifugation at 16,000 x g for 30 minutes at 4°C.
Microinjection needles were pulled from glass capillary tubes using a Kopf 
Instruments  gravity puller (model 720)  and loaded using Eppendorf microloaders. 
Microinjection was performed using a Zeiss Axiovert 200 microscope fitted with a 
heated  stage  and  C02   chamber,  with  Eppendorf  transjector  (5246)  and 
micromanipulator (5171).
872.2.7  Immunocytochemistry
Neurons  grown  on  glass  coverslips  were  rinsed  in  PBS  and  fixed  in  4% 
paraformaldehyde  at  room  temperature  for  30  minutes,  rinsed  in  PBS  and 
permeabilized with 0.5% Triton X-100 in PBS  for 5  minutes at room temperature. 
After  permeablization,  coverslips  were  rinsed  in  PBS  and  non-specific  binding 
blocked  using  50%  horse  serum  in  1%  BSA  in  PBS  for  30  minutes  at  room 
temperature. Coverslips were rinsed in PBS and incubated with primary antibody at 
the appropriate dilution in 1% BSA in PBS for 1  hour at room temperature. Cells were 
rinsed again in PBS and incubated with TRITC-conjugated anti-guinea pig antibody 
and the appropriate FITC-conjugated secondary antibody in  1%  BSA in PBS  for  1  
hour at room temperature. Cells were rinsed for a final time in PBS and nuclei were 
stained with Hoechst dye at 10 pg/ml in water for 5-10 minutes. The coverslips were 
finally  rinsed  in  water,  air  dried  and  mounted  on  glass  slides  using  Citifluor 
glycerol/PBS solution and sealed using clear nail varnish.
88Chapter 3:  Affymetrix GeneChip® Analysis
3.1  Introduction
PC 12  cells  are  a  useful  in  vitro  model  for  studying  neuronal  apoptosis 
mechanisms because many of the events that are characteristic of sympathetic neuron 
apoptosis also occur in PC 12 cells. These cells are a clonal cell line derived from a rat 
adrenal  pheochromocytoma,  which  respond  to  NGF by  exiting  the  cell  cycle  and 
forming long, branching neurite-like processes (Greene and Tischler,  1976). Removal 
of  NGF  from  neuronally  differentiated  PC 12  cells  leads  to  apoptosis,  which  is 
promoted by the JNK/c- Jun pathway (Xia et al., 1995). PC6-3 cells are a sub-clone of 
PC 12 cells that have increased sensitivity to NGF removal, and apoptosis of this sub­
clone requires de novo transcription and translation (Pittman et al., 1993). These cells 
are  therefore  a  useful  tool  for  studying  changes  in  transcription  involved  in 
programmed neuronal cell death.
To date only a small number of genes have been reported to be induced by 
NGF withdrawal.  It is likely that there are many others to be discovered,  some of 
which may be c-Jun targets with important functions in the neuronal death pathway. A 
useful technique for studying changes in the transcription of large numbers of cellular 
genes is microarray analysis. There are many different types of this technology that 
analyse the expression levels of thousands of genes in a cell population. Affymetrix 
GeneChip® expression arrays have  10,000-100,000 different oligonucleotide probes 
synthesized on each array to represent thousands of genes and EST sequences from a 
particular genome. The GeneChip® Rat Genome U34  Set provides  gene expression 
data  for  more  than  24,000  known  genes  and  EST  clusters.  This  includes  all  rat 
sequence  clusters  from  Build  34  of  the  UniGene  database  supplemented  with 
additional annotated sequences from Genbank  110. The U34A array contains probe 
sets of 7,000 full length or annotated genes and thousands of EST clusters. Figure 3.1 
shows an outline of the Affymetrix GeneChip® experiment. Briefly, RNA extracted 
from the different populations of cells to be studied is converted into cDNA, which is 
transcribed to form biotin-labelled cRNA. These cRNA samples are then fragmented 
and hybridised to the DNA on the chip. This is stained with streptavidin phycoerythrin 
conjugate  and  scanned  at  488  nm.  The  amount  of  light  emitted  at  570  nm  is
89Figure 3.1  GeneChip® eukaryotic target labelling assay for expression analysis
Outline  of  the  Affymetrix  GeneChip®  experiment  (reproduced  from 
www.affymetrix.com). RNA is extracted from the different populations of cells to be 
studied and reverse transcribed into cDNA using Oligo(dT) primer. Samples are then 
converted into biotin-labelled cRNA using an in vitro transcription labelling kit. The 
cRNA is purified and subsequently fragmented for hybridisation to the DNA on the 
chip. The chip is then stained with streptavidin phycoerythrin conjugate and scanned 
at 488 nm. The amount of light emitted at 570 nm is proportional to the bound target at 
each location on the array and therefore to the level of the mRNA species in the RNA 
sample being tested. Comparison of the levels of fluorescence produced by each chip 




























91proportional to the amount of bound target at each location on the array and therefore 
to the level of the mRNA species in the RNA sample being tested. Comparison of the 
levels of fluorescence produced by each chip can identify differential gene expression 
between cell populations.
Affymetrix GeneChip® Rat Genome U34A arrays were used to identify genes 
whose expression  was regulated during  neuronal  apoptosis  after NGF withdrawal. 
PC6-3  cells were used as a model system to generate  sufficient RNA for analysis. 
Genes involved in the apoptosis of PC6-3 cells are induced relatively early after NGF 
withdrawal. One such gene is the BH3-only protein DP5, which peaks in level at  16 
hours after NGF withdrawal in PC 12 cells and sympathetic neurons (Imaizumi et al., 
1997).  In the case of sympathetic neurons, the cell death commitment point,  when 
50% of neurons can no longer be rescued from apoptosis by re-addition of NGF, is 
around 22 hours after NGF withdrawal (Deckwerth and Johnson, 1993). Therefore, 16 
hours was chosen as the time point at which RNA was extracted from PC6-3 cells for 
analysis. This is after the induction and activation of c-Jun and prior to the cell death 
commitment point.
3.2  Results
3.2.1  PC6-3 cells undergo cell death after NGF withdrawal
PC6-3 cells were differentiated in the presence of NGF for 7 days, and then 
cultured in the presence or absence of NGF for 16 hours. After NGF withdrawal, the 
cells  display  the  classic  morphological  changes  associated  with  programmed  cell 
death, such as shrunken cell bodies, membrane blebbing and neurite fragmentation. 
Figure 3.2 shows PC6-3 cells at different stages of differentiation and during cell death 
after NGF withdrawal.
3.2.2  Isolation of RNA for Affymetrix GeneChip® analysis
RNA was extracted from neuronally differentiated PC6-3 cells that had been 
cultured in the presence or absence of NGF for  16 hours.  Initially, samples of total 
RNA (15-20 pg) were electrophoresed on an agarose-formaldehyde gel in the presence 
of ethidium bromide to determine RNA integrity (Figure 3.3A). The presence of intact 
28S and 18S ribosomal RNA bands indicated that the RNA had not become degraded
92during purification. The dp5 RNA is known to be induced in PC 12 cells after NGF 
withdrawal (Imaizumi et a l, 1997). To further examine the integrity of RNA samples, 
northern  blot  analysis  of dp5  levels  in  PC6-3  cells  cultured  in  the  presence  and 
absence of NGF was performed. mRNA was purified from total RNA and samples (5 
p,g) electrophoresed on an agarose-formaldehyde gel. Dp5 probe DNA was amplified 
from  a rat brain  cDNA  library  by  PCR  and  bcl-xL probe  DNA  was  generated  by 
digesting the pCDFLAGBcl-xL  vector with Bglll and EcoRI restriction enzymes.  In 
the  northern  blot  shown,  dp5  was  up-regulated  3.2  fold  after  16  hours  of NGF 
deprivation (Figure 3.3B). This induction of dp5 following NGF withdrawal in PC6-3 
cells established that the RNA samples were of an appropriate quality for Affymetrix 
GeneChip analysis.
The quality of mRNA was also assessed using the Agilent 2100 Bioanalyzer 
with the Agilent RNA 6000 Nano LabChip kit. This assay produced an mRNA trace 
that had  standard features,  including  a broad  peak  indicating  the  range  of mRNA 
species size isolated, two ribosomal RNA peaks and a marker peak.
3.2.3  Preparation of samples for Affymetrix GeneChip® hybridisation
Three independent Affymetrix GeneChip® array experiments were performed 
using RNA from differentiated PC6-3 cells cultured for  16 hours in the presence or 
absence  of NGF.  In  each  experiment,  the RNA quality  was  assessed  as  described 
above and each set of two populations of RNA was prepared for chip hybridisation 
(Figure 3.4). Initially, cDNA was prepared from mRNA samples isolated from PC6-3 
cells in the presence or absence of NGF (Figure 3.4A). The intense bands correspond 
to cDNA generated from the 28S  and  18S ribosomal RNA bands. The DNA smear 
indicates cDNA in the range of 400 to 2,000 base pairs.  Biotin-labelled cRNA was 
prepared from the cDNA and purified using Qiagen RNeasy columns (Figure 3.4B). 
This is observed as a smear on the gel indicating the presence of different sized RNA 
fragments. Some sample was lost during purification, with less labelled cRNA present 
in the -NGF sample. Approximately equal amounts of labelled RNA were fragmented 
to prepare target RNA for hybridisation to the Affymetrix GeneChip® arrays, with the 
appropriate control samples as described previously (Figure 3.4C).
93Figure 3.2  PC6-3 cells at different stages of differentiation and cell death
PC6-3 cells were maintained undifferentiated (i) in normal growth medium. In 
experiments, cells were differentiated by the addition of NGF.  After 3  days in the 
presence of NGF (ii) cells begin to form neurites and after 7 days in NGF-containing 
medium (iii) the cells have exited from the cell cycle and become fully differentiated 
with long neurite-like projections. PC6-3 cells cultured in the presence of NGF for 7 
days and then in the absence of NGF for 16 hours (iv) and 24 hours (v) have begun to 
display signs of cell death. White arrows indicate dead cells. Cells become rounded 
and  shrunken  in  appearance,  neurites  fragment  and  the  cells  detach  from the cell 
culture  dish.  Cells  were  examined  on  a  Zeiss  Axiovert  200  microscope  and 
photographed using an Axiocam digital camera and Axiovision software. Images were 




95Figure 3.3  DPS is up-regulated in PC6-3 cells deprived of NGF for 16 hours
(A)  PC6-3  cells  were  differentiated  for  7  days  in  the  presence  of NGF  and  then 
cultured for 16 hours in the presence or absence of NGF. Total RNA was isolated and 
electrophoresed  on  a  1%  agarose-formaldehyde  gel  in  the  presence  of ethidium 
bromide for visualisation of the 28S and  18S ribosomal RNA bands. The molecular 
weight marker (M) used was the 0.24 kb - 9.5 kb RNA ladder from Invitrogen.
(B)  mRNA  was  purified  from  total  RNA  and  mRNA  samples  (5  pg)  were 
electrophoresed on a  1% agarose-formaldehyde gel and transferred to nitrocellulose. 
Northern  blotting  was  performed  using  32P-labelled  dp5 and bcl-xL   probe  DNAs. 
Membranes  were  exposed  to  a  phosphorimager  screen  for  1-4  nights  at  room 
temperature and the screens were scanned using a Typhoon™ 8600 phosphorimager to 
quantitate the levels of dp5 and bcl-xL  mRNA. RNA bands were quantitated using the 
ImageQuant analysis program and the ratio of dp5 to bcl-xL  was calculated. Bcl-xL  
RNA levels remain relatively constant for the first 24 hours after NGF withdrawal and 
were used as a control for gel loading. In the northern blot shown, dp5 is up-regulated 
3.2 fold after 16 hours of NGF deprivation. The size of the dp5 and bcl-xL  mRNAs is 
indicated.
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97Figure 3.4  Preparation of samples for Affymetrix GeneChip® hybridisation
(A) RNA was isolated from differentiated PC6-3 cells cultured for  16 hours in the 
presence (+)  or absence  (-) of NGF.  mRNA samples  were reverse transcribed into 
cDNA and  1/12th  volume (1  pi) of each cDNA sample was electrophoresed on a  1% 
agarose gel.
(B) Biotin-labelled cRNA was prepared from the cDNA using the ENZO BioArray™ 
HighYield™ RNA transcript labeling kit and purified using Qiagen RNeasy columns. 
1   pi samples before (pre) and after (post) purification were removed and analysed on a 
1  % agarose gel.
(C)  Labelled  RNA  was  fragmented  to  prepare  target  RNA  for  hybridisation  to 
Affymetrix GeneChip® arrays and 2 pi samples were electrophoresed on a 1  % agarose 
gel for quantification. The marker (M) was the 1  kb ladder from Invitrogen.
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993.2.4  78 genes were induced or repressed in PC6-3 cells after NGF withdrawal
Data was collected using Affymetrix Microarray Suite 5.0 software with the 
U34A gene set. This provides an indication of sample integrity, assay execution, and 
hybridization performance through the assessment of control hybridizations.  These 
parameters indicated that each experiment had been performed successfully.
The abundance of each transcript represented on the array was generated as the 
raw data and was further analysed using GeneSpring 6 data analysis software (Silicon 
Genetics). The level of each transcript in the presence of NGF was given a value of 
one. The data from samples in the absence of NGF was normalised to the data from 
samples in the presence of NGF for each of the individual GeneChip® experiments. 
Three  lists of genes were compiled that show the changes in  gene expression after 
NGF withdrawal.  Graphs  representing  these  lists  are  shown  in  Figure  3.5.  List  A 
(Figure 3.5A) contains 134 genes and EST sequences that changed more than  1.5 fold 
and  were  detected  in  all  3  experiments.  Further  analysis  of  the  data  generated 
statistically significant gene changes. List B (Figure 3.5B) contains 57 genes and EST 
sequences that changed significantly (p<0.05) by at least 1.5 fold and were detected in 
2 of the 3 experiments performed.  List C (Figure 3.5C) contains 39 genes and EST 
sequences that changed significantly (p<0.05) by at least 1.5 fold and were detected in 
all 3 experiments. The mean fold change was calculated for each gene based on the 
three sets of raw data for the GeneChip® experiments.
The EST sequences were removed to give lists of known genes. The known 
genes in list A were selected as the basis for future experiments since this list provided 
a manageable number of genes and included a selection of genes that are known to 
change in neurons undergoing cell death. This list contains 78 genes, 41  genes that 
increased and 37 genes that decreased, after 16 hours of NGF withdrawal. These genes 
were  classified  into  tables  according  to  their  proposed  function  and  include, 
transcription factors, cell growth/apoptosis regulators,  signalling molecules, protein 
regulators,  receptors,  ion transporters,  electron  transporters  and  genes  involved  in 
various types of metabolism. These results are shown on the following pages in Tables 
1-11. Gene lists B and C are represented in the form of tables in Appendix A and B.
100Figure  3.5  Graphical  representation  of the  lists  showing  changes  in  gene 
expression after NGF withdrawal
Data  was  analysed  using  GeneSpring  6  data  analysis  software  (Silicon 
Genetics). The level of each transcript in the presence of NGF was given a value of 
one.  Data from  samples  in the absence of NGF were  normalised to the data from 
samples in the presence of NGF, for each of the individual GeneChip® experiments. 
Three lists of genes were compiled that show the changes in gene expression after 
NGF withdrawal. Graphs representing these lists are shown. (A) List A contains  134 
genes and EST sequences that changed more than  1.5  fold and were detected all 3 
experiments.  (B)  List  B  contains  57  genes  and  EST  sequences  that  changed 
significantly (p<0.05) by at least 1.5 fold and were detected in 2 of the 3 experiments.
(C)  List C contains 39 genes and EST sequences that changed significantly (p<0.05) 
by at least  1.5 fold and were detected in all 3 experiments. The average fold change 
was calculated for each gene based on the 3 GeneChip® experiments. The y-axis on 
the  graphs  is  a  log  scale.  Increases  in  gene  expression  are  shown  in  purple  and 
decreases in blue. The level of expression in the presence of NGF (+) is shown as 1  on 
the left of the graph. Expression levels in the absence of NGF (-) are shown on the 
right of the graph.
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M63282 2.68 activating transcription factor 3 Atf3 regulation of transcription, DNA-dependent nucleus / transcription factor 
complex
U80054 1.63 mismatch repair protein Mlhl DNA repair / mismatch repair nucleus
AI175959 1.61 c-Jun c-Jun regulation of cell cycle / regulation of transcription, 
DNA-dependent / cell growth / apoptosis
intracellular / nucleus
AF096835 1.59 eukaryotic translation initiation 
factor 2 alpha kinase 3
Eif2ak3 / 
PERK
protein serine/threonine kinase activity / response to 
unfolded protein
endoplasmic reticulum / membrane 
protein / cytoplasm
AA893611 1.58 Max interacting protein 1 Mxil regulation of transcription, DNA-dependent nucleus
Y08138 1.57 dHand protein Hand2 angiogenesis / regulation of transcription, DNA- 
dependent / development / heart development
nucleus
D84418 1.53 high mobility group box 2 Hmgb2 regulation of transcription, DNA-dependent / 
neurogenesis
chromatin / nucleus / chromosome




regulation of transcription, DNA-dependent / ER- 
overload response / cell cycle arrest
nucleus
U92564 1.49 Olf-l/EBF associated Zn finger 
protein Roaz
Roaz transcription factor activity / olfactory neuronal 
differentiation
nucleus
















regulation of cell proliferation / inhibition of thioredoxin cytoplasm




regulation of cell growth / apoptosis endoplasmic reticulum / ribosome
M60921 1.57 B-cell translocation gene 2 Btg2 anti-proliferative / signal transduction / cellular 
differentiation / transcription factor activity / DNA repair
nucleus
L26268 1.51 B-cell translocation gene 1 Btgl anti-proliferative / t(8;12)(q24;q22) chromosomal 
translocation in a B-cell chronic lymphocytic leukemia
nucleus / cytoplasm









J03754 1.9 ATPase, Ca++ transporting, plasma 
membrane 2
Atp2b2 cation transport / calcium ion transport / perception of 
sound / metabolism
plasma membrane / integral to 
membrane
L33869 1.86 Ceruloplasmin Cp iron ion homeostasis / plasma membrane copper ion 
transport
extracellular / extrinsic to plasma 
membrane, GPI-anchored
J05087 1.76 ATPase, Ca++ transporting, plasma 
membrane 3 / PMCA3
Atp2b3 / 
PMCA3
ATPase / calcium ion transport plasma membrane
S75359 1.74 bone morphogenetic protein 
receptor, type 1A
Bmprla serine/threonine kinase receptor / bone formation membrane
AI236721 1.58 14-3-3 protein gamma-subtype Ywhag intracellular signaling cascade / enzyme activator activity 
/ protein kinase C binding / protein targeting / cell cycle
cytoplasm
D17352 1.57 low Mr GTP-binding protein Rab27a GTP binding / GTPase activity / intracellular membrane 
trafficking
cytoplasm
AJ000556 1.56 Janus kinase 1 Jakl protein amino acid phosphorylation / intracellular 
signaling cascade
cytoskeleton
U03120 1.52 solute carrier family 5 (sodium 
/glucose cotransporter), member 1
Slc5al sodium ion transport / glucose transport / metanephros 
development
membrane / integral to membrane / 












protein binding postsynaptic membrane / 
synaptosome
AA893357 2.58 Membrane associated guanylate 
kinase interacting protein-like 1
Magil kinase activity integral to membrane
E03344 2.48 peroxisomal membrane protein 3 Pxmp3 peroxisome organization and biogenesis peroxisomal membrane / integral to 
membrane





activity / protein modification
cytoplasmic
Y09333 1.94 mitochondrial acyl-CoA 
thioesterase 1
Mtel catalytic activity / hydrolase / palmitoyl-CoA hydrolase 
activity / serine esterase activity / lipid metabolism
mitochondrion
E04239 1.86 choline kinase alpha Chka Acetylcholine synthesis / choline kinase activity / 
kinase activity / transferase activity / cell growth
cytoplasm
M64755 1.55 cysteine-sulfinate decarboxylase Csad amino acid metabolism / taurine biosynthesis cytoplasm (?)
S85184 1.5 cathepsin L Ctsl proteolysis and peptidolysis extracellular space / lysosome
U38379 1.59 gamma-glutamyl hydrolase Ggh gamma-glutamyl hydrolase activity / hydrolase activity 
/ peptidase
extracellular space / lysosome
AI145502 1.57 prostaglandin F2 receptor negative 
regulator
Ptgfm negative regulation of protein biosynthesis integral to membrane
AA892897 1.49 procollagen lysine, 2-oxoglutarate 
5-dioxygenase 2
Plod2 hydroxylation of lysine residues in procollagen / 
collagen formation
endoplasmic reticulum / integral to 
membrane
M62388 1.47 ubiquitin conjugating enzyme LOC81816 ubiquitin-dependent proteolysis nucleus
AB000199 1.46 CCA2 protein Hsd3b7 steroid biosynthesis / oxidoreductase activity / 
regulation of cell growth
endoplasmic reticulum / integral to 














secreted acidic cysteine rich 
glycoprotein
Sparc calcium ion binding / structural protein basement membrane / extracellular 
/ extracellular matrix (sensu 
Metazoa)
D85183 1.55 protein tyrosine phosphatase, non­
receptor type substrate 1
Ptpnsl cell motility / actin filament organization / cell-matrix 
adhesion / cell migration
extracellular space / integral to 
membrane
S61868 1.53 syndecan 4 Sdc4 cell adhesion / cell-cell signaling extracellular space / membrane / 
integral to membrane








AJ131888 2.01 sperm autoantigenic protein 17 Spa 17 protein binding / fertilisation sperm acrosome
M13100 2.01 LINE retrotransposable element 3 LlRn/Lre3 retrotransposon / genome diversification DNA / nucleus








AF030089 1.87 activity and neurotransmitter- 
induced early gene protein 4
Ania4 regulation of transcription, DNA dependent nucleus
S69329 1.64 ISL1 transcription factor, 
LIM/homeodomain 1
Isll energy pathways / regulation of transcription, DNA- 
dependent / development
nucleus
Y00396 1.62 c-myc / v-myc myelocytomatosis 
viral oncogene homolog (avian)
Myc regulation of cell cycle / transcription initiation / 
regulation of transcription, DNA-dependent / cell 
growth and/or maintenance / pathogenesis
nucleus
U75397 1.61 early growth response 1 / nerve 
growth factor-induced gene
Egrl regulation of transcription, DNA-dependent / learning 
and/or memory / positive regulation of transcription 
from Pol II promoter / thymocyte differentiation
nucleus
M19651 1.52 Fra-1 / fos-like antigen 1 Fra-1 regulation of transcription, DNA-dependent / positive 
regulation of transcription from Pol II promoter, 
mitotic / Wnt signaling
nucleus
AA891041 1.51 Jun-B oncogene Junb regulation of transcription, DNA-dependent / positive 
regulation of transcription from Pol II promoter, 
mitotic
nucleus
Y09507 1.51 hypoxia inducible factor 1, alpha 
subunit
Hifla response to hypoxia / regulation of transcription, 
DNA-dependent / signal transduction
















protein amino acid dephosphorylation / cell 








ret proto-oncogene Ret regulation of cell cycle / protein phosphorylation / cell 
adhesion / transmembrane receptor protein tyrosine 
kinase ligand binding / cell growth / morphogenesis






brain derived neurotrophic factor Bdnf neurogenesis / neuron differentiation / regulation of 
long-term and short-term neuronal synaptic plasticity
extracellular space
S63521 1.78 glucose-regulated protein GRP78 GRP78 Heat shock protein family / antiapoptotic ER 
chaperone-glucose-regulated protein / inhibit PERK 
phosphorylation / ER stress








U36895 1.8 putative vomeronasal receptor 3 Vnr3/VN3 olfactory receptor / putative transmembrane receptor putative membrane protein
X80187 1.75 bradykinin receptor b2 Bdkrb2 G-protein coupled receptor protein signaling pathway / 
perception of pain
integral to membrane
AA998446 1.72 phosphatidylinositol transfer 
protein, beta
Pitpnb transport intracellular









Htr3a synaptic transmission / transport / ion transport extracellular space / integral to 
plasma membrane
U93306 1.59 kinase insert domain protein 
receptor
Kdr angiogenesis / protein amino acid phosphorylation / 
transmembrane receptor protein tyrosine kinase 
signaling pathway / cell fate commitment
extracellular space / membrane / 
integral to membrane
X05137 1.56 nerve growth factor receptor (TNFR 
superfamily, member 16)
Ngfr lipid metabolism / apoptosis / induction of apoptosis / 
signal transduction / neurogenesis / axon guidance / 
central nervous system development
extracellular space / integral to 
membrane
AF061266 1.52 transient receptor protein 1 Trpl cation channels / receptor-dependent activation / Store- 
operated calcium entry
membrane
L35558 1.47 solute carrier family 1 
(neuronal/epithelial high affinity 
glutamate transporter), member 1
Slclal transport / dicarboxylic acid transport integral to plasma membrane / 














Hmgcr lipid metabolism / cholesterol biosynthesis / 
biosynthesis
endoplasmic reticulum / 







Coenzyme A synthase 1





sterol-C4-methyl oxidase-like Sc4mol metabolism / sterol biosynthesis endoplasmic reticulum / integral to 
membrane
D37920 1.85 squalene epoxidase Sqle electron transport / aromatic compound metabolism / 







farensyl diphosphate synthase Fdps cholesterol biosynthesis / isoprenoid biosynthesis cytoplasm
AF003835 1.71 isopentenyl-diphosphate delta 
isomerase
Idil cholesterol biosynthesis / isoprenoid biosynthesis / 








stearoyl-Coenzyme A desaturase 2 Scd2 fatty acid synthesis integral to membrane
M95591 1.65 famesyl diphosphate famesyl 
transferase 1
Fdftl cholesterol biosynthesis / isoprenoid biosynthesis / 
lipid biosynthesis
endoplasmic reticulum / famesyl- 
diphosphate famesyl transferase 







cytochrome P450, subfamily 51 
(Cyp51)
Cyp51 electron transport / proteolysis and peptidolysis / 
cholesterol biosynthesis
extracellular space / integral to 








AA963839 1.54 diaphorase 1 Dial electron transport soluble fraction / endoplasmic 
reticulum / membrane
J02585 1.51 stearoyl-Coenzyme A desaturase 1 Scdl fatty acid synthesis integral to membrane
U53706 1.49 mevalonate (diphospho) decarboxylase Mvd cholesterol biosynthesis / isoprenoid biosynthesis / 
sterol biosynthesis / phosphorylation
Peroxisome / cytoplasm
U22424 1.49 hydroxy steroid 11-beta dehydrogenase 
2
Hsdllb2 Glucocorticoid/mineralocorticoid metabolism extracellular space / microsome








AA892506 1.78 coronin, actin binding protein 1A Coro la cytoskeletal protein actin cytoskeleton / lysosomal 
membrane
X05834 1.72 fibronectin 1 Fnl acute-phase response / cell adhesion / metabolism / 
wound healing / inflammatory response pathway
extracellular / extracellular matrix 
(sensu Metazoa) / extracellular 
space
U81037 1.6 neuron-glia-CAM-related cell adhesion 
molecule
Nrcam cell adhesion molecule / control of axonal growth / 
cell growth and motility
integral to membrane
X02412 1.47 tropomyosin 1, alpha Tpml actin-binding protein / muscle contraction / 
development / cytoskeleton
cytoskeleton3.3  Discussion
Three Affymetrix GeneChip® experiments  were  performed  using RNA  from 
neuronally differentiated PC6-3  cells cultured either in the  presence or absence of 
NGF for  16 hours. The RNA prepared was carefully checked for integrity using the 
Agilent  2100 Bioanalyzer with  the  Agilent  RNA  6000  Nano  LabChip  kit  and  by 
northern analysis of dp5 levels in PC6-3 cells maintained in the presence and absence 
of NGF. Both methods indicated that the RNA was intact and not degraded.
Analysis of the data produced by the GeneChip® experiments gave three lists of 
genes that showed a change in expression after NGF withdrawal from PC6-3 cells. 
List A contains 78 genes whose transcripts changed in level by at least  1.5 fold and 
which  could  be  detected  in  all  three  experiments.  Further  filtering  of  the  data 
generated statistically significant gene changes. List B contains 34 genes whose level 
of expression  changed  significantly  (p<0.05)  by  at  least  1.5  fold  and  for  which 
transcripts  were detected  in 2  of the  3  experiments  performed.  List C  contains  26 
genes  whose  expression changed significantly  (p<0.05)  by  at least  1.5  fold in  and 
detected in all 3 experiments.
List A contains 78 genes, 41  genes that increased and 37 genes that decreased 
in expression level, after 16 hours of NGF withdrawal. These genes were sorted into 
tables according to their proposed function. Some of the genes have previously been 
described as being NGF regulated, or induced in neurons undergoing apoptosis.
The AP-1 family member c-Jun is up-regulated on average 1.61 fold in the three 
GeneChip® experiments. Induction of this transcription factor was previously observed 
in PC12 cells deprived of NGF (Mesner et al., 1995) and c-Jun plays an important role 
in  neuronal  apoptosis.  When  sympathetic  neurons  and  PC 12  cells  are  deprived of 
NGF, the JNK protein kinase cascade is activated and this leads to an increase in the 
level of c-Jun and increased c-Jun N-terminal phosphorylation. Overexpression of c- 
Jun kills sympathetic neurons in the presence of NGF and inhibition of the function of 
c-Jun, either by microinjection of antibodies against c-Jun or by expression of a c-Jun 
dominant  negative  mutant,  protected  sympathetic  neurons  from  NGF  withdrawal- 
induced death (Estus et al.,  1994; Ham et al.,  1995). In addition, a floxed c-jun gene 
has been successfully knocked out in sympathetic neurons  in vitro (infected with a 
CRE adenovirus) and this inhibited NGF withdrawal-induced death (Palmada et al., 
2002).
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regulated 2.68  fold following NGF withdrawal  in  PC6-3  cells.  ATF-3  is  a  stress- 
inducible gene that is up-regulated following myocardial ischemia, DNA damage and 
neuronal axotomy (Chen et al.,  1996; Hai et al.,  1999; Mashima et al., 2001; Tsujino 
et al., 2000). It has also been reported that atf-3 RNA is induced in PC6-3 cells and 
sympathetic  neurons  following  NGF  withdrawal  (Mayumi-Matsuda  et al.,  1999). 
ATF-3 is a member of the ATF/CREB family of basic/leucine zipper proteins and can 
repress or activate transcription as a homodimer or heterodimer, respectively. It can 
heterodimerise with c-Jun to activate transcription (Hai and Curran,  1991; Hsu et al.,
1992)  and ATF-3 expression correlates with that of c-Jun after nerve injury (Takeda et 
al., 2000; Tsujino et al., 2000).
ATF-3 is also induced in response to endoplasmic reticulum (ER) stress by a 
mechanism requiring eIF2  kinases,  such  as  PERK/EIF2AK3,  in  mouse  embryonic 
fibroblasts (Jiang et al., 2004). PERK phosphorylates eIF2 leading to the inhibition of 
translation initiation. In the absence of stress, PERK associates with the ER chaperone 
GRP78 (BiP). This ER chaperone serves to repress PERK activity and thus translation 
is  allowed  to  proceed.  Release  of ER  chaperones  from  PERK  (when  misfolded 
proteins  accumulate  in the ER)  results  in the increased phosphorylation  of eIF2a, 
which impedes translation initiation in the cell. This allows the cell sufficient time to 
correct the folding problem incurred by the ER stress prior to synthesizing additional 
proteins (Ma et al., 2002). Although PERK-mediated eIF2a phosphorylation leads to a 
general suppression of translation, it promotes the preferential translation of certain 
mRNAs, for example those encoding ATF-3 and ATF-4. Induction of ATF-3 and eIF2 
phosphorylation has also been reported following exposure to ethanol, homocysteine, 
and oxidizing conditions (Cai et al., 2000; Clemens,  1996; Hai and Hartman, 2001; 
Hai et al.,  1999). Increased expression of PERK and decreased expression of GRP78 
were  observed  in  my  GeneChip®  experiments  suggesting  that  ER  stress  may  be 
involved  in  PC6-3  cell  apoptosis  following  NGF  withdrawal.  Up-regulation  of 
GADDI 531  CHOP, a transcription factor involved in the ER-overload response would 
support this idea. It has been reported that this gene is up-regulated in mouse cerebral 
cortical neurons exposed to hypoxia for 24 hours (Jin et al., 2002) and induction can 
be mediated by  PERK (Jiang et al., 2004).
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This  is  a  member of the  CCAAT/enhancer-binding  protein  (C/EBP)  transcription 
factor family and is transcriptionally activated by cellular stress signals. It has been 
demonstrated  that  arsenite  treatment  of  PC 12  cells  results  in  the  induction  of 
GADD153 mRNA expression. There is enhanced binding of ATF4 to a C/EBP-ATF 
site in the GADD153 promoter after 2 hours of arsenite treatment, as the GADD153 
mRNA levels increase. Subsequently, there is enhanced binding of ATF3 complexes 
after 6 hours of arsenite treatment, as GADDI53 expression declines. ATF4 activates, 
while  ATF3  represses,  GADDI53  promoter activity  through  the  C/EBP-ATF  site 
(Fawcett  et al.,  1999).  In  addition,  ATF-3  can  interact  with  the  bZIP  protein 
GADDI53 to regulate transcription and forms a nonfunctional heterodimer that does 
not bind to the ATF/CRE consensus site and does not repress transcription (Chen et 
al.,  1996).  There  seems  to  be  mutual  negative  regulation  between  ATF-3  and 
GADDI53, which could allow fine-tuning of the levels of these proteins within the 
cell (Wolfgang et al.,  1997). Ectopic expression of GADD153  induces apoptosis in 
Ml myeloblastic leukaemia cells and this is accompanied by a down-regulation of bcl- 
2 (Matsumoto et al., 1996). Oxidative stress leads to increased binding of Fos and Jun 
proteins to the AP-1  site in the GADDI53 promoter when transfected into HeLa cells 
(Guyton et al., 1996). Thus, GADDI53 expression may be regulated by the ATF/AP-1 
family during apoptosis.
Increased expression of GADD34 correlates with apoptosis (Hollander et al., 
1997), and forced overexpression of the protein leads to apoptosis. GADD34 protein 
modulates  protein  phosphatase  type  1   activity  through  both  direct  binding  to  the 
protein, as well as through binding to other proteins that also modulate phosphatase 
activity (Connor et al., 2001). Expression of GADD34 has also been linked to eIF2 
dephosphorylation  (Novoa  et  al.,  2001)  and  mRNA  levels  increase  following 
activation of PERK. In addition, GADD34 is induced by ATF-3. In mouse embryonic 
fibroblasts lacking ATF-3, reduced GADD34 expression  is observed following ER 
stress (Jiang et al., 2004). In my GeneChip® experiments GADD34 was induced 1.6 
fold following NGF withdrawal from PC6-3 cells. It has been reported that GADD34 
mRNA is  induced following transient forebrain  ischemia in  mice (Doutheil  et al., 
1999).
114Vdupl/Txnip  (Vitamin  D3  up-regulated  protein  1/thioredoxin  inhibitor 
protein) mRNA is induced rapidly in cerebellar granule neurons undergoing apoptosis 
during  removal  of high  potassium  and  in  sympathetic  neurons  deprived  of NGF 
(Saitoh et al., 2001). Txnip inhibits the antioxidant protein thioredoxin. Thioredoxin 
can inhibit the apoptosis signal-regulating kinase  1  (ASK1). In sympathetic neurons 
and  PC 12  cells,  ASK1  activates  the  JNK  pathway  and  thus  promotes  apoptosis 
(Kanamoto  et  al.,  2000).  Inhibition  of thioredoxin  by  Txnip  would  remove  the 
inhibition on ASK1  and thus facilitate activation of the JNK pathway. This transcript 
is up-regulated 1.78 fold in my microarray experiment.
Dual specificity phosphatase 6/MAP kinase phosphatase-3 (Dusp6/MKP-3) is 
a protein tyrosine phosphatase that dephosphorylates the extracellular signal-regulated 
protein kinase (ERK). Expression of this phosphatase is induced by NGF in PC 12 cells 
(Camps et al.,  1998) and levels decrease following NGF withdrawal. This was found 
to decrease ~ 5.4 fold in my microarray experiments.
JunB and Fra-1 (Fos-related antigen 1) are members of the Jun/AP-1 family of 
transcription factors. In contrast to c-jun, the expression of these genes decreased  1.5 
fold after NGF withdrawal from PC6-3 cells. JunB can antagonise the DNA binding 
and function of c-Jun (Chiu et al., 1989; Deng and Karin, 1993; Schlingensiepen et al.,
1993). It has weak DNA binding activity and so is thought to act as transcriptional 
repressor.  It has been reported to form dimers with both c-Jun and ATF-3,  and so 
would thus repress their activity. Fra-1 can also form dimers with c-Jun and is thought 
to function as a negative regulator since it lacks transactivation domains and fails to 
activate transcription when fused to the DNA-binding domain of Gal4 (Metz et al.,
1994). NGF induces Fra-1 and JunB expression in PC12 cells (Boss et al., 2001; Ham 
et al., 1995) and therefore levels may drop after NGF withdrawal. Decreased levels of 
these transcription factors could therefore lead to increased c-Jun or ATF-3 activity 
within a cell.
The mRNA encoding the BH3-only protein DP5  increases in level in PC 12 
cells and sympathetic neurons after NGF withdrawal (Imaizumi et al.,  1997) and this 
was confirmed in my northern blotting experiments (Figure 3.3). However, dp5 was 
not  one  of  the  up-regulated  genes  in  my  GeneChip®  experiments.  The  dp5 
oligonucleotide  probes  on  the  arrays  were  designed  to  be  complementary  to  the 
mRNA at the 5' end of the sequence. The dp5 mRNA is 5.5 kb in length and therefore
115it is  unlikely that the IVT reaction,  during the target preparation,  produced cRNA 
sequences  of sufficient  length  to  include  the  very  5'  end.  This  would result  in  an 
inaccurate assessment of dp5 levels within the different RNA populations.
The  statistically significant lists B  and C reduced the number of genes that 
were found to change after NGF withdrawal from differentiated PC6-3 cells. Many of 
the genes previously reported to change after NGF withdrawal were no longer on the 
lists, for example c-jun and atf-3. This is possibly due to the nature of the experiment 
performed. The RNA samples were extracted 16 hours after NGF withdrawal, and thus 
the kinetics of induction of a gene will determine whether it is detected at a higher 
level or not. For example, c-Jun is induced by 6 hours after NGF withdrawal in PC 12 
cells (Mesner et al., 1995). By 24 hours, levels are comparable to those in the presence 
of NGF. If all cells are not synchronous in their kinetics of induction some may take 
longer to induce c-jun and thus a higher level could be detected at  16 hours and in 
other experiments levels of c-jun may have decreased again by  16 hours. This could 
also be true for the expression level of aft-3. ATF-3 is not present in the statistically 
significant lists of genes, even though its level of expression was increased on average 
2.68  fold in  3  experiments.  Looking at the raw data for this  gene  shows that atf-3 
expression levels did not change in one of the experiments and changed by 4.99 fold in 
another.  This  therefore cannot be classified as  a  statistically  significant change  in 
expression.
However, ATF-3  was selected for more detailed analysis because it was the 
most highly up-regulated gene  in the  Affymetrix GeneChip® experiments  and  is  a 
potential c-Jun dimerisation partner and c-Jun target gene,  whose role  in  neuronal 
apoptosis had not been investigated in detail previously.
116Chapter  4:  ATF-3  is  induced  during  neuronal
apoptosis
4.1  Introduction
Sympathetic  neuron  apoptosis  following  NGF  withdrawal,  is  blocked  by 
inhibitors of RNA and protein synthesis (Martin et al.,  1988). This suggests that this 
cell death requires new gene expression and therefore that transcription factors play a 
critical role in the death process. The AP-1 family member c-Jun has been shown to be 
an important component of this process. When sympathetic neurons are deprived of 
NGF an  intracellular signalling cascade  is  activated that induces  the  basic/leucine 
zipper transcription  factor c-Jun.  Removal  of NGF  from  its  receptors  on  the  cell 
surface  leads  to  the  activation  of c-Jun  N-terminal  kinase  (JNK).  JNK  activity  is 
necessary  for  c-Jun  phosphorylation,  c-jun  promoter  activation  and  the  NGF 
withdrawal-induced death of sympathetic neurons (Eilers et al., 2001; Harding et al., 
2001).  This  phosphorylation  of c-Jun  increases  the  transcriptional  activity  of the 
protein. The c-Jun transcription factor acts via AP-1 DNA binding sites present in the 
promoters of target genes and also in c-jun itself (Angel et al.,  1988). c-Jun binds to 
DNA as  a homodimer or heterodimer with other basic/leucine  zipper transcription 
factors, such as c-Fos, Jun D, ATF-2 and ATF-3, to regulate gene expression (Deng 
and Karin, 1993; Hai and Curran, 1991; Hsu et al., 1992).
The transcription factor ATF-3 is a member of the ATF/CREB family of basic 
leucine  zipper  proteins  originally  defined  by  their  ability  to  bind  the  consensus 
ATF/CRE site (5'-TGACGTCA-3').  These proteins bind DNA via the basic leucine 
zipper  (bZIP)  region,  where  there  is  most  homology  between  different  family 
members.  ATF-3  acts as a transcriptional repressor when a homodimer (Hai et al., 
1999), but has been reported to act as a transactivator when a heterodimer with other 
proteins, such as c-Jun (Hai and Curran,  1991; Hsu et al.,  1992). ATF-3 is a stress- 
inducible  gene that is up-regulated following  myocardial  ischemia,  DNA damage, 
neuronal axotomy and excitotoxic insult (Chen et al.,  1996; Hai et al., 1999; Mashima 
et al.,  2001;  Tsujino  et al.,  2000).  The  injury  specific  expression  of ATF-3  in 
axotomised dorsal root ganglia and spinal cord following sciatic nerve cut (Tsujino et 
al., 2000)  and retinal ganglion cells  after optic nerve  injury  (Takeda et al.,  2000)
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number of AP-1  binding sites and can be activated by overexpression of c-Jun and 
ATF-2 in HeLa cells (Liang et al.,  1996) and by MEKK1, an upstream activator of 
JNK, in HCT116 colorectal carcinoma cells (Fan et al., 2002). ATF-3 therefore has 
the  potential  to  be  a  dimerisation  partner  of c-Jun  and/or  a  c-Jun  target  gene  in 
sympathetic neurons undergoing apoptosis.
My  Affymetrix GeneChip® results  showed  that  ATF-3  expression  was  up- 
regulated  2.68  fold  following  NGF  withdrawal  in  differentiated  PC6-3  cells.  In 
addition it has previously been reported that atf-3 RNA is induced in PC6-3 cells and 
sympathetic  neurons  following  NGF  withdrawal  (Mayumi-Matsuda  et al.,  1999). 
ATF-3  was  selected  for  more  detailed  analysis  because  it  is  a  potential  c-Jun 
dimerisation partner and c-Jun target gene, whose role in neuronal apoptosis had not 
been investigated in detail previously. In the following experiments, ATF-3 protein 
and RNA levels were examined in PC6-3  cells and sympathetic neurons following 
NGF withdrawal  and  the  potential  involvement  of the  JNK/c-Jun  pathway  in  the 
induction of ATF-3 expression was studied using chemical inhibitors.
4.2  Results
4.2.1  ATF-3 is up-regulated in PC6-3 cells after NGF withdrawal
To confirm the GeneChip® result, atf-3 RNA levels in PC6-3 cells cultured in 
the  presence  and  absence  of  NGF  were  examined.  Northern  blot  analysis  was 
performed. mRNA was purified from total RNA and samples (5  p,g) electrophoresed 
on  an  agarose-formaldehyde  gel.  Aft-3 probe DNA was amplified from a rat brain 
cDNA  library  by  PCR  and  bcl-xL   probe  DNA  was  generated  by  digesting  the 
pCDFLAGBcl-xL  vector with Bglll and EcoRI restriction enzymes. Northern analysis 
of RNA isolated from differentiated PC6-3 cells cultured in the presence or absence of 
NGF for  16 hours  showed that the atf-3 mRNA increases in level by 2.6 fold after 
NGF deprivation  (Figure  4.1 A).  This  correlates  with  the  GeneChip® result  of an 
average induction of 2.68 fold and that of previously published results, which show 
enhanced  levels  of atf-3  RNA  after  6  hours  of NGF  withdrawal  in  PC6-3  cells 
(Mayumi-Matsuda et al., 1999).
118Figure 4.1  The aft-3  mRNA  increases  in  level  in  differentiated  PC6-3  cells
following NGF withdrawal
(A)  PC6-3  cells  were  differentiated  for 7  days  in  the  presence  of NGF  and  then 
cultured in the presence or absence of NGF for  16 hours. Total RNA was isolated, 
mRNA  was  purified  from  the  total  RNA,  and  mRNA  samples  (5  pg)  were 
electrophoresed on a  1% agarose-formaldehyde gel and transferred to nitrocellulose. 
Northern blotting  was  performed using  32P-labelled atf-3  and  bcl-xL  probe  DNAs. 
Membranes  were  exposed  to  a  phosphorimager  screen  for  1-4  nights  at  room 
temperature and the screens were scanned using a Typhoon™ 8600 phosphorimager to 
quantitate the levels of atf-3 and bcl-xL  mRNA. RNA bands were quantitated using the 
ImageQuant analysis program and the ratio of atf-3 to bcl-xL  was calculated. Bcl-xL  
RNA levels remain relatively constant for the first 24 hours after NGF withdrawal and 
were used as a control for gel loading. In the northern blot shown, the level of atf-3 
mRNA is 2.6 fold higher after 16 hours of NGF deprivation. The size of the aft-3 and 
bcl-xL  mRNAs is indicated.
(B)  PC6-3  cells  were  differentiated  for 7  days  in  the  presence  of NGF  and  then 
cultured for various times in the absence of NGF. RNA was extracted and converted 
into cDNA before being analysed by PCR. The PCR products were separated on 1.5% 
agarose gels. Representative gels for dp5, aft-3 and nf-m are shown.
(C) Images of bands for atf-3, dp5 and nf-m were captured using ImageMaster VDS- 
CL and quantitated using ImageMaster Total Lab. Levels of atf-3 and dp5 relative to 
nf-m were calculated and displayed on the graphs as relative level of RNA. The data 
shown  represents  the  average  of two  independent  experiments.  The  bars  indicate 
range. Atf-3 levels increased 3.2 fold over 16 hours.
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120To  get  a  better  idea  of  the  kinetics  of  gene  induction  following  NGF 
withdrawal, semi-quantitative RT-PCR was performed on RNA extracted at various 
time-points following the removal of NGF from PC6-3 cells. RNA was extracted and 
converted into cDNA before being analysed by PCR (Figure 4.IB). The level of atf-3 
RNA relative to neurofilament-m  (nf-m) was determined. Atf-3 levels increased 3.2 
fold over  16 hours (Figure 4. IB, C). Once again this correlates with the Affymetrix 
GeneChip® result, which gave an average induction of 2.68 fold at this time-point. The 
mRNA encoding the BH3-only protein DP5 has previously been shown to be induced 
in PC 12 cells and sympathetic neurons after NGF withdrawal (Imaizumi et al, 1997). 
RT-PCR  experiments  with  primers  specific  for dp5  were performed as  a control. 
Levels of dp5 RNA increased following NGF withdrawal reaching a maximum level 
relative to nf-m after 24 hours (Figure 4.IB, C).
Previous work has shown that ATF-3 protein levels increase within 9 hours 
after NGF depletion in PC6-3 cells (Mayumi-Matsuda et al,  1999). In addition it is 
known that the c-Jun protein is induced and phosphorylated in PC 12 cells at 4-8 hours 
after  NGF  withdrawal  (Ham  et  al,  1995;  Mesner  et  al,  1995).  ATF-3  can 
heterodimerise with Jun proteins (Hai and Curran, 1991; Hsu et al,  1992) and the aft-
3 promoter can be activated by overexpression of c-Jun in HeLa cells (Liang et al,
1996).  It  was  therefore  of interest  to  examine  the  levels  of ATF-3  and  c-Jun  in 
differentiated PC6-3 cells during a timecourse of NGF withdrawal to establish the time 
of induction of these proteins relative to each other (Figure 4.2). Figure 4.2A shows a 
western blot for ATF-3, c-Jun and Bcl-xL . Levels of ATF-3 and c-Jun were normalised 
to the levels of Bcl-xL  to control for any differences in protein loading (Figure 4.2B). 
ATF-3 protein levels started to increase between 8 and 16 hours after NGF withdrawal 
and remained elevated at 24 hours. However, c-Jun levels started to increase between
4 and 8 hours after NGF withdrawal and reached a peak at 8 hours. The c-Jun protein 
had decreased again to minimum levels after 16 hours of NGF deprivation. In the case 
of this one experiment, the induction of c-Jun occurs prior to the induction of ATF-3 
in PC6-3 cells, which suggests that ATF-3 might be a potential target of c-Jun in this 
cell system and thus perhaps also in sympathetic neurons.
121Figure 4.2  ATF-3 and c-Jun protein levels increase in differentiated PC6-3 cells
after NGF withdrawal
(A)  PC6-3  cells  were  differentiated  for 7  days  in  the  presence  of NGF and  then 
cultured for various times in the presence or absence of NGF. Protein was isolated and 
15 pg samples were run on a 15% SDS-polyacrylamide gel and western blot analysis 
performed. Blots were incubated with antibodies for ATF-3, c-Jun and Bcl-xL . ATF-3 
and c-Jun are present at low levels in undifferentiated (UD) PC6-3 cells. The results of 
a single experiment are shown.
(B) Western blots were scanned on a Bio-Rad GS800 densitometer to quantitate levels 
of protein.  Images of bands were captured and quantitated using Bio-Rad Quantity 
One® software. The graph represents the levels of c-Jun and ATF-3 protein relative to 
that of Bcl-xL. Bc1-xl protein levels remain relatively constant for the first 24 hours 
after  NGF  withdrawal  and  were  used  as  a control  for  any  differences  in  protein 
loading. The data shown represents one experiment. In neuronally-differentiated PC6- 
3 cells, ATF-3 protein levels peaked at 16 hours after NGF withdrawal. c-Jun protein 
increases in level between 4 and 8 hours after NGF withdrawal, reaching a peak at 8 
hours.
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1234.2.2  ATF-3 RNA and protein levels increase in sympathetic neurons after NGF 
withdrawal
Sympathetic neurons have proved to be a useful in vitro model for studying 
neuronal apoptosis mechanisms (Deshmukh and Johnson,  1997). These cells die by 
apoptosis between days 3  and 7 of postnatal development in the rat and depend on 
NGF for survival at that time (Wright et al.,  1983). Figure 4.3 shows representative 
pictures of sympathetic neurons cultured in the presence of NGF for 7 days and then in 
the presence or absence of NGF for 24 hours. After 24 hours in the absence of NGF, 
the neurons display the classic features of apoptosis,  such as  shrunken cell bodies, 
membrane blebbing, distorted nuclei, fragmented neurites and condensed chromatin. 
Eventually the dying neurons detach from the culture substrate.
The pattern of ATF-3 expression in sympathetic neurons undergoing apoptosis 
was investigated. RNA was extracted at various times following NGF withdrawal and 
converted  into  cDNA  for semi-quantitative RT-PCR  analysis  (Figure 4.4A).  Atf-3 
RNA levels, relative to nf-m RNA levels, were determined (Figure 4.4B). On average, 
the  atf-3  RNA  had  increased  2.1  fold  at  16  hours  after  NGF  withdrawal.  This 
correlates  with previously  published results,  which  show  enhanced  levels  of atf-3 
RNA in sympathetic neurons after 18 hours of NGF withdrawal (Mayumi-Matsuda et 
al., 1999). Dp5 is induced in sympathetic neurons after NGF withdrawal (Imaizumi et 
al.,  1997) and therefore RT-PCR with primers specific for dp5 was performed as a 
control (Figure 4.4A).  Levels of dp5 RNA had increased by 8 hours and reached a 
maximum at 16-24 hours following NGF deprivation (Figure 4.4B).
To determine whether the increase in atf-3 RNA level leads to an increase in 
the  amount  of  ATF-3  protein,  a  timecourse  immunoblotting  experiment  was 
performed. Sympathetic neurons were grown for 6-7 days in the presence of NGF and 
then in the absence of NGF for specific times over 24 hours and protein extracted. 
Figure 4.5A shows typical western blots for ATF-3, c-Jun and tubulin. Levels of ATF- 
3 and c-Jun were normalised to the levels of tubulin to control for any differences in 
protein  loading  (Figure  4.5B).  The  level  of  c-Jun  protein  and  c-Jun  N-terminal 
phosphorylation (manifested as a mobility shift) began to increase between 4 and 8 
hours after NGF withdrawal and remained elevated at 16 and 24 hours. This correlates 
with previously published results that showed that c-Jun increases between 8 and 24 
hours after NGF withdrawal (Ham et al,  1995). The ATF-3 protein started to increase
124Figure 4.3  Morphology of sympathetic neurons cultured  in  the  presence or 
absence of NGF
Sympathetic neurons were cultured for 7 days in the presence of NGF. In NGF 
withdrawal  experiments  (-NGF)  neurons  were  cultured  without  NGF by  carefully 
rinsing the cells twice in  SCG medium lacking NGF and then refeeding with SCG 
medium supplemented with anti-NGF antibody at 100 ng/ml. Cells in the presence of 
NGF  (+NGF)  were  also  rinsed  twice  in  SCG  medium  and  refed  with  medium 
containing NGF (+NGF) and left for 24 hours. Cells were then examined on a Zeiss 
Axiovert 200 microscope and photographed using an Axiocam digital camera. Images 
were exported as TIFFs  and processed in Adobe photoshop.  After 24 hours  in the 
absence of NGF, the neurons have begun to display signs of cell death. Cells become 
rounded and smaller in appearance, nuclei become  shrunken  and have an irregular 
shape, neurites fragment and the neurons detach from the coverslip. The bar represents 
10 pM.
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126Figure 4.4  Atf-3 RNA levels increase in sympathetic neurons deprived of NGF
(A) Sympathetic neurons were grown in the presence of NGF for 6-7 days and then 
cultured for various times in the absence of NGF. RNA was extracted and converted 
into cDNA before being analysed by PCR. The PCR products were separated on 1.5% 
agarose gels and representative images are shown.
(B) Images of bands for atf-3, dp5 and nf-m were captured using ImageMaster VDS- 
CL and quantitated using ImageMaster Total Lab software. Levels of atf-3 and dp5 
relative to nf-m were calculated and displayed on the graphs as relative level of RNA. 
The data shown represents the average of three independent experiments. Error bars 
indicate  SEM.  There  was  a 2.1  fold increase  in atf-3 RNA  at  16 hours  after NGF 
withdrawal.
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128Figure 4.5  ATF-3 protein levels increase in sympathetic neurons deprived of 
NGF
(A) Sympathetic neurons were grown in the presence of NGF for 6-7 days and then 
cultured in the absence of NGF. Protein was extracted at various times over the course 
of 24 hours.  Protein isolated from two coverslips of neurons (approximately  16,000 
cells) was loaded per lane of a 15% SDS-polyacrylamide gel and western blot analysis 
performed.  Blots  were  incubated  with  antibodies  specific  for  c-Jun,  ATF-3  and 
tubulin. Representative western blots are shown.
(B) Western blots were scanned on a Bio-Rad GS800 densitometer to quantitate levels 
of protein.  Images of bands were captured and quantitated using Bio-Rad Quantity 
One® software. The graph represents the levels of c-Jun and ATF-3 protein relative to 
that of tubulin (to normalise for any differences in protein loading). The data shown 
represents the average of three independent experiments. Error bars indicate SEM. c- 
Jun protein  levels  start to increase  within the  first  8  hours  after NGF withdrawal, 
whereas ATF-3 levels start to increase between 8 and 16 hours.
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130between 8 and  16 hours after NGF withdrawal and continued to increase between  16 
and 24  hours  in the absence of NGF.  Thus  the  increase  in level  of ATF-3  protein 
correlates  with  the  increase  in  level  of atf-3  transcripts  at  these  time-points.  In 
addition, as seen in PC6-3 cells, the c-Jun protein starts to increase in level before 
ATF-3 levels increase, following NGF withdrawal.
4.2.3  The  increase  in  ATF-3  protein  after  NGF  withdrawal  is  inhibited  by 
chemical inhibitors of the JNK/c-Jun pathway
JNK activity increases in sympathetic neurons after NGF withdrawal (Eilers et 
al.,  1998; Virdee et al.,  1997). This kinase activity is necessary for c-Jun N-terminal 
phosphorylation, c-jun promoter activation and NGF withdrawal-induced death (Eilers 
et al.,  2001;  Harding  et al.,  2001).  The JNK/c-Jun  pathway  inhibitor,  CEP-1347 
rescues sympathetic neurons from death by NGF deprivation (Maroney et al.,  1999). 
CEP-1347 inhibits mixed-lineage kinases (MLKs) upstream of JNK in the JNK/c-Jun 
pathway  (Maroney  et  al.,  2001).  To  further  investigate  the  role  of  ATF-3  in 
sympathetic  neuron  apoptosis,  the  closely  related  MLK  inhibitor CEP-11004  was 
added  to  neurons  at  the  time  of NGF  withdrawal.  Neurons  were  cultured  in  the 
presence or absence of NGF for 24 hours and in the presence of CEP-11004 (400 nM) 
or DMSO (control). Protein was extracted and western blot analysis performed using 
antibodies  specific for c-Jun, ATF-3  and tubulin (Figure 4.6A).  Three independent 
experiments were performed and typical blots are shown. Levels of ATF-3 and c-Jun 
were  normalised  to  the  levels  of tubulin  to  control  for  any  differences  in  protein 
loading  (Figure  4.6B).  As  expected,  the  increase  in  c-Jun  protein  level  and 
phosphorylation  observed  after  NGF  withdrawal  (DMSO)  was  reduced  by  the 
presence  of CEP-11004.  ATF-3  was  induced  dramatically  after  NGF  withdrawal 
(DMSO) and this was completely inhibited by CEP-11004.
The JNK inhibitor SP600125 was also used to investigate the involvement of 
the JNK/c-Jun pathway in ATF-3 protein induction after NGF withdrawal. Neurons 
were cultured in the presence or absence of NGF for 24 hours and in the presence of 
SP600125  (20  pM)  or  DMSO  (control).  Protein  was  extracted  and  western  blot 
analysis performed for c-Jun, ATF-3 and tubulin  (Figure 4.7A). Three independent 
experiments were performed and typical blots are shown. Levels of ATF-3 and c-Jun 
were  normalised  to  the  levels  of tubulin  to  control  for  any  differences  in  protein
131loading  (Figure  4.7B).  As  expected,  the  increase  in  c-Jun  protein  level  and 
phosphorylation observed after NGF withdrawal (DMSO) was completed inhibited by 
the presence of SP600125. ATF-3 induction after NGF withdrawal (DMSO) was also 
completely prevented by SP600125.
These results suggest that ATF-3  is regulated by the JNK/c-Jun pathway in 
sympathetic neurons. A hypothetical model of the regulation of ATF-3 by the JNK/c- 
Jun pathway in neurons is shown in Figure 4.8.
132Figure 4.6  The increase in the level of the ATF-3 and c-Jun proteins following
NGF withdrawal is reduced by the MLK inhibitor CEP-11004
(A) Sympathetic neurons were grown in the presence of NGF for 6-7 days and then 
cultured in the presence or absence of NGF for 24 hours. At this time, neurons were 
also treated with DMSO (control) or CEP-11004 (400 nM) for 24 hours. Protein was 
extracted  from  two  coverslips  of  neurons  (approximately  16,000  cells)  for  each 
treatment.  Samples  were  electrophoresed  on  a  15%  SDS-polyacrylamide  gel  and 
western blot analysis performed. Blots were incubated with antibodies specific for c- 
Jun, ATF-3 and tubulin. Typical western blots are shown.
(B) Western blots were scanned on a Bio-Rad GS800 densitometer to quantitate levels 
of protein.  Images of bands  were captured and quantitated using Bio-Rad Quantity 
One® software. The graph represents the levels of c-Jun and ATF-3 protein relative to 
that of tubulin (to normalise for any differences in protein loading). The data shown 
represents the average of three independent experiments. Error bars indicate SEM. The 
increase in the level of c-Jun and ATF-3  following NGF withdrawal is reduced by 
CEP-11004.
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134Figure 4.7  The increase in the level of the ATF-3 and c-Jun proteins following
NGF withdrawal is inhibited by the JNK inhibitor SP600125
(A) Sympathetic neurons were grown in the presence of NGF for 6-7 days and then 
cultured in the presence or absence of NGF for 24 hours. At this time, neurons were 
also treated with DMSO  (control) or SP600125  (20  pM) for 24 hours.  Protein was 
extracted  from  two  coverslips  of  neurons  (approximately  16,000  cells)  for  each 
treatment.  Samples  were  electrophoresed  on  a  15%  SDS-polyacrylamide  gel  and 
western blot analysis performed. Blots were incubated with antibodies specific for c- 
Jun, ATF-3 and tubulin. Typical western blots are shown.
(B) Western blots were scanned on a Bio-Rad GS800 densitometer to quantitate levels 
of protein.  Images of bands were captured and quantitated using Bio-Rad Quantity 
One® software. The graph represents the levels of c-Jun and ATF-3 protein relative to 
that of tubulin (to normalise for any differences in protein loading). The data shown 
represents the average of three independent experiments. Error bars indicate SEM. The 
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136Figure  4.8  Hypothetical  model  of  how  ATF-3  expression  is  regulated  in 
sympathetic neurons deprived of NGF
NGF withdrawal leads to a decrease in signalling from TrkA receptors on the 
cell surface and activation of mixed-lineage kinases (MLK), which activates a cascade 
of kinases including c-Jun N-terminal kinase (JNK) kinases (JNKK)  and JNK.  The 
chemical inhibitors of the pathway used in this study are indicated. c-Jun levels and c- 
Jun N-terminal phosphorylation increase after NGF withdrawal and expression of a 
dominant  negative  c-Jun  mutant,  FLAGA169,  blocks  NGF  withdrawal-induced 
apoptosis  (Ham et al.,  1995).  In  sympathetic  neurons, ATF-3  is  induced following 
NGF withdrawal and this is observed after the initial induction and phosphorylation of 
c-Jun. The atf-3 promoter can be activated by overexpression of c-Jun and ATF-2 (Cai 
et al., 2000, Liang et al.,  1996), thus implicating it as a potential c-Jun target gene. 
ATF-3 and c-Jun can dimerise to regulate transcription (Hai and Curran,  1991, Hsu et 
al.,  1992) and may do so during neuronal apoptosis. The increase in the level of ATF- 
3 after NGF withdrawal, is inhibited by the MLK inhibitor CEP-11004 and the JNK 
inhibitor SP600125, suggesting that ATF-3 is regulated by the JNK/c-Jun pathway in 
sympathetic neurons.  The induction of DP5 and Bim is partially dependent on JNK 
signalling. The MLK inhibitor CEP-1347 reduced the induction of DP5  and Bim in 
sympathetic neurons following NGF withdrawal (Harris and Johnson, 2001). This is 
consistent  with  the  findings  of  Whitfield  et al.  (2001),  who  reported  that  Bim 
induction is decreased in NGF-deprived sympathetic neurons that express dominant 
negative  c-Jun  (Whitfield  et al.,  2001).  These  BH3-only  proteins  may  directly 
dimerise with Bcl-2 or Bcl-xL  to inhibit their action (Yang et al, 1995; O’Connor et al., 
1998). The cell death induced by DP5 is inhibited by Bcl-2 (Imaizumi et al., 1999).
During NGF withdrawal-induced sympathetic neuron apoptosis, cytochrome c 
is released from the mitochondria (Deshmukh and Johnson, 1998; Neame et al., 1998). 
Cytochrome  c  is  required  for  this  cell  death  because  microinjection  of blocking 
antibodies increases cell survival (Neame et al., 1998). When released into the cytosol, 
cytochrome c binds procaspase-9 and Apaf-1, which leads to activation of caspase-9 in 
the presence of ATP. This cleaves executioner caspases, such as procaspase-3, into 
their active forms, which cleave the protein substrates that lead to the cellular changes 
that  are  characteristic  of  apoptosis.  These  events  occur  downstream  of  c-Jun 
activation, because expression of FLAGA169 blocks cytochrome c release from the 
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In the experiments described in this chapter I have confirmed my Affymetrix 
GeneChip® result that ATF-3 is induced in neuronal cells following NGF withdrawal. 
The  atf-3  RNA  increased  in  neuronally  differentiated  PC6-3  cells  after  NGF 
deprivation. This induction peaked at 16 hours after NGF withdrawal. This correlates 
with the GeneChip® result of an average induction of 2.68 fold and with previously 
published results, which showed enhanced levels of atf-3 RNA after 6 hours of NGF 
withdrawal in PC6-3 cells (Mayumi-Matsuda et al., 1999). The increase in RNA led to 
an increase in the level of ATF-3 protein. ATF-3 protein levels had increased by  16 
hours after NGF withdrawal and remained elevated after 24 hours.  Following NGF 
withdrawal  from  PC6-3  cells,  c-Jun  is  induced  and  phosphorylated  prior  to  the 
induction  of ATF-3.  The expression of ATF-3  in  sympathetic  neurons  undergoing 
apoptosis  was also investigated.  There was  a 2.1  fold increase in atf-3 RNA  at  16 
hours  after NGF withdrawal.  This  agrees with previously published results,  which 
show enhanced levels of atf-3 RNA after 18 hours of NGF withdrawal in sympathetic 
neurons  (Mayumi-Matsuda et al.,  1999).  I  also  observed  that  the  ATF-3  protein 
increased in level between 8  and  16 hours after NGF withdrawal  and continued to 
increase in level after 24 hours in the absence of NGF. This increase in expression was 
observed after the induction and phosphorylation of c-Jun protein, which began to 
increase between 4 and 8 hours after NGF withdrawal and remained elevated at 16 and 
24 hours.
The induction of ATF-3 after NGF withdrawal, was completely inhibited by 
the MLK inhibitor CEP-11004 and the JNK inhibitor SP600125, suggesting that ATF- 
3 is a component of the JNK/c-Jun pathway. However, the induction of c-Jun was not 
completely inhibited by CEP-11004.  At the concentration of CEP-11004 used (400 
nM), there are low levels of phospho-JNK (Thr 183/Tyr 185) present in NGF-deprived 
sympathetic  neurons  (Wang  et al.,  2005).  This may be  sufficient to activate c-Jun 
and/or  ATF-2  and  induce  c-Jun  expression,  but  insufficient  to  initiate  ATF-3 
induction.  The effect of these chemical inhibitors  is  not definitive proof of ATF-3 
regulation by the JNK/c-Jun pathway.  Cephalon have found that in  in vitro kinase 
assays for CEP-11004 the IC5 0  for MLKs and other kinases is: MLK1, 45 nM; MLK2, 
89 nM; MLK3, 31 nM; DLK, 160 nM; MLK6, >10,000 nM; PKC (brain a, p, y), 930 
nM; TrkA, >1000 nM (datasheet supplied by Cephalon, Inc). However, CEP-11004
139has been found to induce an increase in TrkA mRNA and protein levels, resulting in 
NGF-independent activation of the TrkA receptor and the downstream PI3K pathway, 
in sympathetic neurons (Wang et al., 2005). In contrast to CEP-11004, SP600125 has 
been shown to directly inhibit JNKs (Bennett et al., 2001; Bogoyevitch et al., 2004), 
but this compound is not as selective as the original reports  suggested (Bain et al., 
2003).
Further evidence  for an  involvement  of the  JNK/c-Jun  pathway  in  ATF-3 
regulation is reported by Cai et al. (2000). Homocysteine-induced vascular endothelial 
cell injury leads to increased atf-3 gene expression and this  induction involves the 
activation  of JNK.  A  complex  containing  ATF-2  and  c-Jun  activated  the  atf-3 
promoter, whereas ATF-3 repressed its own promoter.  In addition, the induction of 
ATF-3 by ionizing radiation in primary human fibroblasts is mediated by signalling 
through  JNKs  and  ATF-2  (Kool  et  al.,  2003).  In  sympathetic  neurons,  the 
phosphorylation of c-Jun and ATF-2 increases after NGF withdrawal. However, the 
increase in ATF-2 phosphorylation  is more transient than the increase in c-Jun  N- 
terminal phosphorylation after NGF withdrawal (Eilers et al., 2001). In addition, c-Jun 
protein  levels  increase but ATF-2  protein  levels  fall  after NGF withdrawal.  Since 
ATF-3 protein induction after NGF deprivation in sympathetic neurons follows that of 
c-Jun and since ATF-3 can dimerise with c-Jun, it is possible that ATF-3 may dimerise 
with  c-Jun  in  neurons  undergoing  apoptosis.  ATF-3  contains  a  putative 
phosphoacceptor site for JNK at Thr-148, however no change in protein migration was 
observed  after  treatment  of  HEK293  cells  with  anisomycin,  a  JNK  activator, 
suggesting that ATF-3 is not a direct target of JNKs (Katz and Aronheim, 2002). It has 
been  reported  that  ATF3  migrates  as  a  21  and  23  kDa  doublet  band  due  to  an 
alternative ATG usage and not due to phosphorylation (Hagmeyer et al., 1996).
ATF-3  and c-Jun have been  found to co-localise  in many  types  of neurons 
following injury. The expression of ATF-3 correlates with expression of c-Jun in the 
dorsal root ganglia and spinal cord following sciatic nerve cut (Tsujino et al., 2000) 
and retinal ganglion cells after optic nerve injury (Takeda et al., 2000). In addition, c- 
Jun is phosphorylated at these sites of injury. In PC 12 cells, overexpressed c-Jun and 
ATF-3  can co-immunoprecipitate and there  is  increased neurite  formation in cells 
transfected with c-Jun as well as c-Jun and ATF-3  together (Pearson et al., 2003). 
Thus, c-Jun activation has been implicated in nerve regeneration after injury as well as
140in  neuronal  cell  death.  The role  of c-Jun  and  ATF-3  in  sympathetic  neurons  may 
depend on the relative levels of each transcription factor present within dying neurons.
In  conclusion,  the  results  described  in  this  chapter  suggest  a  potential 
involvement of the JNK/c-Jun pathway in ATF-3 up-regulation after NGF withdrawal 
from differentiated PC6-3 cells and sympathetic neurons. The increase in ATF-3 level 
follows that of c-Jun and these transcription factors may physically and functionally 
interact to regulate neuronal death and survival.
141Chapter 5:  The function of ATF-3 in sympathetic
neurons
5.1  Introduction
The  stress-inducible  ATF-3  transcription  factor  can  activate  or  repress 
transcription. The induction of ATF-3 correlates with cellular damage and signals that 
do not induce ATF-3 do not induce damage (Hai et al.,  1999). However, the actual 
function of ATF-3 is not clear, with both protective and detrimental roles proposed. 
ATF-3 is induced in beta cells of the pancreas undergoing apoptosis via the NF-kB 
and JNK pathways (Hartman et al., 2004). Overexpression of ATF-3 in these cells in 
transgenic mice, leads to abnormal development and dysfunction, whereas inactivation 
of the atf-3 gene partially protected the cells from apoptosis induced by cytokines or 
nitric oxide. ATF-3 has also been implicated in the acceleration of caspase activation 
during DNA damage-induced apoptosis (Mashima et al., 2001).  On the other hand, 
overexpression of ATF-3 can protect rat hippocampal neurons in vivo against kainic 
acid-induced death (Francis et al., 2004) and can promote the survival of PC 12 cells 
and sympathetic neurons following JNK activation by MEKK1  or in the absence of 
NGF  respectively  (Nakagomi  et  al.,  2003).  A  protective  role  for  ATF-3  in 
cardiomyocytes has also been described (Nobori et al.,  2002).  In these rat neonatal 
cardiomyocytes,  doxorubicin  rapidly  activated  JNK,  c-Jun  and  ATF-3  and 
overexpression of ATF-3 protected the cells from apoptosis.
ATF-3 is thought to repress transcription by stabilizing inhibitory co-factors on 
the promoters of target genes (Chen et al.,  1994).  Alternatively spliced isoforms of 
ATF-3 have been described that lack the leucine zipper domain and which therefore do 
not bind to DNA. The human isoforms ATF-3AZIP,  ATF-3AZIP2a, ATF-3AZIP2b, 
ATF-3AZIP2c  and  ATF-3AZIP3  are  induced  along  with  ATF-3  by  various  stress 
signals and may modulate the activity of full length ATF-3 (Hashimoto et al., 2002; 
Pan et al., 2003).  It has been proposed that these isoforms antagonise the action of 
ATF-3 by binding inhibitory co-factors, sequestering them away from the transcription 
machinery and thus stimulating transcription.  Another ATF-3  isoform ATF-3b was 
identified in mouse pancreatic aTC1.6 cells (Wang et al., 2003). This lacks  106 base 
pairs in exon 2 of the full length ATF-3 coding sequence but retains the bZIP domain.
142In these cells, both ATF-3 and ATF-3b are down-regulated by glucose.  ATF-3  and 
ATF-3b  bind  to  CRE/ATF  binding  sites  in  the  proglucagon  gene  promoter  as 
homodimers and heterodimers with each other to activate transcription. This describes 
a novel mechanism of transcriptional activation by ATF-3 binding at the CRE/ATF 
site in the promoter.
Several ATF-3 target genes have been identified.  ATF-3 has been shown to 
regulate its own transcription by binding to a non-consensus ATF-3 site immediately 
downstream of the TATA box in the atf-3 promoter (Wolfgang et al., 2000). This site 
is necessary for efficient autorepression by  ATF-3.  ATF-3  homodimers have been 
reported to repress  the transcription of TNF-a-induced E-selectin gene expression 
(Nawa et al., 2000) and arsenite-induced GADDI53 expression (Fawcett et al.,  1999; 
Wolfgang et al., 1997). In addition, ATF-3 can interact with the GADD153 to regulate 
transcription  and  forms  a  nonfunctional  heterodimer  that  does  not  bind  to  the 
ATF/CRE element consensus site and which does not repress transcription (Chen et 
al.,  1996).  ATF-3  can  also activate transcription  when  dimerised  with  other bZIP 
proteins,  such  as  c-Jun  (Hai  and  Curran,  1991;  Hsu  et  al.,  1992).  In  sympathetic 
neurons, overexpressed ATF-3 promotes heat shock protein 27 (Hsp27) expression by 
binding to an atypical CRE site in the gene promoter,  and this  may  involve c-Jun 
(Nakagomi et al., 2003).
ATF-3  is  induced  in  many  examples  of nerve  injury.  The  injury  specific 
expression of ATF-3  in axotomised dorsal root ganglia and  spinal cord following 
sciatic nerve cut (Tsujino et al., 2000) and in retinal ganglion cells after optic nerve 
injury  (Takeda et al.,  2000) correlates  with expression of c-Jun  in these  surviving 
cells.  The  induction  of  c-Jun  has  been  associated  with  neurite  sprouting  in 
undifferentiated PC 12 cells (Dragunow et al., 2000)  and ATF-3  has been shown to 
enhance this process in both PC 12 cells  and mouse Neuro-2a cells (Pearson et al, 
2003).
The study of c-Jun in the nervous system in vivo has been limited because c- 
jun knockout mice  die  during  embryonic  development  at day  12.5  due  to  hepatic 
failure  (Hilberg et al.,  1993).  However,  a floxed  c-jun gene has been successfully 
knocked out in sympathetic neurons in vitro (infected with a CRE adenovirus) and this 
inhibited NGF withdrawal-induced death (Palmada et al, 2002). Overexpression of c- 
Jun kills sympathetic neurons in the presence of NGF and a dominant negative c-Jun
143protein  (FLAGA169)  protects  sympathetic  neurons  from NGF withdrawal-induced 
death (Ham et al.,  1995). This mutant lacks the N-terminal  168 amino acids encoding 
the transactivation domain, but can still dimerise and bind DNA via the bZIP domain 
(Hirai et al.,  1989) and acts as a dominant negative mutant against all AP-1  family 
members (Brown et al.,  1994; Castellazzi et al.,  1991). ATF-3 also contains a bZIP 
domain and can dimerise with c-Jun to activate transcription (Hai and Curran,  1991; 
Hsu  et al.,  1992).  A  protein  containing  only  the  bZIP  domain  of ATF-3  could 
potentially regulate ATF-3 function by binding the full length transcription factor and 
preventing transactivation or repression of target genes. Alternatively the ATF-3bZIP 
domain could potentiate the role of ATF-3 in a similar manner to the ATF-3b isoform 
found  in  mice  (Wang  et al.,  2003).  Another way  of inhibiting  ATF-3  function  in 
neurons would be to use the pSUPER RNAi system to knock down the expression of 
ATF-3.  This  vector system ensures  efficient expression  of small  interfering  RNA 
(siRNA)  under  the  control  of  an  RNA  polymerase-III  dependent  promoter 
(Brummelkamp et al., 2002). The RNA transcript forms a short hairpin structure with 
a 19 base-pair double-stranded region and a short loop formed by a spacer region and 
has been designed to be an optimal substrate for the enzyme Dicer, which cleaves the 
hairpins to generate short double stranded RNA. These RNA species bind to newly 
synthesised  RNA  in  the  cell  and  cause  sequence-specific  mRNA  degradation 
(Brummelkamp et al., 2002; Elbashir et al., 2001).
In the following experiments, the function of ATF-3  in sympathetic neurons 
undergoing apoptosis was investigated using both the truncated ATF-3bZIP domain 
and RNAi specific for ATF-3.
5.2  Results
5.2.1  Construction of ATF-3 and ATF-3bZIP expression vectors
To  investigate  the  function  of ATF-3  in  sympathetic  neurons,  expression 
vectors  encoding  the  full  length  ATF-3  protein  or the basic/leucine zipper (bZIP) 
domain of ATF-3, were constructed. The ATF-3 coding sequence was amplified by 
PCR from a rat brain cDNA library. The forward and reverse primers used contained a 
BamHI site (GGATCC) and an EcoRI site (GAATTC) respectively, for cloning into 
the pCDFLAG expression vector. This vector is the pcDNAl  expression vector with
144the FLAG epitope inserted between the Hindlll  and BamHI  sites  (Vekrellis et al.,
1997). The bZIP domain of ATF-3 was amplified by PCR using the ATF-3 cDNA as 
template. The forward and reverse primers used for this also contained a BamHI and 
an EcoRI site respectively, for cloning into the pCDFLAG vector (Figure 5.1 A). The 
PCR products were purified by gel extraction and digested with BamHI and EcoRI 
(Figure 5.IB) and the inserts encoding ATF-3 or the ATF-3bZIP domain were cloned 
into  pCDFLAG  (Figure  5.1C)  to  generate  pCDFLAGATF-3  and pCDFLAGATF- 
3bZIP respectively. The constructs were sequenced to verify that the insert DNAs did 
not contain any mutations and had the correct structure.
5.2.2  The ATF-3 and ATF-3bZIP proteins are expressed in transfected Cos-7 
cells and microinjected sympathetic neurons
To verify that proteins of the correct size were expressed,  Cos-7 cells were 
transiently  transfected  with  the  pCDFLAGATF-3  and  pCDFLAGATF-3bZIP 
expression vectors. Cos-7 cells were plated in 9 cm dishes and 5  pg of pCDFLAG, 
pCDFLAGATF-3, pCDFLAGATF-3bZIP or pCDFLAGA169 (dominant negative c- 
Jun)  were  transfected  into  the  cells  using  Lipofectamine  2000.  48  hours  after 
transfection, protein was extracted and western blot analysis performed with the anti- 
FLAG M2 antibody (Figure 5.2A). pCDFLAGA169 was used as a positive control for 
the expression  of FLAG-tagged proteins.  All  constructs  expressed proteins  of the 
expected  sizes,  although  the  level  of expression  of the  FLAG-tagged  ATF-3bZIP 
protein appeared to be much lower than that of the full length ATF-3  or dominant 
negative c-Jun proteins.  This  small protein  (7.2 kDa)  may be  less  stable than full 
length ATF-3.  Alternatively, it might be less efficiently retained by the membranes 
used in western blots.
To  confirm that the  FLAG-tagged  proteins  were  expressed  in  sympathetic 
neurons,  the  expression  vectors  were  microinjected  into  neurons  cultured  in  the 
presence of NGF. Sympathetic neurons were injected with guinea pig IgG (2.5 pg/pl) 
and 0.1  pg/pl of either pCDFLAGATF-3  or pCDFLAGATF-3bZIP.  24 hours after 
injection, the cells were fixed and stained for the injection marker and FLAG-tagged 
proteins.  In  these  immunocytochemistry  experiments,  injected  cells  were  detected 
using a rhodamine-conjugated anti-guinea pig IgG  antibody  and the FLAG-tagged 
proteins were detected using the M2 monoclonal antibody and then a FITC-conjugated
145Figure 5.1  Construction of ATF-3 and ATF-3bZIP expression vectors
(A)  Sequence  of the  primers  used to  amplify  the  ATF-3  and  ATF-3bZIP  coding 
sequences  by  PCR.  Restriction  enzymes  sites  for BamHI  (GGATCC)  and  EcoRI 
(GAATTC) are shown in bold type.
(B) The ATF-3 and ATF-3bZIP PCR products were digested with BamHI and EcoRI 
to generate DNA inserts suitable for ligation into the pCDFLAG vector. The codons 
amplified are indicated in brackets after the insert name. The full length ATF-3 (1- 
541)  and the bZIP domain of ATF-3,  ATF-3bZIP (247-440)  were cloned into the 
BamHI and EcoRI sites of pCDFLAG.
(C)  Structure  of pCDFLAG.  This  vector contains  the  following  features:  Col  El 
origin, bases  1-587; M13 origin, bases 588-1180; Ampicillin gene, bases  1360-2303; 
CMV promoter, bases 2304-2954; T7 primer sequence, bases 2938-2957; Polylinker, 
bases 2956-3074; Sp6 primer, bases 3075-3093; Splice and poly A, bases 3094-3792; 
Polyoma origin,  bases  3798-4693  and  SV40  origin,  bases 4634-4797.  The  FLAG 
epitope is cloned between the Hindlll and BamHI sites of the multiple cloning site. 
The  ATF-3  and  ATF-3bZIP  inserts  were  cloned  between  the  BamHI  and  EcoRI 
restriction sites.
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Forward  5'-GTTGGATCCCCTGAAGAAGATGAGAGAAAAAG-3' 
BamHI
Reverse  5 '-CG  AGAATTCTT  G  AGC  AT  GT  AAATC  AG  AT  GCTG-3' 
EcoRI
BamHI EcoRI
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HindlllFigure 5.2  Expression of FLAG-tagged ATF-3 and ATF-3bZIP in Cos-7 cells
and sympathetic neurons
(A) The expression vectors pCDFLAG, pCDFL  AG  ATF-3, pCDFLAGATF-3bZIP and 
pCDFLAGA169 (a dominant negative c-Jun construct)  were transfected into Cos-7 
cells  using  Lipofectamine  2000.  Cos-7  cells  (approximately  1.8  x  106  cells)  were 
plated in 9 cm dishes. The DNA (5  pg) and Lipofectamine (40  pi) were both mixed 
with 821  pi of Opti-MEM® I reduced serum medium as instructed and gently added to 
the  cells.  Protein  was  extracted  after 48  hours.  Samples  were  run  on  a  15%  SDS 
polyacrylamide gel and western blot analysis performed. Blots were hybridised with 
the anti-FLAG M2 antibody. All constructs expressed proteins of the expected sizes. 
pCDFLAGA169 was used as a positive control for the expression of FLAG-tagged 
proteins.  A representative western blot is  shown.  The position of molecular weight 
markers run in parallel is indicated. A non-specific band recognised by the anti-FLAG 
M2 monoclonal antibody is indicated. This band was detected in the extract prepared 
from cells transfected with empty vector (pCDFLAG) and is present at a similar level 
in all four lanes, suggesting that the protein loadings were equal.
(B) Sympathetic neurons were microinjected with guinea pig IgG (2.5  pg/pl) and 0.1 
pg/pl of either pCDFLAGATF-3 or pCDFLAGATF-3bZIP. 24 hours after injection, 
cells were fixed and stained for the injection marker and the FLAG-tagged proteins. 
Injected  cells  were  detected  using  a  rhodamine-conjugated  anti-guinea  pig  IgG 
antibody  (diluted  1-100).  FLAG-tagged  proteins  were  detected  using  the  M2 
monoclonal antibody  (1-200) and then a FITC-conjugated anti-mouse IgG antibody 
(1-100). Nuclei were stained using Hoechst dye (10 pg/ml). Representative images of 
ATF-3 and ATF-3bZIP expression in microinjected sympathetic neurons are shown. 
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149anti-mouse IgG antibody. Both FLAG-tagged proteins were expressed in the injected 
cells (Figure 5.2B). FLAGATF-3 mainly localised to the nucleus whereas FLAGATF- 
3bZIP was distributed throughout the whole cell. The truncated ATF-3bZIP protein 
may lack the appropriate nuclear localisation signal to localise all of the protein in the 
nucleus. Alternatively, the bZIP protein may be small enough to move freely in and 
out of the nucleus, whereas the full length ATF-3 protein is retained within the nucleus 
once it has crossed the nuclear membrane.
5.2.3  Overexpression  of ATF-3 kills sympathetic neurons in the presence of 
NGF, but can protect against death induced by NGF withdrawal
The role of ATF-3 in sympathetic neurons was investigated in microinjection 
experiments. Sympathetic neurons were injected with guinea pig IgG (2.5 p-g/pl) and 
0.1  pg/pJ of each expression  vector,  CMVlacZ (as  a negative  control),  pCDc-Jun, 
pCDFLAGATF-3  or  pCDc-Jun  and  pCDFLAGATF-3  together.  Neurons  were 
maintained in medium containing NGF and at 72 hours after injection, the cells were 
fixed and stained for the injection marker and overexpressed proteins. Injected cells 
were  detected  using  a  rhodamine-conjugated  anti-guinea  pig  IgG  antibody. 
Overexpressed proteins were detected using anti-p-galactosidase, anti-c-Jun or anti- 
ATF-3  antibodies  and  then  FITC-conjugated  anti-mouse  IgG  antibody  or  FITC- 
conjugated anti-rabbit IgG antibody. All of the overexpressed proteins were detected 
in  the  injected  cells  (Figure  5.3A).  Injected  neurons  were  scored  for  nuclear 
morphology (visualised by Hoechst staining). Cells with normal nuclei were counted 
for each of the four injection mixes tested (Figure 5.3B). 71.7% of neurons injected 
with CMVlacZ had normal nuclei. In contrast, 39.1% of the neurons overexpressing 
ATF-3 had normal nuclei, in the presence of NGF. c-Jun killed neurons to a similar 
extent with only 39.3% of nuclei having a normal morphology. This is in agreement 
with previously published results that showed that overexpression of c-Jun can kill the 
neurons  in the presence of NGF (Ham et al.,  1995).  A significant reduction in the 
percentage  of normal  nuclei  was  also  observed  when  ATF-3  and  c-Jun  were  co­
expressed. Injection of both of the expression vectors for ATF-3 and c-Jun together 
lead to 46.8% of injected neurons with normal nuclei. Thus, co-expression of c-Jun 
and ATF-3 did not have an additive effect.
150Figure 5.3  Overexpression of ATF-3 and c-Jun kills sympathetic neurons in the
presence of NGF
(A) Sympathetic neurons were microinjected with guinea pig IgG (2.5 pg/pl) and 0.1 
pg/pl of each expression vector, CMVlacZ, pCDc-Jun, pCDFLAGATF-3 or pCDc- 
Jun and pCDFLAGATF-3 together. Where necessary, injection mixes were made up 
to a concentration of 0.2 pg/pl with pcDNAl. 72 hours after injection the cells were 
fixed and stained for the injection marker and overexpressed proteins. Injected cells 
were  detected  using  rhodamine-conjugated  anti-guinea  pig  IgG  antibody  (1-100). 
Overexpressed proteins were detected using anti-p-galactosidase (1-400), anti-c-Jun 
(1-200) or anti-ATF-3 (1-200) antibodies and then a FITC-conjugated anti-mouse IgG 
antibody (1-100) or FITC-conjugated anti-rabbit IgG antibody (1-100). Nuclei were 
stained using  Hoechst  (10  pg/ml).  Coverslips  were mounted on  glass  slides  using 
Citifluor. Representative images of sympathetic neurons expressing (3-galactosidase, c- 
Jun or ATF-3 are shown. Pyknotic nuclei are indicated by the white arrowheads. The 
bar represents 10 pM.
(B) Injected neurons were scored for nuclear morphology. Cells with normal nuclei 
were  counted  for  each  of the  four  injection  mixes  tested.  The  graph  shows  the 
percentage of injected cells, expressing the proteins, that have normal nuclei. The data 
shown  represents  the  average  of six  independent experiments.  Error bars  indicate 
SEM. The decrease in the percentage of normal nuclei observed for cells expressing 
ATF-3, c-Jun or ATF-3 and c-Jun together, was significantly different to that of p- 
galactosidase (Student’s t-test: *p<0.005, **p<0.001).
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152To further characterise the role of ATF-3 in sympathetic neurons, the effect of 
expressing ATF-3 and ATF-3bZIP in the absence of NGF was examined. Infection of 
sympathetic neurons with an adenovirus expressing ATF-3 was previously shown to 
induce  nerve  elongation  and  the  infected  cells  were  protected  against  NGF 
withdrawal-induced death to a certain extent  (Nakagomi et al., 2003). Microinjection 
of an expression vector for a c-Jun dominant negative mutant, pCDFLAGA169, also 
protects  sympathetic  neurons  against NGF withdrawal-induced  death  (Ham  et al., 
1995).  Sympathetic neurons were injected with guinea pig IgG (2.5  pg/pl)  and 0.1 
pg/pl of each expression vector, either pcDNAl, pCDFLAGA169, pCDFLAGATF-3 
or pCDFLAGATF-3bZIP. Neurons were allowed to recover from injection overnight 
in medium containing NGF.  The following day  the  neurons  were  withdrawn  from 
NGF for 48  hours.  Cells were then fixed and  stained for the  injection marker and 
overexpressed proteins. Injected cells were detected using rhodamine-conjugated anti­
guinea pig IgG antibody and the FLAG-tagged proteins were detected using the M2 
monoclonal  antibody  followed by  the  FITC-conjugated  anti-mouse  IgG  antibody. 
ATF-3 was detected using anti-ATF-3 antibody and then FITC-conjugated anti-rabbit 
IgG antibody, since this worked better than the anti-FLAG antibody for this protein. 
Injected  neurons  were  scored  for  nuclear  morphology  (Figure  5.4).  In  control 
experiments  with  the  empty  vector pcDNAl,  45.85%  of the  injected neurons  had 
normal nuclei after 48 hours of NGF withdrawal. Expression of FLAGA169 increased 
the percentage of neurons with normal nuclei to 62.45%. Overexpression of ATF-3 
also lead to increased survival of the neurons after NGF withdrawal.  65.55% of the 
injected  cells  had  normal  nuclei.  This  is  similar  to  the  results  obtained  with 
adenovirus-infected sympathetic neurons, which showed 60% survival in the case of 
the  ATF-3  virus  after  48  hours  of  NGF  withdrawal  (Nakagomi  et  al.,  2003). 
Interestingly the bZIP domain of ATF-3 alone inhibited cell death to an even greater 
extent than full length ATF-3. 79.68% of the neurons had normal nuclear morphology 
after  48  hours  in  the  absence  of  NGF.  The  ATF-3bZIP  protein  lacks  any 
transcriptional activation or repression domains. The bZIP domain, by binding to full 
length  transcription  factors,  such  as  c-Jun,  may  prevent them  from  activating  the 
transcription of target genes. This would suggest that overexpressed ATF-3 may be 
acting as a transcriptional repressor after NGF withdrawal in  sympathetic neurons, 
since it has the same effect as the bZIP domain alone.
153Figure  5.4  Overexpression  of ATF-3  or  the  ATF-3bZIP  domain  protects
sympathetic neurons against NGF withdrawal-induced death
Sympathetic neurons were injected with guinea pig IgG  (2.5  ptg/pil) and 0.1 
(Lxg/ptl of each expression vector, either pcDNAl, pCDFLAGA169, pCDFLAGATF-3 
or pCDFLAGATF-3bZIP.  Neurons  were  allowed  to  recover overnight  in  medium 
containing NGF. The following day the neurons were withdrawn from NGF for 48 
hours.  Cells  were  fixed  and  stained  for  the  injection  marker  and  overexpressed 
proteins. Injected cells were detected using rhodamine-conjugated anti-guinea pig IgG 
antibody  (1-100).  FLAG-tagged  proteins  were  detected  using  the  M2  monoclonal 
antibody (1-200) and then FITC-conjugated anti-mouse IgG antibody (1-100). ATF-3 
was detected  using  anti-ATF-3  (1-200)  and then FITC-conjugated anti-mouse  IgG 
antibody (1-100). Injected neurons were scored for nuclear morphology.  Cells with 
normal  nuclei  were  counted  for each  of the  four injection  mixes  tested.  The  data 
shown represents the  average of four independent experiments.  Error bars  indicate 
SEM. The increase in normal nuclei observed for cells expressing A169, ATF-3, or 
ATF-3bZIP,  was  significantly  different  to  that  of  cells  not  expressing  protein 
(pcDNAl) [Student’s t-test: *p<0.05, **p<0.01].
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pcDNAl5.2.4  Construction of ATF-3 RNAi expression vectors
To study the role of the endogenous ATF-3 protein  in sympathetic  neurons 
deprived of NGF, an ATF-3 RNAi expression vector was constructed to knock down 
the level of the transcription factor within cells. RNAi sequences were designed using 
the Oligoengine™ design tool on the website oligoengine.com. Three  19-nucleotide 
sequences  were  selected,  at  positions  158  (5’-CCTTTGCCATCGGATGTCC-3’), 
268  (5 ’ -GG  AGGCG.GCGGG  A  A  AG  A  A  A-3 ’)  and  484  (5 ’ -CGCCGG  A  AG ACG  AG 
AGGAA-3’) of the ATF-3 coding sequence (Figure 5.5A). These were chosen because 
of their predicted high efficiency of binding to the atf-3 mRNA and because they were 
least  likely  to  hybridise  to  other  mRNA  sequences  (as  determined  by  a  BLAST 
search).  Each  sequence  was  incorporated  into  two  complementary  64-nucleotide 
sequences  containing a hairpin  sequence and Bglll  and Hindlll  restriction  enzyme 
sites  as  illustrated  in  Figure  5.5B  for  sequence  158.  Each  pair  of  64  base 
oligonucleotides  were  phosphorylated,  annealed  and  cloned  into  the  pSUPER 
expression vector (Figure 5.5Ciii) digested with Bglll and Hindlll  and treated with 
calf intestine alkaline phosphatase to prevent the re-ligation of vector without insert 
(Figure 5.5Civ). Cloning of the DNA inserts for the sequences at positions  158, 268 
and  484  of  ATF-3  into  pSUPER  generated  pSUPER(158),  pSUPER(268)  and 
pSUPER(484), respectively. DNA constructs were sequenced to verify the insertion of 
the correct DNA.
5.2.5  ATF-3  RNAi  constructs  reduce  the  level  of overexpressed  ATF-3  in 
transfected PC6-3 cells and microinjected sympathetic neurons
To  verify  that  ATF-3  protein  levels  were  knocked  down  by  the  RNAi 
constructs,  undifferentiated  PC6-3  cells  were  transfected  with  pSUPER, 
pSUPER(158),  pSUPER(268)  or pSUPER(484)  along  with  the  expression vectors 
pCDFLAGATF-3 or pCDFLAGA169. PC6-3 cells (approximately 6 x 105  cells) were 
plated in 6 cm dishes and transfected using Lipofectamine 2000. Protein extracts were 
prepared after 48  hours  and western blot analysis  performed  with the  anti-tubulin 
antibody and the anti-FLAG M2 antibody to detect expression of FLAG-tagged ATF- 
3 and A169 (Figure 5.6A). FLAGA169 was used as a control to measure non-specific 
effects of the RNAi. Western blots were scanned on a densitometer to quantitate levels 
of  protein.  The  graph  in  Figure  5.6B  represents  the  levels  of  overexpressed
156Figure 5.5  Construction of ATF-3 RNAi expression vectors
(A)  RNAi  sequences  were  designed  using  the  Oligoengine™  design  tool  on  the 
website oligoengine.com.  Three  19-nucleotide sequences were selected at positions 
158  (5'-CCTTTGCCATCGGATGTCC-3'),  268  (5'-GG  AGGCGGCGGG  A  A  AG  A  A 
A-3') and 484 (5'-CGCCGGAAGACGAGAGGAA-3') of the ATF-3 coding sequence.
(B) The 64-nucleotide oligos containing the RNAi sequence at position 158 of ATF-3. 
The 19-nucleotide sequence is shown in bold type in the sense and antisense direction, 
joined together by a hairpin sequence shown in blue. The 5' end corresponds to a Bglll 
site, while the 3' end contains the Hindlll restriction site.
(C)  The  process  of generating  RNAi  using  pSUPER.  Each  pair of 64-nucleotide 
sequences (500 ng) was phosphorylated, annealed (iii) and inserted into the Bglll and 
Hindlll sites of the pSUPER vector (iv). This positions the forward oligo at the correct 
position downstream from the HI promoter’s TATA box to generate the desired RNAi 
duplex. In addition the Bglll site is destroyed upon ligation to enable more efficient 
screening of positive clones. The RNA transcript is expressed under the control of the 
polymerase-III based expression system and forms a short hairpin structure with the 19 
base-pair double-stranded region and a hairpin loop formed by the spacer region (ii). 
The insert is designed such that the first two 5'  bases of the spacer region  (hairpin 
loop)  are  transcribed uridines  and  includes  a  specific T5  terminator sequence  that 
incorporates two final uridines at the 3' end of the transcript. When expressed within 
cells, the hairpin structure is cleaved by the enzyme Dicer to generate a short dsRNA, 
both strands having a two uridine 3' overhang (i). This generates an efficient effector 
of RNAi that complies with the design principles established by Tuschl and colleagues 
(Elbashir et al., 2001).
157ATG ATF-3 TGA 3’
158 268 484
CCTTTGCCATCGGATGTCC  GGAGGCGGCGGGAAAGAAA  CGCCGGAAGACGAGAGGAA
(Bglll)  target sequence 158: sense  Hairpin  target sequence 158: antisense
5,-GATCCCCCCnTGCCATCGGATGTCCTTCAAGAGAGGACATCCGATGGCAAAGGTTnTGGAA-3'









(Bglll)  target sequence 158: sense  Hairpin  target sequencel58: antisense
5’-GATCCCCCCmTGCCATCGGATGTCCTTCAAGAGAGGACATCCGATGGCAAAGGTTTTTGGAA-3,
3'-GGGGGAAACGGTAGCCTACAGGAAGTTCTCTCCTGTAGGCTACCGTTTCCAAAAACCTTTTCGA-5'
(Hindlll)Figure  5.6  ATF-3  RNAi  knocks  down  the  level  of overexpressed  ATF-3  in
transfected PC6-3 cells
(A)  PC6-3  cells  (approximately  6  x  105   cells)  were  plated  in  6  cm  dishes.  DNA 
mixtures contained 2 pg of pCDFLAGATF-3 or pCDFLAGA169 together with 6 pg 
of pSUPER, pSUPER(158), pSUPER(268) or pSUPER(484).  DNA was transfected 
into PC6-3 cells using Lipofectamine 2000. The DNA (8  pg) and Lipofectamine (20 
pi) were both mixed with 273 pi of Opti-MEM® I reduced serum medium as instructed 
and gently added to the cells. Protein was extracted after 48 hours. Samples were run 
on a 15% SDS polyacrylamide gel and western blot analysis performed with the anti­
tubulin antibody and the anti-FLAG M2 antibody to detect expression of tubulin and 
FLAG-tagged ATF-3  and A169.  The transfection experiment  was  performed more 
than once to determine the best concentration of RNAi vector to use. A representative 
experiment is shown.
(B)  The  blots  shown  in  (A)  were  scanned  on  a  Bio-Rad  GS800  densitometer  to 
quantitate levels of protein expression. Images of bands were captured and quantitated 
using Bio-Rad Quantity One® software. The graph represents the levels of ATF-3 and 
A169 protein expression relative to that of tubulin to normalise for loadings. All three 
RNAi constructs strongly reduced FLAGATF-3 levels. In addition, pSUPER(268) had 
no effect on the level of FLAGA169, but pSUPER(158)  and pSUPER(484)  caused 
48% and 77% decreases in the level of FLAGA169, respectively.
159A
+ATF-3________ +A169
OO 00 Tf 00 00 r r
10 vo 00 V O 00
<N T t- C N
ex: c* s s s e* s K o4
U J U J U J U J U J U J U J U J U J
ex ex ex X X X X X X
P P P p p P p P D
CO CO CO CO CO CO CO CO CO






Relative  30 








s   §
CO  CO 











T T O O ^r
00  00
<0  VO




e*  o<  
U J  U J 
ex  ex
P  p














160A169 and ATF-3 protein relative to that of tubulin, to normalise for any differences in 
protein loading. The levels of FLAGATF-3 protein are strongly knocked down by all 
three RNAi constructs.  In addition, the level of A169 was not reduced to the same 
extent. pSUPER(268) did not affect the level of A169 expression, suggesting that it 
might be the best construct for further experiments.
The  RNAi  constructs  were  also  microinjected  into  sympathetic  neurons  to 
verify that overexpressed ATF-3 protein levels could be knocked down in these cells. 
The ATF-3  antibody that I  used does not detect the endogenous ATF-3  protein in 
sympathetic neurons in immunocytochemistry experiments, although it can do so in 
western blot analysis.  However,  it can detect the overexpressed ATF-3  protein by 
immunocytochemistry. Therefore, the effect of the RNAi constructs on overexpressed 
FLAGATF-3 was studied. Neurons were cultured in the presence of NGF for 5-7 days 
before injection. Cells were injected with guinea pig IgG (2.5  pig/pil) as an injection 
marker and pSUPER, pSUPER(158), pSUPER(268)  or pSUPER(484)  at 0.4  pg/pl 
along with the expression vector pCDFLAGATF-3 (0.001  pg/pl).  At 24 hours after 
injection,  the  neurons  were  fixed  and  stained  for  the  injection  marker  and 
overexpressed ATF-3.  Injected neurons  were  scored for ATF-3  expression  (Figure 
5.7). 61% of cells injected with the empty pSUPER vector expressed ATF-3. This was 
reduced to 33.3%,  11.7% and 21.7% by expression of pSUPER(158), pSUPER(268) 
and pSUPER(484), respectively. The RNAi construct pSUPER(268) knocked down 
ATF-3 expression most efficiently and was therefore chosen for further experiments to 
study the role of ATF-3 in neurons. This was based on the assumption that it would 
knock down the expression of the endogenous ATF-3  protein as effectively as the 
overexpressed protein.
5.2.6  Knocking down ATF-3 in sympathetic neurons increases the rate of cell 
death after NGF withdrawal
The  role  of  ATF-3  in  sympathetic  neuron  apoptosis  was  examined  in 
microinjection experiments using the pSUPER(268) RNAi construct.  Neurons were 
cultured in the presence of NGF for 5-7 days before injection. Cells were injected with 
guinea  pig  IgG  (2.5  pg/pl)  as  injection  marker  and  0.2  pg/pl  of  pSUPER  or 
pSUPER(268).  The injected neurons were allowed to recover overnight in medium 
containing NGF.  The  following day  the  neurons  were  deprived of NGF.  After 48
161hours, the cells were fixed and stained for the injection marker using a rhodamine- 
conjugated anti-guinea pig IgG antibody.  Injected neurons were  scored for nuclear 
morphology (Figure 5.8). In the case of pSUPER, 59.7% of the neurons had normal 
nuclei after 48 hours of NGF withdrawal. This was reduced to 42.6% in the case of 
pSUPER(268). This 17.1% decrease is significant and suggests that the level of ATF-3 
regulates the rate of cell death after NGF withdrawal.
162Figure 5.7  Expression of ATF-3 RNAi knocks down the level of overexpressed 
ATF-3 in microinjected sympathetic neurons
Sympathetic neurons were  cultured  in  the  presence  of NGF  for  5-7  days. 
Neurons were injected with guinea pig IgG (2.5 pg/pl) as an injection marker and the 
constructs  pSUPER,  pSUPER(158),  pSUPER(268)  or pSUPER(484)  at 0.4  pg/pl 
along with the expression vector pCDFLAGATF-3 (0.001  pg/pl). Neurons were left 
for 24 hours and then immunocytochemistry was performed.  Cells  were fixed and 
stained  for  the  injection  marker  and  overexpressed  ATF-3.  Injected  cells  were 
detected using rhodamine-conjugated anti-guinea pig IgG antibody (1-100).  ATF-3 
was detected using anti-ATF-3 antibody (1-200) and then FITC-conjugated anti-rabbit 
IgG antibody (1-100). Injected neurons were scored for ATF-3 expression. Injected 
cells were considered to be expressing ATF-3 if the anti-ATF-3 antibody staining was 
clearly greater than the background staining observed for uninjected cells. The data 
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164Figure 5.8  Microinjection of pSUPER(268) increases the amount of cell death
in sympathetic neurons deprived of NGF
Sympathetic  neurons  were  cultured  in  the  presence  of NGF  for  5-7  days 
before  injection.  Cells  were  injected with guinea pig IgG  (2.5  p-g/p-l)  as  injection 
marker and 0.2  p.g/p.1  of pSUPER  or  pSUPER(268).  The  injected  neurons  were 
allowed to recover overnight in medium containing  NGF.  The  following  day,  the 
neurons were withdrawn from NGF for 48 hours. Cells were fixed and stained for the 
injection marker using rhodamine-conjugated anti-guinea pig IgG antibody (1-100). 
Nuclei were stained with Hoechst dye at 10 p-g/ml. Injected neurons were scored for 
nuclear morphology.  The  data  shown  represents  the  average  of five  independent 
experiments.  Error  bars  indicate  SEM.  The  percentage  of injected  neurons  with 


















In this chapter, I investigated the function of ATF-3 in sympathetic neurons. 
Expression vectors encoding full length ATF-3 and the bZIP domain of ATF-3 were 
constructed and shown to express the proteins in transiently transfected Cos-7 cells 
and microinjected sympathetic neurons. The bZIP protein was apparently expressed at 
a  lower  level  in  Cos-7  cells  than  the  full  length  protein,  perhaps  due  to 
instability/degradation of the shorter peptide.
The  role  of ATF-3  in  sympathetic  neurons  was  studied  in  microinjection 
experiments. ATF-3 kills neurons when overexpressed in the presence of NGF. 39.1% 
of the cells overexpressing ATF-3  had normal nuclei compared with 71.7%  of the 
neurons injected with CMVlacZ. c-Jun killed neurons to a similar extent with 39.3% 
of nuclei having normal morphology. This agrees with previously published results 
that showed that overexpression of c-Jun can kill sympathetic neurons in the presence 
of NGF (Ham et al.,  1995).  When  overexpressed  in  the  presence  of NGF,  ATF-3 
might induce  cell death by binding  as  a homodimer to  ATF/CRE elements  in the 
promoters  of  genes  that  promote  cell  survival,  and  thereby  repressing  their 
transcription.  For  example,  CREB  has  been  shown  to  promote  the  survival  of 
sympathetic neurons by activating the transcription of the antiapoptotic  bcl-2 gene 
(Riccio et al., 1999). The CREBml mutant, which can bind CRE sites but not activate 
transcription, kills neurons in the presence of NGF.  ATF-3 may bind similar target 
genes, repressing their transcription, which could lead to apoptosis. A reduction in the 
number of cells with normal nuclei was also observed when ATF-3 and c-Jun were co­
expressed. Expression of both c-Jun and ATF-3 may result in heterodimer formation 
and therefore the activation of similar gene targets as c-Jun homodimers.
Interestingly,  overexpressed ATF-3  did not kill  sympathetic  neurons  in the 
absence of NGF. In control experiments, 45.8% of sympathetic neurons injected with 
CMVlacZ had normal nuclei after 48 hours of NGF withdrawal.  Overexpression of 
ATF-3 led to increased survival of neurons after NGF withdrawal (65.55% of injected 
cells had normal nuclei). This is in agreement with a report that 60% of adenovirus- 
infected sympathetic neurons  overexpressing ATF-3  were  viable  after 48  hours of 
NGF withdrawal (Nakagomi et al., 2003). In an organ culture of these neurons, ATF-3 
induced neurite outgrowth after NGF withdrawal. Expression of ATF-3 in sympathetic 
neurons led to a slight increase in expression of Hsp27, but only in cells cultured in the
167absence of NGF,  suggesting that activation of the JNK/c-Jun pathway  is required. 
ATF-3 is able to bind to the hsp27 promoter in PC 12 cells and transcription of hsp27 
is inhibited by a dominant negative mutant of c-Jun (c-Jun223NLS), again suggesting 
that the c-Jun/JNK pathway is required.
I also found that expression of the bZIP domain of ATF-3 inhibited cell death 
to  an  even  greater extent than full  length  ATF-3.  79.68%  of neurons  had  normal 
nuclear morphology after 48 hours in the absence of NGF. The ATF-3bZIP protein 
lacks any transcriptional activation or repression domains. This protein may bind as a 
homodimer to AP-1 or CRE/ATF sites and prevent endogenous proteins from binding 
these sites. Alternatively, ATF-3bZIP may form heterodimers with other proteins such 
as  c-Jun,  and  form  complexes  with  reduced  activity.  This  could  imply  that 
overexpressed  ATF-3  may  be  acting  as  a  transcriptional  repressor,  after  NGF 
withdrawal in sympathetic neurons, since it has the same effect as the bZIP domain 
alone. This is the opposite of the effect observed by an alternatively spliced form of 
ATF-3, ATF-3AZip.  This  protein  lacks  the  bZIP  domain,  and  has  been  shown  to 
stimulate transcription, presumably by sequestering inhibitory cofactors away from the 
promoter (Chen et al., 1994).
As  expected,  expression  of FLAGA169  protected  the  neurons  from  NGF 
withdrawal-induced death. The percentage of injected cells with normal nuclei was 
significantly higher at 62.45%.  This  was not as high as the  approximately  80%  of 
neurons surviving after 48 hours of NGF withdrawal previously reported (Ham et al., 
1995).  In  those  experiments,  any  neurons  that  did  not  have  normal  nuclei  after 
injection  were  excluded  and  survival  was  scored  after  2  days  using  calcein  AM 
staining, which is converted to fluorescent green calcein in viable cells. This would 
likely lead to a higher percentage of normal cells compared with my assay, which 
included all injected cells.
ATF-3 expression was inhibited using the pSUPER RNAi vector system. The 
RNAi construct pSUPER(268) inhibited FLAGATF-3 expression in Cos-7 cells and 
sympathetic neurons to the greatest extent and had a minimal effect on the level of 
overexpressed dominant negative c-Jun  (FLAGA169).  All  of the  RNAi  sequences 
tested are specific for rat ATF-3 (NCBI blastn search) but may have varying degrees 
of accessibility to the ATF-3 RNA secondary structure. This would affect their ability 
to bind the RNA and therefore their ability to lead to the destruction of the double
168stranded RNA. The construct pSUPER(268) reduced the percentage of sympathetic 
neurons with normal nuclei, at 48 hours after NGF withdrawal, to 42.6% compared 
with the pSUPER control (59.7%). This suggests that the level of ATF-3 regulates the 
rate of cell death after NGF withdrawal. This agrees with my overexpression results, 
which  found that ATF-3  protected  sympathetic  neurons  against NGF withdrawal- 
induced death. A reduction in the amount of ATF-3 in sympathetic neurons deprived 
of NGF could result in increased formation of c-Jun homodimers, which could lead to 
increased cell death.
The differences in ATF-3  function observed in the presence and absence of 
NGF may  be  due  to  differences  in  the  dimerisation  partners  present  and/or other 
proteins necessary for NGF withdrawal-induced apoptosis, for example proteins of the 
c-Jun/JNK  pathway.  If  c-Jun  is  the  dimerisation  partner  of  ATF-3  after  NGF 
withdrawal, the outcome of either cell death or survival will depend on the relative 
levels of each transcription factor present within dying neurons.  c-Jun homodimers 
could  activate  transcriptional  targets  that  lead  to  apoptosis,  whereas  ATF-3 
homodimers could repress the same or different transcriptional targets and cause cell 
survival.  Initially  after NGF  withdrawal,  c-Jun  levels  and  c-Jun  activity  begin  to 
increase.  c-Jun homodimers or c-Jun/X heterodimers may promote apoptosis, since 
knocking out c-jun in sympathetic neurons in vitro inhibited NGF withdrawal-induced 
death (Palmada et al, 2002). The delayed induction of ATF-3 may be a compensatory 
mechanism to rescue neurons from NGF withdrawal-induced death.  High levels of 
ATF-3  could  suppress the transcription of gene targets  necessary for apoptosis.  In 
sympathetic neurons deprived of NGF, the actual increase in ATF-3 levels may not be 
high  enough  to  inhibit  apoptosis  due  the  presence  of high  levels  of proapoptotic 
proteins already induced at this time. In addition, the absolute levels of ATF-3 and c- 
Jun within the dying neurons are unknown and may determine the outcome of cell 
death or survival. If ATF-3 is much lower than c-Jun at the peak of ATF-3 induction, 
for  example,  c-Jun  homodimers  or  c-Jun/X  heterodimers  might  predominate.  A 
hypothetical model of the functional role of these transcription factors is  shown in 
Figure 5.9.
169Figure 5.9  Hypothetical model of the function of ATF-3 in sympathetic neurons
(A)  In  the  presence  of NGF,  the  levels  of c-Jun  and  ATF-3  are  low  and  their 
transcriptional  targets  are  unlikely  to  be  bound  by  these  factors.  Genes  encoding 
transcription factors, such as CREB, promote the survival of sympathetic neurons in 
the presence of NGF. For example, CREB can bind to and activate the bcl-2 promoter 
(Riccio et al., 1999).
(B) In the absence of NGF, the levels of c-Jun and then ATF-3  begin to rise.  The 
outcome of either cell death or survival will depend on the relative levels of each 
transcription factor present within dying neurons.
(i) Initially after NGF withdrawal, c-Jun levels and c-Jun activity begin to increase, c- 
Jun homodimers or c-Jun/X heterodimers may promote apoptosis by activating cell 
death genes. Microinjection of sympathetic neurons with a dominant negative c-Jun 
(FLAGA169)  or antibodies  specific  for c-Jun,  protects  sympathetic  neurons  from 
NGF  withdrawal-induced  death  (Ham  et  al.,  1995).  Knocking  out  c-jun  in 
sympathetic neurons in vitro inhibits NGF withdrawal-induced death (Palmada et al, 
2002).
(ii) The levels of ATF-3 begin to rise after that of c-Jun. ATF-3 may be induced by 
the JNK/c-Jun pathway to form c-Jun/ATF-3 heterodimers and ATF-3 homodimers 
that function in cell survival and neurite outgrowth (Nakagomi et al., 2003).  When 
overexpressed in  neurons,  ATF-3  decreases  the  number of dying  cells  after NGF 
withdrawal and knocking down ATF-3 in sympathetic neurons in vitro increases the 
rate of cell death. ATF-3 could suppress the transcription of gene targets necessary for 
apoptosis,  as  suggested  by  the  protective  effect  observed  when  ATF-3bZIP  is 
expressed  in  neurons.  Alternatively  c-Jun/ATF-3  heterodimers  may  activate 
antiapoptotic genes,  such as hsp27. The relative levels of ATF-3  and c-Jun within 































gene,  e.g. hsp27
171Chapter 6:  Discussion
Neuronal apoptosis occurs extensively during the normal development of the 
mammalian  nervous  system.  This  death  is  important  for  establishing  neuronal 
populations of the correct size and for ensuring that appropriate connections are made 
between  neurons  and  their  target  cells  (Barde,  1989;  Cowan  et  al.,  1984;  Levi- 
Montalcini,  1987). In addition, neuronal apoptosis may contribute to the pathology of 
human  neurodegenerative  disorders.  Sympathetic  neurons  and  neuronally 
differentiated  PC6-3  cells  have  proved  to  be  useful  in  vitro  models  for  studying 
neuronal apoptosis mechanisms. Developing sympathetic neurons and differentiated 
PC6-3  cells  depend  on  NGF  for  survival  and  die  by  apoptosis  in  a transcription- 
dependent manner when this survival factor is removed (Martin et al., 1988; Pittman et 
al.,  1993). The JNK/c-Jun pathway is activated and promotes apoptosis in these cells 
following NGF withdrawal, but little is known about the transcriptional targets of this 
pathway.
To  study  the  genes  involved  in  neuronal  apoptosis,  Affymetrix  GeneChip® 
arrays were used. In three independent experiments, PC6-3 cells were differentiated 
for 7  days in the presence of NGF, before being deprived of NGF for  16 hours, at 
which time samples were prepared for microarray experiments.  16 hours was chosen 
as the time point at which RNA was extracted from PC6-3 cells because this is after 
the induction and activation of c-Jun and prior to the cell death commitment point. In 
the  case  of sympathetic  neurons,  the  cell  death  commitment  point,  when  50%  of 
neurons can no longer be rescued from apoptosis by re-addition of NGF, is around 22 
hours after NGF withdrawal (Deckwerth and Johnson,  1993).  The expression of 78 
genes was found to change in level in differentiated PC6-3 cells deprived of NGF for 
16 hours. Some of the genes have previously been described as NGF-regulated genes, 
or as genes induced in neuronal cells undergoing apoptosis, for example c-Jun, ATF-3, 
GADD153, Txnip and MKP-3. This initial microarray data will be the basis for future 
experiments. Some of the 78 regulated genes could be characterised further using the 
approaches described for ATF-3. It would also be informative to perform Affymetrix 
GeneChip®  experiments  with  RNA  isolated  from  primary  sympathetic  neurons 
cultured in the presence and absence of NGF. Methods are now available to amplify 
the RNA species isolated from small amounts of cells, for use on the arrays. Two cycle
172target  labelling  can  be  performed  using  as  little  as  10  -  100  ng  of total  RNA.  In 
addition,  more  comprehensive  rat  arrays  are  now  available.  The  GeneChip®  Rat 
Genome 230 Array contains over 28,000 known genes,  substantially more than the 
7,000 known genes on the U34A array used in this study. This would provide a more 
detailed analysis of the changes in gene expression in neurons after NGF withdrawal. 
Another variation would be to perform the NGF withdrawal for different lengths of 
time,  for example 4,  8  and  16 hours,  to establish the kinetics  of the  gene changes 
observed.  To  specifically  identify  targets  of the JNK/c-Jun  pathway,  experiments 
could be performed using JNK inhibitor compounds such as CEP-11004 or SP600125. 
RNA isolated from neurons cultured in the presence and absence of NGF and with and 
without inhibitor, could be used on the GeneChip® Rat Genome 230 Array, to help 
indicate which genes are regulated by the JNK/c-Jun pathway.
ATF-3 was selected for more detailed analysis because it was the most highly 
up-regulated  gene  in  the  Affymetrix  GeneChip®  experiments  and  because  it  is  a 
potential  c-Jun  dimerisation partner and c-Jun  target gene,  whose  role  in  neuronal 
apoptosis had not been investigated in detail. The increase in ATF-3 expression level 
detected in the microarray experiments was confirmed at both the RNA and protein 
level, in agreement with previously published results (Mayumi-Matsuda et al.,  1999). 
The induction of c-Jun occurs prior to the induction of ATF-3  in PC6-3  cells. The 
expression pattern of ATF-3 in sympathetic neurons undergoing apoptosis was also 
investigated.  There  was  a 2.1  fold  increase  in  atf-3  RNA  at  16  hours  after NGF 
withdrawal, which agrees with previously published results (Mayumi-Matsuda et al, 
1999). This increase in atf-3 RNA leads to an increase in the amount of ATF-3 protein. 
The ATF-3  protein  started to increase  in  level between  8  and  16 hours  after NGF 
withdrawal and continued to increase between 16 and 24 hours in the absence of NGF. 
The  level  of c-Jun  protein  and c-Jun N-terminal  phosphorylation  (manifested  as  a 
mobility shift) began to increase between 4 and 8 hours after NGF withdrawal and 
remained  elevated  at  16  and  24  hours.  It  has  been  shown  previously  that  c-Jun 
increases in level and is phosphorylated between 8 and 24 hours after NGF withdrawal 
(Ham et al,  1995). The kinetics of induction of these two proteins shows that c-Jun is 
induced and phosphorylated prior to ATF-3 induction. The atf-3 promoter contains a 
number of AP-1  binding sites and can be activated by overexpression of c-Jun and 
ATF-2 in HeLa cells (Liang et al.,  1996) and by MEKK1, an upstream activator of
173JNK, in HCT116 colorectal carcinoma cells (Fan et al., 2002). Induction of ATF-3 by 
ionizing radiation  in primary  human fibroblasts  is  mediated by  signalling through 
JNKs and ATF-2 (Kool et al., 2003). ATF-3 therefore has the potential to be a c-Jun 
and/or ATF-2 target in sympathetic neurons. ATF-2 N-terminal phosphorylation has 
been shown to increase when sympathetic neurons are deprived of NGF (Eilers et al., 
2001).  Thus,  ATF-2  and  c-Jun  may  activate  the  transcription  of atf-3  after NGF 
withdrawal. It would be interesting to investigate whether c-Jun and ATF-2 can bind 
to the aft-3  promoter  in  PC6-3  cells  and  sympathetic  neurons  undergoing  NGF 
withdrawal-induced apoptosis. Chromatin immunoprecipitation experiments could be 
performed  with  chromatin isolated from differentiated PC6-3  cells  cultured  in the 
presence and absence of NGF. Antibodies specific for c-Jun, ATF-2 and ATF-3 and 
primers  specific for the atf-3 promoter could be used to determine which of these 
transcription  factors  are  bound  to  the  atf-3  promoter  in  PC6-3  cells  undergoing 
apoptosis.  Nuclear  extracts  from  PC6-3  cells  and  possibly  sympathetic  neurons, 
cultured  in  the  presence  and  absence  of  NGF,  could  also  be  used  in  EMSA 
experiments.  32P-labelled oligonucleotides  containing  potential  AP-l/ATF binding 
sites in the aft-3 promoter could be incubated with the nuclear extracts to determine 
which transcription factors bind to the promoter during apoptosis.
The  involvement  of  the  JNK/c-Jun  pathway  in  ATF-3  induction  was 
investigated using chemical inhibitors. The MLK inhibitor CEP-11004 was added to 
neurons at the time of NGF withdrawal. This compound is closely related to CEP- 
1347, which rescues sympathetic neurons from death by NGF deprivation (Maroney et 
al.,  1999), by inhibiting MLKs upstream of JNK in the JNK/c-Jun pathway (Maroney 
et al., 2001). The induction of ATF-3 after NGF withdrawal was completely inhibited 
by CEP-11004.  However, in contrast to the effect on ATF-3, the increase in c-Jun 
protein level and phosphorylation observed after NGF withdrawal was reduced but not 
completely  inhibited  by  addition  of CEP-11004.  This  difference  could  be  due  to 
incomplete inhibition of JNK activity at the concentration of CEP-11004 used (Wang 
et al., 2005). This reduced JNK activity may be sufficient to induce the expression of 
some c-Jun protein but not sufficient to induce ATF-3. The JNK inhibitor SP600125 
was  also used to investigate the  involvement of the JNK/c-Jun pathway  in ATF-3 
protein induction after NGF deprivation.  Addition of this compound at the time of 
NGF  withdrawal  completely  inhibited  the  increase  in  c-Jun  protein  level  and
174phosphorylation,  as  expected.  ATF-3  induction  after  NGF  deprivation  was  also 
completely  prevented  by  SP600125.  These  results  suggest  that  ATF-3  levels  are 
regulated by the JNK/c-Jun pathway. However, CEP-11004 can also have effects on 
other signalling pathways.  The protective action of CEP-11004 could be mediated 
through activation of the PI3K survival pathway as well as inhibition of the JNK/c-Jun 
death pathway (Wang et al., 2005). Therefore it could be  argued that the effect of 
CEP-11004 on ATF-3 protein expression may not be through inhibition of the JNK 
pathway. However, taken together with the fact that the JNK inhibitor, SP600125, also 
caused inhibition of ATF-3 induction following NGF-withdrawal, it seems likely that 
the JNK/c-Jun pathway is involved in ATF-3 regulation. To back up the experiments 
with chemical inhibitors, it would be  interesting to  see  if direct JNK  activation  in 
sympathetic neurons, perhaps using a MLK3 or MEKK1  adenovirus, would lead to 
induction  of ATF-3,  and  whether ATF-3  induction  following  NGF  withdrawal  is 
inhibited by expressing the JNK binding domain of JIP-1, a direct inhibitor of JNKs.
Having  shown  that  ATF-3  is  induced  following  NGF  withdrawal  from 
sympathetic neurons and PC6-3 cells, I  next investigated the function of ATF-3  in 
sympathetic neuron apoptosis. ATF-3 can either act as a transcriptional repressor or 
activator depending  upon  whether it is  a homodimer or heterodimer,  respectively. 
However, the actual biological function of ATF-3 is not clear, with both protective and 
detrimental roles proposed. In microinjection experiments, I found that overexpression 
of ATF-3 kills sympathetic neurons in the presence of NGF. The expression of c-Jun 
killed neurons to a similar extent and is in agreement with previously published results 
(Ham et al.,  1995). A significant reduction in the percentage of normal neurons was 
also observed when ATF-3 and c-Jun were expressed together. When overexpressed in 
the presence of NGF, ATF-3 might induce cell death by binding as a homodimer to 
ATF/CRE elements in the promoters of genes that promote cell survival, such as bcl-2, 
repressing  their  transcription.  It  would  be  interesting  to  investigate  whether 
overexpressed ATF-3  homodimers  repress  such genes.  ATF-3/c-Jun  heterodimers, 
however, may act on different target genes to activate transcription of death promoting 
genes in the presence of NGF. These targets could be the same or different to those 
targeted by c-Jun homodimers.
Interestingly,  overexpressed ATF-3  did not kill  sympathetic  neurons  in the 
absence  of NGF.  Injection  of an  expression  vector  for  ATF-3  lead  to  increased
175survival of neurons after NGF withdrawal. This is in agreement with a report that 60% 
of adenovirus-infected sympathetic neurons overexpressing ATF-3 were viable after 
48  hours  of  NGF  withdrawal  (Nakagomi  et  al.,  2003).  I  have  shown  that 
microinjection  of an  expression  vector for dominant negative  c-Jun,  FLAGA169, 
protected the neurons  from NGF withdrawal-induced death, as previously reported 
(Ham  et al.,  1995).  These  results  suggest  that  ATF-3  acts  to  protect  neurons,  in 
contrast to c-Jun, which kills sympathetic neurons after NGF withdrawal. I also found 
that the bZIP domain of ATF-3  alone inhibited cell death to an even greater extent 
than full length ATF-3. The ATF-3bZIP protein lacks any transcriptional activation or 
repression domains. This protein may form heterodimers with other proteins, such as 
c-Jun, and these complexes may have reduced activity. Alternatively, ATF-3bZIP may 
bind  as  a homodimer to  AP-1  or CRE/ATF  sites  and thereby  prevent endogenous 
proteins from binding to these sites. This would imply that overexpressed ATF-3 may 
be acting as a transcriptional repressor after NGF withdrawal in sympathetic neurons, 
since  it  has  the  same  effect  as  the  bZIP  domain  alone.  For example,  ATF-3  may 
repress the transcription of death promoting genes.
To  further  investigate  the  function  of ATF-3  in  sympathetic  neurons,  the 
expression  of  ATF-3  was  inhibited  using  the  pSUPER  RNAi  vector  system.  A 
pSUPER vector containing an RNAi sequence specific for ATF-3 reduced the level of 
overexpressed ATF-3 in Cos-7 cells and sympathetic neurons. This construct reduced 
the number of normal  neurons  observed after 48  hours of NGF withdrawal.  If the 
RNAi construct has the same effect on the endogenous ATF-3 as overexpressed ATF- 
3, then this result would suggest that the level of ATF-3 regulates the rate of cell death 
after NGF withdrawal.  The  absence of ATF-3  in  sympathetic  neurons deprived of 
NGF could result in increased formation of c-Jun homodimers, which should lead to 
increased cell death. In addition, if ATF-3 homodimers can repress the transcription of 
death promoting genes, then a lack of ATF-3 would lead to increased expression of 
these genes.
The differences in ATF-3  function observed in the presence and absence of 
NGF may  be  due  to  differences  in  the  dimerisation  partners  present and/or other 
proteins necessary for NGF withdrawal-induced apoptosis, for example proteins of 
the JNK/c-Jun pathway. It seems that ATF-3 kills sympathetic neurons in the absence 
of a factor that becomes available after NGF withdrawal.
176The kinetics of ATF-3 and c-Jun induction may play a large part in the effects 
observed in sympathetic neurons. Initially after NGF withdrawal, c-Jun levels and c- 
Jun  activity  begin  to  increase.  c-Jun  homodimers  or  c-Jun/X  heterodimers  may 
promote apoptosis, since knocking out c-jun in sympathetic neurons in vitro inhibited 
NGF withdrawal-induced death (Palmada et al, 2002). Subsequently ATF-3 levels rise 
and remain elevated at 24 hours after NGF withdrawal. At this time, the levels of c- 
Jun  are  also  high.  My  results  suggest  a protective  role  for ATF-3  in  sympathetic 
neurons when deprived of NGF.  In the ATF-3  overexpression experiments, ATF-3 
would be expressed at the time when NGF is removed from the cells and may inhibit 
c-Jun  dimer  formation  and  the  activation  of cell  death  genes,  thereby  promoting 
survival. However, sympathetic neurons cultured in vitro and deprived of NGF die by 
apoptosis, when both c-Jun and ATF-3 are present in the cell. This would suggest that 
ATF-3/c-Jun  heterodimers  could  play  a  role  in  promoting  apoptosis.  Perhaps  the 
balance between c-Jun and ATF-3 is critical and each protein regulates the function of 
the other.  High levels of c-Jun  promote  cell  death,  whereas  high  levels  of ATF-3 
promote  survival.  Experiments  in  which  both  ATF-3  and  c-Jun  are  either 
overexpressed or knocked down in sympathetic neurons, deprived of NGF, would help 
establish more precisely  their role  in  apoptosis.  I have  shown that knocking down 
ATF-3 protein levels, in the absence of NGF, increased the rate of cell death. Is this 
due to increased formation of c-Jun homodimers? What happens when c-Jun is also 
absent? Immunoprecipitation experiments could be performed at different times after 
NGF  withdrawal  to  determine  if  and  when  c-Jun  and  ATF-3  form  homo-  or 
heterodimers after NGF withdrawal from sympathetic neurons, as has been reported in 
cell lines  (Hai and Curran,  1991;  Pearson et al., 2003).  In addition, identifying the 
genes that are targeted by these transcription factors,  after NGF withdrawal, would 
help in our understanding of the apoptosis/survival process in neurons.
The targets  of ATF-3  within  sympathetic  neurons are unknown.  The hsp27 
gene has been reported as one possible target of c-Jun/ATF-3 heterodimers after NGF 
withdrawal (Nakagomi et al., 2003). This study suggested that ATF-3 is able to bind 
to the hsp27 promoter at an atypical CRE site in PC 12 cells but it was not shown 
whether c-Jun can directly bind the same site. However, this was suggested because 
transcription  of hsp27  is  inhibited  by  a  dominant  negative  mutant  of c-Jun  (c- 
Jun223NLS),  in  the  presence  of  activated  MEKK1.  ATF-3  can  repress  the
177transcription of GADDI53 and form a non-functional heterodimer that does not bind 
to the ATF/CRE element consensus site and does not repress transcription (Chen et 
al.,  1996). My Affymetrix GeneChip® experiment showed that the GADDI53 mRNA 
increased in level in PC6-3 cells deprived of NGF. GADDI53 can induce apoptosis 
and  this  is  accompanied by  a  downregulation  of bcl-2 (Matsumoto  et al.,  1996). 
Oxidative stress leads to increased binding of Fos and Jun proteins to the AP-1 site in 
the GADDI53 promoter when transfected into HeLa cells (Guyton et al., 1996). Thus, 
GADDI53 expression may be regulated by the ATF/AP-1 family during apoptosis. It 
would  of interest  to  examine  the  kinetics  of induction  of this  protein  after NGF 
deprivation  in  sympathetic  neurons,  and  whether  ATF-3  can  regulate  GADDI53 
expression in neurons or PC6-3 cells.
ATF-3 is up-regulated in response to axotomy with a similar expression pattern 
to c-Jun (Takeda et al., 2000; Tsujino et al., 2000). Expression of ATF-3 enhances c- 
Jun-mediated neurite sprouting in PC 12 cells (Pearson et al., 2003) and infection of 
sympathetic neurons with an adenovirus expressing ATF-3 was shown to induce nerve 
elongation (Nakagomi et al., 2003). This suggests that expression of these proteins 
following axotomy represents an attempt by an injured cell to activate a regeneration 
response and that they may cooperate to initiate cell survival.  A recent study using 
mice with a conditional knockout of c-Jun in neural cells (c- J m« an), showed that CNS- 
specific inactivation of c-jun caused severe defects in the axonal response, leading to 
impaired target reinnervation (Raivich  et al., 2004).  In addition, these motoneurons 
were  resistant to  axotomy-induced cell  death,  supporting  a role  for c-Jun  in  both 
neuronal apoptosis  and axonal regeneration.  If c-Jun is the dimerisation partner of 
ATF-3 after NGF withdrawal, the outcome of either cell death or survival may depend 
on the relative levels of each transcription factor present within dying neurons.
In  conclusion,  I  have  shown that the transcription factor ATF-3  is  induced 
following NGF deprivation in PC6-3 cells and sympathetic neurons. This increase in 
expression occurs after the increase in level of c-Jun and the JNK/c-Jun pathway is 
potentially  involved  in  this  up-regulation  of  ATF-3  after  NGF  withdrawal.  The 
overexpression  of ATF-3  kills  sympathetic  neurons  in  the  presence  of NGF,  but 
increases survival of these cells in the absence of NGF. The bZIP domain of ATF-3 
also  increases  neuronal  survival,  suggesting  that  full  length  ATF-3  may  inhibit 
transcription after NGF withdrawal. Knocking down ATF-3 in sympathetic neurons
178increases  the  rate  of  cell  death,  further  suggesting  that  ATF-3  is  involved  in 
controlling the extent of neuronal apoptosis  after NGF withdrawal.  Experiments to 
knock down c-Jun  in cells  in which  ATF-3  has  been knocked down,  will  confirm 
whether this increased rate of death is due to increased formation of c-Jun homodimers 
in the  absence of ATF-3.  The RNAi  results  could  also be  confirmed by  culturing 
neurons from aft-3'1 ' knockout mice (Hartman et al., 2004). The rate of cell death of 
sympathetic neurons deprived of NGF from these knockout mice could be compared 
to wild-type and heterozygous littermates. Sympathetic neurons expressing a floxed c- 
jun gene could be used to knock out this gene in vitro  (following infection with an 
adenovirus expressing CRE recombinase). These neurons could be used to investigate 
whether the levels of ATF-3 induction are affected by the absence of c-Jun and thus 
indicate whether ATF-3 is a c-Jun target gene.
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List B  Statistically significant gene changes, genes detected in 
2 of 3 experiments








M34253 2.37 interferon regulatory factor 1 Irfl immune response / regulation of transcription, 
DNA-dependent
nucleus
J03754 1.9 ATPase, Ca++ transporting, plasma 
membrane 2
Atp2b2 calcium ion transport / cation transport / 
metabolism / perception of sound
integral to membrane / membrane / 
plasma membrane
E04239 1.86 choline kinase alpha Chka choline kinase activity / kinase activity / transferase 
activity
cytoplasm
AF006664 1.81 NK2 transcription factor related, locus 
5 (Drosophila)
Nkx2-5 transcription factor activity / cardiac development nucleus
AI014169 1.78 up-regulated by 1,25-dihydroxy  vitamin 
D-3
Txnip regulation of cell proliferation cytoplasm
AI171090 1.61 3-hydroxy-3-methylglutaryl CoA lyase Hmgcl catalytic activity / hydroxymethylglutaryl-CoA 
lyase activity / Cholesterol biosynthesis / Synthesis 
and degradation of ketone bodies
mitochondrion
Y08138 1.57 dHand protein Hand2 angiogenesis / development / heart development / 
positive regulation of transcription, DNA- 
dependent
nucleus
AF067727 1.54 MAD homolog 1 (Drosophila) Madhl/
SMAD1
regulation of transcription, DNA-dependent intracellular cytoplasm / peripheral 
membrane / nucleus
AFO18261 1.54 Epsin 1 Epnl endocytosis cytoplasm / peripheral membrane
L26268 1.51 B-cell translocation gene 1, anti­
proliferative
Btgl anti-proliferative / t(8;12)(q24;q22) chromosomal 
translocation in a case of B-cell chronic 
lymphocytic leukemia
nucleus / cytoplasm
M26125 1.49 epoxide hydrolase EPHX aminopeptidase activity / catalytic activity / epoxide 
hydrolase activity / proteolysis and peptidolysis / 
xenobiotic metabolism
endoplasmic reticulum / 
extracellular space / integral to 








M14775 6.43 cytochrome P450, 2c39 Cyp2c39 monooxygenase micosomal / mitochondrial / 
integral membrane




protein amino acid dephosphorylation / cell 








Hmgcsl acetyl-CoA metabolism / cholesterol biosynthesis / 
transferase activity
cytoplasm
El2625 2.1 sterol-C4-methyl oxidase-like Sc4mol metabolism / sterol biosynthesis / catalytic activity / 
oxidoreductase activity
endoplasmic reticulum / integral to 
membrane
X55286 2.01 3-hydroxy-3-methylglutaryl-Coenzyme 
A reductase
Hmgcr biosynthesis / cholesterol biosynthesis / lipid 
metabolism / hydroxymethylglutaryl-CoA 
reductase activity / oxidoreductase activity
endoplasmic reticulum / 
endoplasmic reticulum membrane / 
integral to membrane





farensyl diphosphate synthase Fdps cholesterol biosynthesis / isoprenoid biosynthesis / 
transferase activity
cytoplasm
U36895 1.8 putative vomeronasal receptor 3 Vnr3/VN3 olfactory receptor / putative transmembrane 
receptor
putative membrane protein
S63521 1.78 glucose-regulated protein GRP78 GRP78 Heat shock protein family / antiapoptotic ER 
chaperone-glucose-regulated protein / inhibit PERK 
phosphorylation / ER stress
endoplasmic reticulum
AA998446 1.72 phosphatidylinositol transfer protein, 
beta
Pitpnb transport / lipid binding / phosphatidylinositol 
transporter activity
intracellular
AF003835 1.71 isopentenyl-diphosphate delta 
isomerase
Idil carotenoid biosynthesis / cholesterol biosynthesis / 
isoprenoid biosynthesis / sterol biosynthesis / 












stearoyl-Coenzyme A desaturase 2 Scd2 fatty acid synthesis integral to membrane
S69329 1.64
1.5
ISL1 transcription factor, 
LIM/homeodomain 1
Isll development / energy pathways / regulation of 
transcription, DNA-dependent
nucleus
Y00396 1.62 c-myc / v-myc myelocytomatosis viral 
oncogene homolog (avian)
Myc regulation of cell cycle / transcription initiation / 
regulation of transcription, DNA-dependent / cell 






cytochrome P450, subfamily 51 Cyp51 electron transport / proteolysis and peptidolysis / 
cholesterol biosynthesis
extracellular space / integral to 
membrane
M19651 1.52 fos-like antigen 1 Fosll positive regulation of transcription from Pol II 
promoter, mitotic / regulation of transcription, 
DNA-dependent / transcriptional activator activity
nucleus
AF061266 1.52 transient receptor protein 1 Trpl cation channels / receptor-dependent activation / 
Store-operated calcium entry
membrane
AA891041 1.51 Jun-B oncogene Junb regulation of transcription, DNA-dependent / 
positive regulation of transcription from Pol II 
promoter, mitotic
nucleus
J02585 1.51 stearoyl-Coenzyme A desaturase 1 Scdl fatty acid synthesis integral to membrane
Y09507 1.51 hypoxia inducible factor 1, alpha 
subunit
Hifla regulation of transcription, DNA-dependent / 
response to hypoxia / signal transduction
nucleus
M81183 1.5 Insulin-like growth factor I IGF1 growth and development / signal transduction / 
hormone activity / growth factor activity / 








X02412 1.47 tropomyosin 1, alpha Tpml muscle contraction / muscle development / actin 
binding / structural constituent of cytoskeleton
cytoskeleton / kinesin complex / 
muscle thin filament tropomyosin
L35558 1.47 solute carrier family 1  
(neuronal/epithelial high affinity 
glutamate transporter), member 1
Slclal transport / dicarboxylic acid transport integral to plasma membrane / 
membrane
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J03754 1.9 ATPase, Ca++ transporting, plasma 
membrane 2
Atp2b2 cation transport / calcium ion transport / perception 
of sound / metabolism
plasma membrane / integral to 
membrane
E04239 1.86 choline kinase alpha Chka Acetylcholine synthesis / choline kinase activity / 
kinase activity / transferase activity / cell growth
cytoplasm
AI014169 1.78 up-regulated by 1,25-dihydroxy  vitamin 
D-3
Txnip regulation of cell proliferation cytoplasm
Y08138 1.57 dHand protein Hand2 angiogenesis / regulation of transcription, DNA- 
dependent / development / heart development
nucleus
AFO18261 1.54 Epsin 1 Epnl endocytosis cytoplasm / peripheral membrane
L26268 1.51 B-cell translocation gene 1 Btgl anti-proliferative / t(8;12)(q24;q22) chromosomal 
translocation in a B-cell chronic lymphocytic 
leukemia












protein amino acid dephosphorylation / cell 








Hmgcsl acetyl-CoA metabolism / cholesterol biosynthesis cytoplasm
El2625 2.1 sterol-C4-methyl oxidase-like Sc4mol metabolism / sterol biosynthesis endoplasmic reticulum / integral to 
membrane
X55286 2.01 3-hydroxy-3-methylglutaryl-Coenzyme 
A reductase
Hmgcr lipid metabolism / cholesterol biosynthesis / 
biosynthesis
endoplasmic reticulum / 




farensyl diphosphate synthase Fdps cholesterol biosynthesis / isoprenoid biosynthesis / 
transferase activity
cytoplasm
U36895 1.8 putative vomeronasal receptor 3 Vnr3/VN3 olfactory receptor / putative transmembrane 
receptor
putative membrane protein
S63521 1.78 glucose-regulated protein GRP78 GRP78 Heat shock protein family / antiapoptotic ER 
chaperone-glucose-regulated protein / inhibit PERK 
phosphorylation / ER stress
endoplasmic reticulum
AA998446 1.72 phosphatidylinositol transfer protein, 
beta
Pitpnb transport / lipid binding / phosphatidylinositol 
transporter activity
intracellular
AF003835 1.71 isopentenyl-diphosphate delta 
isomerase
Idil carotenoid biosynthesis / cholesterol biosynthesis / 
isoprenoid biosynthesis / sterol biosynthesis / 















ISL1 transcription factor, 
LIM/homeodomain 1
Isll development / energy pathways / regulation of 
transcription, DNA-dependent
nucleus
Y00396 1.62 c-myc / v-myc myelocytomatosis viral 
oncogene homolog (avian)
Myc regulation of cell cycle / transcription initiation / 
regulation of transcription, DNA-dependent / cell 






cytochrome P450, subfamily 51 Cyp51 electron transport / proteolysis and peptidolysis / 
cholesterol biosynthesis
extracellular space / integral to 
membrane
M19651 1.52 fos-like antigen 1 Fosll positive regulation of transcription from Pol II 
promoter, mitotic / regulation of transcription, 
DNA-dependent / transcriptional activator activity
nucleus
AF061266 1.52 transient receptor protein 1 Trpl cation channels / receptor-dependent activation / 
Store-operated calcium entry
membrane
AA891041 1.51 Jun-B oncogene Junb regulation of transcription, DNA-dependent / 
positive regulation of transcription from Pol II 
promoter, mitotic
nucleus
J02585 1.51 stearoyl-Coenzyme A desaturase 1 Scdl fatty acid synthesis integral to membrane
Y09507 1.51 hypoxia inducible factor 1, alpha 
subunit
Hifla regulation of transcription, DNA-dependent / 
response to hypoxia / signal transduction
nucleus
X02412 1.47 tropomyosin 1, alpha Tpml muscle contraction / muscle development / actin 
binding / structural constituent of cytoskeleton
cytoskeleton / kinesin complex / 
muscle thin filament tropomyosin
L35558 1.47 solute carrier family 1  
(neuronal/epithelial high affinity 
glutamate transporter), member 1
Slclal transport / dicarboxylic acid transport integral to plasma membrane / 
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